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ABSTRACT 
Synthetic and naturally occurring substances present in food and feed, together with their possible 
breakdown or reaction products, represent a large number of substances, many of which require 
risk assessment. EFSA’s Scientific Committee was requested to evaluate the threshold of 
toxicological concern (TTC) approach as a tool for providing scientific advice about possible 
human health risks from low level exposures, its applicability to EFSA’s work, and to advise on 
any additional data that might be needed to strengthen the underlying basis of the TTC approach. 
The Scientific Committee examined the published literature on the TTC approach, undertook its 
own analyses and commissioned an in silico investigation of the databases underpinning the TTC 
approach. The Scientific Committee concluded that the TTC approach can be recommended as a 
useful screening tool either for priority setting or for deciding whether exposure to a substance is 
so low that the probability of adverse health effects is low and that no further data are necessary. 
The following human exposure threshold values are sufficiently conservative to be used in EFSA’s 
work; 0.15 μg/person per day for substances with a structural alert for genotoxicity, 18 μg/person 
per day for organophosphate and carbamate substances with anti-cholinesterase activity, 90 
μg/person per day for Cramer Class III and Cramer Class II substances, and 1800 μg/person per 
day for Cramer Class I substances, but for application to all groups in the population, these values 
should be expressed in terms of body weight, i.e. 0.0025, 0.3, 1.5 and 30 μg/kg body weight per 
day, respectively. Use of the TTC approach for infants under the age of 6 months, with immature 
metabolic and excretory systems, should be considered on a case-by-case basis. The Committee 
defined a number of exclusion categories of substances for which the TTC approach would not be 
used. 
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SUMMARY 
The European Food Safety Authority (EFSA) asked its Scientific Committee to develop an opinion 
on exploring options for providing  advice about possible human health risks based on the concept 
of Threshold of Toxicological Concern (TTC). 
  
In Europe, substances that are the active or primary ingredients in products added to or occurring 
as residues in food or feed are assessed, prior to authorisation, on the basis of dossiers that include 
the results of toxicity tests. A requirement for toxicity testing is appropriate for such substances. 
However, the use of such substances may also result in the presence in food or feed of low-level 
impurities, metabolites, breakdown and reaction products, on which there are few toxicological 
data. The continuing improvements in analytical sensitivity are also resulting in the detection of a 
growing number of chemical contaminants in food and feed at low concentrations, as well as in the 
identification of substances on which there are few toxicological data.  
 
In the light of the above considerations, EFSA needs to develop, validate and apply, where 
possible, practical risk assessment approaches that can be used as priority setting tools and as a 
means to enable more rapid provision of advice about the possibility of health risks. Such practical 
approaches should not in any way compromise the high scientific quality of EFSA’s output. 
Accordingly, as a self task, the Scientific Committee was requested to evaluate the relevance and 
reliability of the threshold of toxicological concern (TTC) approach as a tool for providing 
scientific advice about possible human health risks from low level exposures, its applicability to 
the work of EFSA’s Scientific Committee and Scientific Panels, and to advise on any additional 
data that might be needed to strengthen the underlying basis of the TTC approach. The TTC 
approach is currently used by EFSA for evaluation of flavouring substances and for the evaluation 
of relevant pesticide metabolites in groundwater. 
 
In this opinion, the Scientific Committee has considered a number of published analyses and 
conducted some analyses itself of both the data originally used to establish human exposure 
threshold values (TTC values) and data from additional studies that are included in EFSA’s 
databases on pesticides and in an EU database of substances classified for reproductive toxicity. 
EFSA also commissioned a project from a contractor to examine the databases underpinning the 
TTC approach, using in silico chemoinformatic methods to assess the representativeness of the 
databases and the opportunities for refining the basis for grouping chemicals. Further analyses of 
oral toxicity data and TTC values have also been conducted and published by others using 
independent databases. The Scientific Committee’s conclusions from this exploration of the TTC 
approach are as follows. 
 
1.  The TTC approach is applicable to substances for which the chemical structure is known 
but for which there are few or no relevant toxicity data. For the work of EFSA, the TTC 
approach is recommended as a useful screening tool either for priority setting or for 
deciding whether exposure to a substance is so low that the probability of adverse health 
effects is low and that no further data are necessary.  
 
2.  For application of the TTC approach it is essential to have exposure assessments that take 
account of high exposure scenarios, and, where possible, take account of exposure from all 
routes and sources. The EFSA Panels already have in place exposure assessment 
methodologies for predicting or estimating average and high exposures in relevant sub-
populations, and the EFSA Comprehensive European Food Consumption Database is 
expanding. 
 
3.  The classification of chemicals according to chemical structure is an essential component 
of the current TTC approach. The classification scheme most widely used is that described 
by Cramer et al. (1978). The Scientific Committee is mindful that this scheme is based on 
the metabolic and toxicological information available at that time. With advances in   
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knowledge over the last three decades, revision and refinement of the scheme is 
recommended.  Nevertheless, the Scientific Committee’s analyses, together with those in 
several other published studies (referenced elsewhere in this opinion) have demonstrated 
that the application of the Cramer classification scheme in the TTC approach is 
conservative and therefore protective of human health.  
 
4.  The Scientific Committee notes that the TTC value for Cramer Class II substances derived 
by Munro et al. in 1996 was based on toxicological data on very few substances. Databases 
compiled subsequently have similarly found few chemicals classifiable as Cramer Class II, 
apart from flavouring substances. The Scientific Committee considers that the TTC value 
for Cramer Class II is not well supported by the presently available databases and therefore 
concludes that consideration should be given to treating substances that would be classified 
in Cramer Class II under the Cramer decision tree as if they were Cramer Class III 
substances.  
 
5.  The Committee’s analysis of the lowest 10
th percentiles of the NOELs in the database of 
Munro et al. (1996) for substances in Cramer Class I and Class III, and confirmation by 
others of similar NOELs using different datasets (Tluczkiewicz et al., 2011), demonstrate 
that the respective TTC values of 1800 and 90 μg/person per day derived by Munro et al. 
are sufficiently conservative to be used.  
 
6.  Following the Scientific Committee’s analysis of NOELs for organophosphate and 
carbamate substances, the TTC value of 18 μg/person per day, first proposed by Kroes et 
al. (2004), is considered sufficiently conservative to cover the anti-cholinesterase activity 
of substances with organophosphate or carbamate structural features.  
 
7.  Removing organophosphate and carbamate substances from Cramer Class III (being the 
most potent substances in that class) would have an impact on the existing TTC value for 
Cramer Class III.  However, pending any future revision of the TTC approach, the 
Scientific Committee concludes that it would be prudent to maintain the value for Cramer 
Class III at 90 μg/person per day.  
 
8.  The Scientific Committee considers that further additions to or subdivisions of existing  
Cramer Classes are likely to detract from the advantageous features of the current TTC 
scheme, that is, its ease of use,  maintaining consistency in application of the approach, 
and its in-built conservatism. 
 
9.  Following the Scientific Committee’s analysis of NOELs for reproductive and 
developmental toxicity for substances classified as such under EU legislation, the TTC 
values for Cramer Classes I and III are considered sufficiently protective for adverse 
effects on reproduction or development. 
 
10. Regarding the issue of substances that may have endocrine-mediated toxicity, the 
Scientific Committee concludes as follows. 
a.  In most situations where the TTC approach might be applied, there would be no a 
priori knowledge that a substance has endocrine activity.  
b.  If there are data showing that a substance has endocrine activity, but the human 
relevance is unclear, then these data should be taken into consideration, case-by-
case, in deciding whether or not to apply the TTC approach.  
c.  If there are data showing that a substance has endocrine-mediated adverse effects, 
then, as would be the case for adverse data on any other endpoint, the risk 
assessment should be based on the data, rather than the TTC approach.    
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d.  In view of the extensive work, currently ongoing, to develop an EU-wide approach 
for defining and assessing endocrine disrupters, once that approach is finalised it 
will be necessary to consider any impact it may have on the use of TTC approach. 
e.  In the meantime, the Scientific Committee recommends that untested substances, 
other than steroids, can be evaluated using the TTC approach recommended in this 
opinion.   
 
11.  For substances with a structural alert for genotoxicity, the TTC value of 0.15 μg/person 
per day was derived by Kroes et al. (2004). This value is sufficiently conservative to be 
used in EFSA’s work, provided the structures already designated as high potency 
carcinogens are excluded from the TTC approach. The Scientific Committee is aware that 
further substances have been added to the Carcinogenic Potency Database since this value 
was derived. However, because a large number of substances were already in the 
Carcinogenic Potency Database, the Committee does not consider that the TTC value for 
substances with a structural alert for genotoxicity would change appreciably. 
 
12. The Scientific Committee has considered the possibility that a genotoxic metabolite could 
be produced from a parent substance. If such metabolites were to be predicted and 
considered relevant, then the TTC value of 0.15 μg/person per day should be applied. The 
Scientific Committee recognises that there is no general agreement at present on how to 
interpret the outcome from the currently available tools used to make such predictions, 
because they have a tendency to generate a large number of potential metabolites.  
 
13. The original FDA Threshold of Regulation value of 1.5 μg/person per day is of historical 
importance, but has little practical application in the overall TTC approach. This is because 
substances without structural alerts for genotoxicity can proceed down the TTC decision 
tree to be considered in relation to the higher TTC values for organophosphates and 
carbamates or Cramer Classes I and III.  
 
14. Non-genotoxic carcinogens are considered to have a threshold and, in general, NOELs for 
these are in the same range or higher than NOELs for other types of toxicity.  Thus the 
TTC values that are higher than the value of 0.15 μg/person per day are appropriate to be 
used for any substance that does not have a structural alert for genotoxicity. 
 
15. The Scientific Committee also notes that the work of the EFSA-commissioned project 
demonstrated that the range of structures in the two main datasets (Carcinogenic Potency 
Database and Munro et al.), which underpin the human exposure threshold values, are 
broadly representative of the world of chemicals, in terms of chemical space, as described 
by molecular descriptors encompassing both structural features and physicochemical 
properties. This provides further confidence in the general utility of the TTC approach. 
 
16. A number of proposals have been put forward for adjusting the TTC value for substances 
with a structural alert for genotoxicity for shorter than chronic durations of exposure. The 
Scientific Committee is not confident about the general applicability of these proposals   It 
therefore recommends that the issue of less than chronic exposure should be addressed 
case-by-case. This could be done for example by considering the margin between the 
appropriate TTC value (without any adjustment for duration of exposure) and the 
estimated dietary exposure.  The Scientific Committee also notes that, with the exception 
of the TTC value for organophosphate and carbamate structures, the current TTC values 
for non-cancer endpoints are derived from databases that do not address effects from acute 
exposure. The Scientific Committee is currently unable to recommend a 
reliable/appropriate general means of adjusting the TTC values for non-cancer endpoints 
for shorter durations of exposure, and recommends that these too should also be addressed 
case-by-case for the time being.   
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17. For application of the TTC approach to the whole population including infants and 
children, all TTC values should be converted to corresponding values that take into 
account body weight (see Figure 2).  
 
18. The Scientific Committee has also considered whether the TTC approach could be applied 
to young infants under the age of 6 months, in whom not all metabolic and elimination 
processes are yet mature. The toxicokinetic differences between young infants and children 
or adults are transient and generally not more than 2- to 5-fold. Thus there is capacity in 
the first weeks of life to metabolise and eliminate substances, particularly when exposures 
are low. The Scientific Committee concludes that the TTC approach can be applied to 
assess exposures in young infants, but in cases where the estimated exposure is in the 
range of the TTC value, additional consideration needs to be given under which conditions 
the TTC approach could be used. Additional considerations might include prediction of 
metabolic routes for the structure concerned and other issues such as frequency and 
duration of the exposure. 
 
19. The Scientific Committee has considered whether TTC approach can be applied in cases 
where exposures are by dermal or inhalation routes (e.g. for assessment of occupational 
exposures). It is concluded that more work is needed in this area to establish separate TTC 
values for routes of exposure other than oral and/or develop systematic schemes for route-
to-route extrapolation. It is noted that such work is ongoing elsewhere. 
 
20. The Scientific Committee considered whether routinely undertaking metabolic prediction 
would be helpful for application of the TTC approach other than for prediction of 
genotoxicity. As the Cramer decision tree and the databases used to derive the TTC values 
for non-cancer endpoints reflect at least in part the toxicity of metabolites formed in the 
test species, the Scientific Committee concluded that it is not essential to undertake such 
metabolic prediction.  However, there are situations where this has been helpful, e.g. in the 
case of flavourings where metabolic data on closely structurally-related substances are 
available. 
 
21. The Scientific Committee considered both previously proposed exclusions and additional 
exclusions that might be necessary and concludes that the TTC approach should not be 
used for the  following (categories of) substances: 
a.  High potency carcinogens (i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, 
benzidines, hydrazines). 
b.  Inorganic substances 
c.  Metals and organometallics 
d.  Proteins 
e.  Steroids 
f.  Substances that are known or predicted to bioaccumulate  
g.  Nanomaterials  
h.  Radioactive substances 
i.  Mixtures of substances containing unknown chemical structures 
 
22.  When the TTC approach is used, it is important for both risk assessors and risk managers 
to keep in mind that it is a probability-based screening tool and, in common with other risk 
assessment approaches, it does not offer complete certainty. The derivation of the various 
TTC values are based on frequency distributions and the TTC values that have been 
proposed for use are not based on the lowest value in each of the distributions but on a 
point close to the lowest value. Thus, when using either the cancer or non-cancer TTC 
values, there is a chance that a substance with an exposure below the relevant TTC value   
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may still pose a potential risk. That probability can be estimated to lie between zero and 
5%. 
 
23. Lastly, the Scientific Committee has considered where the TTC approach could be applied 
in EFSA’s work and concludes as follows: 
a.  In principle, the science supports the application of the TTC approach in any area 
of chemical risk assessment for which human exposures are low, whether exposure 
is from deliberate addition or due to contamination. However, for substances for 
which EU legislation requires the submission of toxicity data, the TTC approach 
would not be used. 
b.  Within EFSA, the Scientific Committee recommends that the TTC approach can 
be used to assess impurities, breakdown and reaction products, metabolites, and 
low-level contaminants in food and feed, where an exposure assessment can be 
conducted, but on which there are few or no toxicological data. 
c.  Wider use of the TTC approach in EFSA’s work, beyond the ones mentioned 
above, can also be envisaged, for example, as part of tiered approaches in which 
toxicity testing requirements are linked to the level of human exposure.  Such uses 
in a particular area of EFSA’s work should be considered on a case-by-case basis, 
in consultation with risk managers. The Scientific Committee further recommends 
that in such cases, if there is a structural alert for genotoxicity, then genotoxicity 
testing data on the substance or information (e.g. from read-across) should be 
sought.  
d.  The Scientific Committee recognises that when the different EFSA Panels apply 
the TTC approach to their respective areas, specific considerations may apply and 
the generic scheme shown in Figure 2 may need to be adapted. 
 
Generic scheme for the application of the TTC approach 
 
Is the substance a member of an 
exclusion category? *
Is there a structural alert for 
genotoxicity
(including metabolites)?
Exposure > 0.3 µg/kg bw/day? ***
Is substance an OP/Carbamate?
Exposure > 1.5 µg/kg bw/day? ***
Is substance in Cramer Class II or III?
Exposure
> 0.0025 µg/kg bw/day? 
Substance
requires non-TTC approach
(toxicity data, read-across etc.)
Low probability of
health effect
**
Low probability of
health effect
**
Exposure > 30 µg/kg bw/day? ***
No
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
*** If exposure only short duration
→ consider margin betweenhuman 
exposure & TTC value
** If exposure of infants < 6 months
is in range of TTC  
→ consider if TTC is applicable
No
No
No
Yes
* Exclusion categories
high potency carcinogens; inorganic substances; 
metals and organometallics; proteins; steroids; 
substances known/predicted to bioaccumulate; 
nanomaterials; radioactive substances; mixtures.
Does the substance have a known structure and 
are exposure data available?
Yes
No TTC approach cannot 
be applied
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BACKGROUND AS PROVIDED BY EFSA 
Human health risk characterisation of chemicals is normally based on substance-specific hazard 
data and on estimations of the level of human exposure. Whereas the latter is often based on 
(conservative) assumptions and theoretical models, rather than quantitative measurements and 
observations, the former is generally based on extrapolation of quantitative hazard characterisation 
data derived from resource-intensive toxicity studies in animals. The unavoidable uncertainties and 
assumptions made during the risk assessment process are usually covered by applying conservative 
safety/uncertainty factors.  
 
Synthetic and naturally occurring substances present in food and feed flavouring agents, food 
contact materials, food supplements, botanicals, and food and feed contaminants, together with 
their possible breakdown or reaction products, represent a very large number of substances, many 
of which still require risk assessment. Moreover, the continuing rapid improvements in analytical 
sensitivity are resulting in the detection of a growing number of chemical contaminants in food and 
feed at low concentrations as well as in the identification of an increasing number of poorly 
understood substances.  
 
In the light of the above considerations, EFSA needs to develop, validate and apply, where 
possible, pragmatic and practical risk assessment approaches as priority setting tools and as a 
means to enable more rapid provision of advice about the possibility of health risks. Such practical 
approaches should not in any way compromise the high scientific quality of EFSA’s output. 
 
Reconsideration of the current concept of risk assessment can be done by promoting the evolution 
of hazard assessment (toxicology) from a predominantly observational science at the level of in 
vivo models to a predominantly predictive science (Collins et al., 2008) focused on broad inclusion 
of computational models and comparative decision trees, as for example: 
 
•  Investing in new approaches, based on scientific innovation and making use of new tools 
and instruments such as genomics and other profiling techniques, systems biology, and 
biological pathway perturbations (NRC, 2007). New approaches also include concepts 
such as ‘intelligent testing and assessment strategies’ (Van Leeuwen et al., 2007), 
‘evidence-based toxicology’ (EC-JRC, 2009), and ‘conceptual risk assessment 
frameworks’ (Goldberg et al., 1997), which are all based on step-wise risk assessment 
procedures defining the next step based on the outcome of the previous steps. 
•  Pragmatic and practical risk assessment approaches aiming at providing preliminary advice 
about the possibility of a human health risk. Some approaches are based on comparative 
analyses of hazard data from structurally - or functionally - related substances, including 
computational prediction of toxicity (Bassan & Worth, 2008), and use of high-throughput 
automated screening assays. Approaches primarily based on presumed safe levels of 
exposure, rather than hazard data, include the tiered assessment as applied in the REACH 
Regulation (EC, 2007), the threshold of regulation (TOR) concept as applied by the US 
FDA for food contact materials (Cheeseman et al, 1999) and, the threshold of toxicological  
concern (TTC) concept, which can be applied using a decision-tree approach, and which is 
useful for substances where human exposure levels are known to be low (Kroes et al., 
2004). 
In accordance with its mission, EFSA aims to invest in new risk assessment approaches based on 
scientific innovation and novel techniques such as genomics and other profiling methods. The 
Scientific Committee is also addressing new risk assessment approaches in the context of animal 
welfare considerations. 
 
The use of pragmatic, science-based approaches in EFSA has already begun. In the area of risk 
assessment of micro-organisms, the Scientific Committee adopted an opinion on the use of the   
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Qualified Presumption of Safety (QPS) approach for setting priorities within the risk assessment of 
microorganisms used in food/feed production referred to EFSA (EFSA, 2007). This practical risk 
assessment approach meets the need of EFSA to assess the safety of large numbers of micro-
organisms deliberately added to food and feed within an acceptable time frame. 
 
In the area of food contact materials, the former Scientific Committee on Food and subsequently 
EFSA have applied a tiered approach to toxicity testing requirements, based on estimates of 
exposure to individual substances via migration from food contact materials into food and the 
principle that lower levels of exposure require less toxicity data for risk assessment (SCF, 2001). 
 
For the assessment of the more than 2800 food flavouring substances, EFSA and the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) apply, where possible and feasible, the 
concept of Threshold of Toxicological Concern (TTC). This concept refers to the establishment of 
a generic human exposure threshold value for chemicals below which there would be no 
appreciable risk to human health (Barlow, 2005). Therefore the safety assessment of food 
flavourings based on very low levels of exposure becomes possible even in the absence of 
substance-specific hazard data.  
 
The TTC approach is currently not applied in EFSA in areas of risk assessment other than food 
flavourings and for exposure to pesticide metabolites in groundwater.  It is recognised that a 
critical element in applying the TTC approach is the need for reliable exposure data and that 
estimates of exposure need to be as complete and accurate as possible, or include adequate 
conservatism to account for possible underestimation of exposure. 
TERMS OF REFERENCE AS PROVIDED BY EFSA 
The Scientific Committee is requested to prepare a scientific opinion in which it explores options 
for the use by EFSA’s Scientific Committee and Scientific Panels and other expert groups of the 
threshold of toxicological concern (TTC) approach as a formalised approach for providing 
scientific advice about possible human health risks. 
In particular the Scientific Committee is requested to: 
 
•  Evaluate the relevance and reliability of the TTC concept for application in the food and 
feed area, taking into account: (i) the discriminative power of the currently available 
databases that underpin the concept and which have been used to define human exposure 
thresholds, (ii) the range and number of chemical entities represented in such databases, 
(iii) the routes of exposure to these chemicals, (iv) the range of reported effects following 
exposure, and (v) the possibilities to assess – with sufficient certainty – human exposure 
levels through food and feed of chemical entities for which EFSA has risk assessment 
responsibility; 
•  Advise on the application of the TTC concept in areas of chemical risk assessment 
addressed by EFSA other than food flavourings and define the general and specific criteria 
for its application as a tool to provide scientific advice on the safety/risk in these areas; 
•  Advise on any additional data development and/or collection needed to strengthen the 
underlying basis of the TTC concept and its use as a practical tool for providing scientific 
advice about possible human health risks related to chemical exposures via food and feed. 
In developing its scientific opinion the Scientific Committee is requested to take into account the 
experience gained by the EFSA in applying the TTC concept in the assessment of food flavouring 
substances, the work currently carried out by the three non-food Scientific Committees of the 
Commission (SCCS, SCHER and SCENIHR) (EC, 2008), and the experience gained by other 
agencies and international organisations/associations including: EMA (formerly EMEA), US FDA, 
JECFA, WHO/IPCS, ILSI (ILSI, 2000; Kroes et al., 2005) and COLIPA.   
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ASSESSMENT 
1.   Introduction 
The threshold of toxicological concern (TTC) approach is a screening tool that has been developed 
in order to assess substances of unknown toxicity present at low levels in the diet. Application of 
the TTC approach requires only knowledge of the chemical structure of the substance concerned 
and information on human exposure, for which there is confidence that it is not an underestimate.  
It utilises generic human exposure threshold values (also called TTC values) that have been 
established for substances grouped according to their chemical structure and likelihood of toxicity. 
There is a range of human exposure threshold values that have been developed based on data from 
extensive toxicological testing in animals, covering both cancer and non-cancer endpoints. The 
TTC approach can be used for substances with or without a structural alert for genotoxicity.   
 
It should be noted that the TTC values are derived using a probabilistic approach.  Hence, at 
exposures below the generic human exposure threshold values, the probability of adverse effects 
on human health is considered to be very low (FDA, 1995; Munro et al., 1996; Kroes et al., 2004).  
Comparison of the known or estimated human exposure to a substance with the relevant TTC value 
allows an initial assessment on whether or not a substance requires a more detailed assessment. In 
this respect, the TTC approach has the potential to be used both for qualitative risk assessment and 
for the setting of priorities for data needs and for risk management action. Its wider use would 
reduce the use of animals in toxicity testing.  
 
The TTC approach is currently used by EFSA and the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA) for evaluation of flavouring substances in food, and for evaluation of 
relevant pesticide metabolites in groundwater in the EU (SCP, 2000). Although the TTC concept 
was originally developed for application to substances that may be ingested by humans from the 
diet, its use has since been agreed in some other contexts. These include oral exposure in the 
following areas: genotoxic impurities in human pharmaceuticals (Müller et al., 2006; EMEA, 
2006; Humfrey, 2007; FDA, 2008), genotoxic constituents in herbal substances and preparations 
(EMEA, 2007), food processing aids (AFSSA, 2005) and micro-pollutants and impurities in 
drinking water (Rodriguez et al., 2007a,b; Fawell, 2008; Australian Guidelines, 2008; 
Brüschweiler, 2010a,b). Its use has also been proposed for assessment of consumer products 
(Blackburn et al., 2005), pesticide metabolites, degradation and reaction products (CRD, 2010;  
Melching-Kollmuß et al., 2010; Dekant et al., 2010), and for industrial chemicals assessed under 
REACH in the context of the exposure based waiving of toxicological testing (ECHA, 2008). 
Adaptation of the TTC concept is also being considered with respect to other routes of human 
exposure such as inhalation (Drew and Frangos, 2007; Carthew et al., 2009; Escher et al., 2010) 
and dermal exposure (Safford, 2008; Safford et al, 2011). Similar principles to those underlying the 
TTC approach are also being considered for use in screening of chemicals for effects on 
environmental species (De Wolf et al., 2005). The Scientific Committee is also aware that a joint 
opinion is being developed on the applicability of the TTC approach in the work of the European 
committees that advise the European Commission on the non-food areas of consumer safety, public 
health and the environment (EC, 2008).  
 
In this opinion, the science underpinning the TTC approach is critically examined and 
recommendations are made concerning the possible wider use of the TTC approach in EFSA’s 
work. This opinion covers only the application of TTC approach to human exposures; it excludes 
the applicability of the TTC approach to target animal species. It also does not consider 
ecotoxicological risk assessment as that is not within the terms of reference for the opinion. 
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2.  Development of the TTC concept 
The TTC approach has been proposed for substances to which there is low human exposure, but 
for which there are few or no toxicity data. The TTC concept has its origin in one of the 
fundamental principles of toxicology, that toxicity is a function of dose and duration of exposure. 
For toxicity endpoints with a threshold, when comprehensive, substance-specific toxicity data are 
available, they usually allow risk assessors to identify a dose or exposure, below which no adverse 
effects of the substance can be detected. For toxicity endpoints that may not be thresholded, a 
practical approach has also been proposed (discussed in 2.1. below).  
2.1.  Derivation of human exposure threshold values for the endpoint of cancer 
A human exposure threshold value was derived by the US Food and Drug Administration (FDA) 
(Rulis, 1986, 1989, 1992) to be applied to substances that do not contain a structural alert for 
genotoxicity/carcinogenicity, but intended to protect against all types of toxicity including 
carcinogenicity. The threshold value was derived by mathematical modelling of risks from animal 
bioassay data on over 500 known genotoxic and non-genotoxic carcinogens, based on their 
carcinogenic potency. Carcinogenic potencies were expressed as TD50s
4 and “virtually safe doses” 
(VSDs) were derived from these by linear extrapolation, assuming that the risks in animals are 
representative of those in humans.  The VSD is an estimate of the dietary exposure to a carcinogen 
which could give rise to less than a one in a million lifetime risk of cancer. From the distribution of 
VSDs, a concentration of 0.5 μg/kg of diet (0.5 ppb) was derived as the value to use for the 
Threshold of Regulation (TOR). This can also be expressed as 1.5 μg/person per day, assuming 
that 3 kg of food and beverages per person are consumed daily. If dietary exposure to an individual 
substance was below the threshold, the FDA considered that consumers would be protected “with 
reasonable certainty of no harm”, even if that substance was later shown to be a carcinogen. In 
1995, the FDA incorporated this threshold value in its TOR policy for substances present in food 
contact materials (FDA, 1995). Under the TOR, substances used in food contact materials that are 
present in the diet at concentrations below 0.5 μg/kg are exempted from regulation (see appendix A 
for further details).  
 
Later, Kroes et al. (2004) refined the human exposure threshold for covering the endpoint of cancer 
by deriving a lower value for substances containing a structural alert for potential genotoxicity. 
The same modelling approach was used as by the FDA. They first focused on identifying high 
potency carcinogens  that would give the highest calculated risks if present at very low 
concentrations in the diet and after excluding them (aflatoxin-like, azoxy-, and N-nitroso- 
compounds), they derived a human exposure threshold value of 0.15 µg/person per day for 
substances with a structural alert for genotoxicity.   
 
The human exposure threshold values for the endpoint of cancer are summarised below in Table 1. 
  
  Table 1: Human exposure threshold values from cancer data  
 
Structures  Human exposure threshold value 
(μg/person/day) 
Reference 
Without a structural alert for genotoxicity  1.5  FDA, 1995  
With a structural alert for genotoxicity  0.15  Kroes et al., 2004 
 
The original FDA Threshold of Regulation value of 1.5 μg/person per day is of historical 
importance, but has little practical application in the overall TTC approach. This is because 
                                                      
 
4 The TD50 is defined as the daily dose-rate in mg/kg body weight per day for life to induce tumors in half of the test 
animals that would have remained tumor-free at zero dose.   
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substances without structural alerts for genotoxicity can proceed down a TTC decision tree to be 
considered in relation to the higher TTC values as discussed below.  
2.2.  Derivation of human exposure threshold values for non-cancer endpoints 
Around the same time as the FDA was developing the TOR policy, Munro and colleagues were 
developing the TTC concept (Munro 1990, 1996; Munro et al., 1996, 1998, 1999). They proposed 
the use of generic thresholds for acceptable human exposures based on an exploration of the 
relationship between chemical structures and toxicity (Munro et al., 1996). They compiled a large 
reference database (in this document referred to as the Munro et al. database) consisting of 613 
chemicals for which oral toxicity data were available on a variety of non-cancer endpoints from 
sub-chronic, chronic, reproductive and developmental toxicity studies. Over 2900 no-observed-
effect levels (NOELs
5) were available from these studies.  
 
The chemicals in the Munro et al. database were divided into three structural classes, based on a 
“decision tree” developed earlier by Cramer et al. (1978). Cramer Class I were chemicals of simple 
structure, with efficient modes of metabolism, suggesting low oral toxicity; Cramer Class III were 
chemicals with structures suggesting significant toxicity or which did not permit any strong initial 
presumption of safety, and Cramer Class II were chemicals with structures that were less 
innocuous than Cramer Class I but without features suggesting significant toxicity (see section 3.1 
for further details). Human exposure threshold values were derived by taking the lower 5
th 
percentile value of the distribution of NOELs for the substances in each of the three Cramer 
structural classes, multiplying by 60 to convert the values expressed as mg/kg bw per day into 
mg/person per day, and then dividing by a factor of 100 to ensure a margin of safety. The Scientific 
Committee notes that an uncertainty factor of 100 is commonly accepted in establishing health-
based guidance values (WHO, 2009a). The issue of selection of 5
th percentile of NOEL values to 
derive human exposure threshold values is addressed later in the opinion (see 4.2.3). The three 
human exposure threshold values derived for non-cancer endpoints are summarised below in Table 
2. 
 
   Table 2: Human exposure threshold values from toxicity data from Munro et al., 1996 
 
Cramer Structural 
Class 
Fifth percentile NOEL 
(mg/kg bw per day) 
Human exposure threshold 
(mg/person per day) 
I 3.0  1.8 
II 0.91  0.54 
III 0.15  0.09 
 
More detailed information on the development of the TTC concept and the derivation of the human 
exposure threshold values is given in Appendix A. 
2.3.  The TTC decision tree 
Many of the above recommendations were incorporated into a decision tree by Kroes et al, (2004) 
shown in Figure 1 below.  
Subsequently, Felter et al. (2009) have suggested further refinements to the TTC decision tree.  
One of their proposals allows for consideration of any available genotoxicity data on substances 
that have structural alerts for genotoxicity (Step 2 of the decision tree). If the genotoxicity data are 
negative (e.g. Ames test and/or other data), they proposed using a higher threshold value of 1.5 
μg/person per day, rather than the value of 0.15 μg/person per day recommended at Step 4 of the 
decision tree. The other issue they addressed was duration of exposure. The existing human 
exposure threshold values assume a lifetime of exposure. Felter et al. proposed using a higher 
                                                      
 
5 NOEL was the term used by Munro et al. Nowadays, it would be more usual to make a distinction between NOELs and 
no-observed-adverse-effect levels (NOAELs). NOELs are sometimes more conservative than NOAELs.    
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threshold value of 1.5 μg/person per day in cases where dietary exposure to a chemical with a 
structural alert for potential genotoxicity is less than 12 months (see section 4.10.2 for further 
discussion).  
In addition to recommendations to exclude substances with structural alerts for high potency 
carcinogenicity (see 2.1.), Kroes et al. (2004) made a number of other recommendations for 
exclusion of particular groups from the TTC approach. They recommended exclusion of 
polyhalogenated-dibenzodioxins, -dibenzofurans and –biphenyls, which are potent substances with 
extremely long toxicokinetic half-lives that show very large species differences in 
bioaccumulation, along with heavy metals, because they are known to accumulate in the body. 
Other non-essential metals in elemental, ionic or organic forms were also recommended to be 
excluded because they were not included in the original database of Munro et al. (1996), nor are 
inorganic substances covered by the structural classification scheme of Cramer et al. (1978). 
Proteins were also recommended to be excluded since they were not included in the Munro et al. 
(1996) database, and their potential for allergenicity and the potent biological activities of some 
peptides make them unsuitable for the TTC approach (see section 4.4 for further details).  
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Figure1: TTC Decision Tree (Kroes et al., 2004) 
(reproduced with copyright permission from Elsevier) 
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2.4.  Initial use of the TTC approach  
In 1995, JECFA was the first to consider using elements of the TTC approach for the evaluation of 
flavourings  (WHO, 1995; Munro et al, 1996), and has since used it to evaluate about two thousand 
flavouring substances. These substances are usually considered in structurally-related groups, 
which also allows read-across in cases where there are toxicity data on one or more members of the 
group. The main modification made by JECFA to the generic TTC approach when applied to 
flavouring substances was to consider metabolism more explicitly, specifically whether a 
flavouring substance can be predicted by expert judgement to be metabolised to innocuous 
products. The modified approach was adopted as the JECFA procedure in 1996 (WHO, 1997). The 
European Commission’s Scientific Committee on Food later considered the JECFA procedure and, 
whilst not formally endorsing the values for human exposure thresholds, concluded that it was a 
reasonable and pragmatic approach that could be used for chemically defined flavouring 
substances within the evaluation programme of the European Commission (SCF, 1999). A slightly 
modified form of the JECFA procedure has been used by EFSA since 2004 for the evaluation of 
about two thousand substances on the European Union Register of Flavouring Substances (EC, 
2002 and its subsequent amendments).  Further information on the JECFA and EFSA procedures 
for evaluation of flavouring substances is given in Appendix B.  
3.  The Cramer classification scheme and its software implementation 
3.1.  Development of the Cramer classification scheme 
The application of the TTC concept as described above utilises the so-called Cramer decision tree 
proposed by Cramer, Ford and Hall (Cramer et al., 1978) as a priority setting tool and as a means 
of making expert judgements in food chemical safety assessment more transparent and 
reproducible. They drew upon their experience in classifying food flavouring substances (Oser & 
Hall, 1977) and in evaluating pesticides and industrial chemicals. The criteria they proposed for the 
three structural classes are shown below.  
 
 
 
 
 
 
 
 
 
 
Cramer et al. (1978) based their decision tree on a series of 33 questions relating mostly to 
chemical structure, and natural occurrence in food and in the body were also taken into 
consideration. The set of 33 questions were intended as a compromise between discrimination (into 
the three classes) and complexity (of the questions and their ordering). The logic of the sequential 
questions was based on the then available knowledge on toxicity and on how chemical structures 
are metabolised in mammalian metabolic pathways. Although many of the questions in the Cramer 
decision tree relate to chemical features associated with toxicity, the Cramer decision tree should 
not be confused with expert systems or quantitative structure-activity relationships (QSARs) that 
are designed to make substance-specific predictions of defined toxicological endpoints. In 
particular, the known limitations of expert systems and QSARs in terms of predictivity should not 
be extended to the Cramer tree.  
 
Structural classes for chemicals in the TTC approach proposed by Cramer et al, 1978. 
Class I  Substances with simple chemical structures and for which efficient modes of 
metabolism exist, suggesting a low order of oral toxicity.  
Class II    Substances which possess structures that are less innocuous than class I 
substances, but do not contain structural features suggestive of toxicity like 
those substances in class III. 
Class III  Substances with chemical structures that permit no strong initial presumption 
of safety or may even suggest significant toxicity or have reactive functional 
groups.   
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Some examples of the way in which substances are classified by the Cramer decision tree are as 
follows: 
-  Class I: normal constituents of the body, excluding hormones; simply-branched, acyclic 
aliphatic hydrocarbons; common carbohydrates; common terpenes; substances that are 
sulphonate or sulphamate salts, without any free primary amines.  
-  Class II: common components of food; substances containing no functional groups other 
than alcohol, aldehyde, side-chain ketone, acid, ester, or sodium, potassium or calcium 
sulphonate or sulphamate, or acyclic acetal or ketal and it is either a monocycloalkanone or 
a bicyclic compound with or without a ring ketone.  
-  Class III: structures that contain elements other than carbon, hydrogen, oxygen, nitrogen or 
divalent sulphur; certain benzene derivatives; certain heterocyclic substances; aliphatic 
substances containing more than three types of functional groups.  
 
Cramer et al. (1978) predicted that the majority of substances would fall into either Class I or Class 
III, rather than Class II, and that is indeed borne out by the Munro et al. database and by 
subsequent experience with the TTC approach. Cramer et al. (1978) tested the validity of their 
decision tree by classifying 81 chemicals (used as food additives, drugs, industrial chemicals or 
pesticides), on which toxicity data from short-term or chronic studies were available, into the three 
structural classes and by tabulating the NOELs. There was overlap in the range of magnitudes of 
the NOELs between the three structural classes, but it was clear that the NOELs of Class I 
substances were generally higher than those of Class III, with those of Class II being in between.  
3.2.  Computer-based implementation of TTC-relevant decision trees 
While the Cramer classification scheme undoubtedly served to improve consistency between the 
toxicological evaluations made by different experts, its paper-based application requires a working 
knowledge of organic chemistry, biochemistry, and food chemistry, and inevitably involves a 
degree of subjectivity. Therefore, following a recommendation made in a JRC workshop 
(Patlewicz et al., 2007), the JRC commissioned the development of a Toxtree rulebase to facilitate 
the consistent application of the Cramer scheme. Toxtree is freely downloadable from the JRC 
website (http://ihcp.jrc.ec.europa.eu/our_labs/computational_toxicology/qsar_tools/toxtree) and 
from Sourceforge (https://sourceforge.net/projects/toxtree). In principle, Toxtree can be applied to 
organic molecules, organic salts, organometallic substances, and structurally well-defined 
oligomers and polymers. However, organometallics, oligomers and polymers were recommended 
for exclusion from the TTC approach by Kroes et al, (2004). The performance of the Cramer 
rulebase in Toxtree v1.2 has been evaluated by Patlewicz et al. (2008). Subsequent releases of the 
software have implemented minor modifications to the Cramer rulebase. 
 
The current version of Toxtree (v2.5.0, August 2011), includes three rulebases relevant to TTC 
assessment: these are (a) the original Cramer rulebase, (b) the Cramer rulebase with extensions, 
and (c) the TTC decision tree of  Kroes et al (2004). The Extended Cramer rulebase works by 
assigning substances to Class I, II, or III, according to the original Cramer rules, and five extra 
rules described below. Some of these extra rules were introduced because it was noted that several 
substances were classified by Munro et al. (1996) into Class I or Class II according to the Cramer 
rules, even though Munro et al. reported low NOEL values upon oral administration (indicating 
relatively high toxicity). To overcome such misclassifications, extra rules (documented in the user 
manual, 
http://ihcp.jrc.ec.europa.eu/our_labs/computational_toxicology/doc/Toxtree_Cramer_extensions.pd
f) were introduced to capture the possible toxicity of these substances.  
 
Two of the extra rules make the Cramer scheme less conservative: firstly, the list of normal body 
constituents is extended from 67 to over 400 so these substances are thus placed into Class I; 
secondly, an additional rule allows natural phosphates that are negatively charged (in contrast to 
uncharged (thio)phosphates in organophosphate pesticides) and widely present in the human body   
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to avoid automatic classification into Class III. Conversely, three additional rules make the Cramer 
scheme more conservative by placing some benzene-like compounds, non-natural divalent sulphur 
compounds, and α,β-unsaturated heteroatom compounds into Class III. On the basis of a survey 
carried out by EFSA and the JRC, the Extended Cramer rulebase does not appear to be widely used 
(Lapenna & Worth, 2011).  
 
Use of the Kroes et al. (2004) TTC decision tree results in three possible outcomes: (a) substance 
would not be expected to be a safety concern, (b) negligible risk (low probability of a life-time 
cancer risk greater than 1 in 10
6), and (c) risk assessment requires compound-specific data. Toxtree 
incorporates the Benigni/Bossa rules for the identification of some genotoxic carcinogens (Benigni 
et al., 2008), and requires the user to input the estimated daily exposure. 
 
It should be noted that the computer-based implementation of the Cramer scheme in Toxtree and 
other software tools (e.g. the OECD QSAR Toolbox (OECD, 2010a)) has inevitably involved some 
decisions by the programmer, such as the chemically-based interpretation of the original rules, and 
the establishment of pre-defined “look-up lists” of normal body constituents and common food 
components.  
3.3   Survey on the use of Toxtree software  
In the survey carried out by the JRC (Lapenna & Worth, 2011), feedback was obtained from 
Toxtree users of the Cramer scheme, with a view to (a) identifying rules for which clarification 
was needed, (b) obtaining recommendations to revise, remove or add a given rule, and (c) 
identifying software problems or inconsistencies in the Toxtree implementation of the Cramer 
rulebase.  
 
The main observations emerging from the JRC survey concerning the scientific refinement of the 
Cramer scheme can be summarised as follows: 
i.  Many of the original Cramer rules are written in a confusing and inter-dependent way, 
which leads to difficulties in the rationalisation of the predictions they make. These rules 
could be rewritten in a clearer way, possibly with modification and re-ordering. 
 
ii.  Two rules are not based on chemical features, but simply make reference to look-up lists of 
chemicals (Q1, normal body constituents; Q22, common food components). These could 
be easily extended, for example recently authorised food additives could be added to the 
list of common food components. Any extended lists could be peer-reviewed. 
Alternatively, the Cramer scheme could be recast by removing these two questions. In 
other words, the revised Cramer scheme would not make reference to any look-up lists (i.e. 
chemicals considered to be safe or otherwise), so any reference to such lists would have to 
be carried out separately.  
 
iii.  Some rules make references to chemical features (e.g. steric hindrance) which would need 
to be better explained or possibly deleted. 
 
The Scientific Committee considers that the potential limitations of the Cramer scheme are that (a) 
it is based  on the knowledge of the late 1970s, (b) Cramer Class II is less well defined and  is 
sparsely populated  (see also section 4.2.3.3), and (c) some structurally determined  endpoints (e.g. 
substances with anti-cholinesterase activity) require specific consideration (see section 4.3.2).  
 
The Scientific Committee also notes that other additions to or subdivisions of existing Cramer 
Classes are being considered elsewhere. The Scientific Committee considers that if there were 
numerous modifications of the existing Cramer classification scheme, they are likely to detract 
from the advantageous features of its use in the TTC approach, that is, its ease of use, maintaining 
consistency in application of the approach, and its in-built conservatism. These aspects are 
discussed in more detail later in the opinion.   
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4.  EFSA’s consideration of the human exposure threshold values 
In evaluating the relevance and reliability of the TTC concept for application in the food and feed 
area, the Scientific Committee considered the question of whether the human exposure threshold 
values, derived by the FDA (1995) and Kroes et al. (2004) for the endpoint of cancer and by 
Munro et al. (1996) for non-cancer endpoints, are sufficiently conservative to apply. This requires 
consideration of the range of structures and number of chemical entities represented in the 
databases that underpin the TTC approach, whether these are sufficiently representative of the 
‘world of chemicals’, the appropriateness of their routes of exposure, the range of reported effects 
following exposure, and the reliability of the NOELs and (for carcinogens) the estimates of 
exposure that would represent a low probability of the risk of cancer. These issues are discussed in 
subsequent sections of Chapter 4. 
4.1.  TTC values for potential (genotoxic) carcinogens 
The TTC value covering the endpoint of cancer of 0.15 µg/person per day for substances with a 
structural alert for genotoxicity is derived from the extensive Carcinogenic Potency Database 
(CPDB) of Gold and co-workers (Gold et al., 1984, 1989; Gold and Zeiger, 1997) (see appendix A 
for details). The issue of substances with a structural alert for genotoxicity requires some further 
discussion in the context of possible wider application of the TTC approach in EFSA’s work. As 
explained earlier, this threshold value was derived by linear extrapolation from the TD50 values 
obtained from animal cancer studies. The TD50 represents a 50% tumour response in the animal 
study. However, there is no international consensus on the use of linear extrapolation from cancer 
bioassays to predict risks in humans.    
Several approaches are currently used by risk assessment bodies and regulatory agencies in various 
parts of the world to assess the risks from substances with genotoxic and carcinogenic properties. 
For carcinogenicity, since in almost all cases adequate human epidemiological data are not 
available, data from animal bioassays are used, and one approach is to use these data to extrapolate 
to the generally much lower levels to which humans are exposed. For extrapolation and 
quantitative risk assessment, several mathematical models can be used. Such models are usually 
based on the assumption that at low doses a linear relationship exists between the exposure level 
and the response for the particular endpoint. The extrapolation of data to human exposures far 
below the observable dose-range in experimental animals has resulted in differing predictions 
about human risks for the same substance, depending on the model chosen. Moreover, for any 
particular substance, it is not known whether or not the model chosen actually reflects the 
underlying biological processes.  
 
Thus the Scientific Committee has expressed serious reservations about extrapolating from data on 
animal tumours observed at high doses using mathematical modelling in order to estimate risks to 
humans at low exposures from substances that are both genotoxic and carcinogenic (EFSA, 
2005a). The Scientific Committee has recommended using a different approach for providing 
advice to risk managers, known as the margin of exposure (MOE) approach
6 (EFSA, 2005a). This 
pragmatic approach avoids generation of a numerical upper bound risk estimate. It uses both 
exposure and cancer potency data, does not require extrapolation outside the observable range in 
animal bioassays, and it can be used for priority setting (a small MOE represents a higher risk than 
a larger MOE). Although the Scientific Committee acknowledged that the magnitude of an MOE 
which is acceptable is a societal judgment and is the responsibility of risk managers, the 
                                                      
 
6 The margin of exposure is defined as the reference point on the dose-response curve (usually based on animal 
experiments in the absence of human data) divided by the estimated intake by humans.   
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Committee proposed that in general an MOE of 10,000 or higher, if it is based on the BMDL10
7 
from an animal study, would be of low concern from a public health point of view. The BMDL10 
represents a 10% tumour response in the animal study. 
 
Although the MOE approach does not generate a numerical upper bound risk estimate, it is 
possible to make an approximate comparison between the MOE approach and the TTC approach. 
For a substance with an MOE of 10,000 based  on a tumor incidence of 10%, and assuming the 
dose response is linear, the human exposure would correspond to an upper bound risk of less than 1 
in 100,000 (10
-5 risk)
8. The TTC value of 0.15 ug/day is derived by linear extrapolation down to a 1 
in a million risk (10
-6 risk). Thus, substances with an exposure below the TTC value, if they were 
to be tested and were shown to be genotoxic carcinogens, they can be expected to have MOEs of 
100,000 or more.  
The Scientific Committee has also stated (EFSA, 2005a) that as the high doses applied in 
carcinogenicity bioassays usually elicit significant toxicity with regenerative cell proliferation in 
target organs, linear extrapolation from experimental data to estimate effects at low doses may lead 
to a considerable overestimation of true incidence. The Scientific Committee in 2005 also noted 
that, based on the current understanding of cancer biology, there are levels of exposure to 
substances which are both genotoxic and carcinogenic below which cancer incidence is not 
increased (biological thresholds in dose-response). Therefore, in the opinion of the Scientific 
Committee, the approach taken to derive the TTC value for substances with a structural alert for 
genotoxicity gives a high probability of protection against carcinogenic effects.  
 
Turning to the details of the CPDB database, it is important to note that it contains data on the most 
potent carcinogens known, which have been prioritised for carcinogenicity testing, for example on 
the basis of their genotoxicity.  In the context of the TOR (see 2.2) and the TTC approach, it was 
noted at an early stage that some potent carcinogens have VSDs derived from the CPDB that are 
lower than the TOR of 1.5 μg/person per day (Munro, 1990; Cheeseman et al., 1999). Kroes et al. 
(2004) later identified that for 86 out of 730 of these substances, the VSDs were also below 0.15 
μg/person per day and that a number of them fell within certain structural groups.  The structural 
features of those groups containing the highest proportion of substances with VSDs below 0.15 
μg/person per day were identified as aflatoxin-like (5 substances), azoxy (4 substances), and N-
nitroso moieties (47 substances). Accordingly, Kroes et al. (2004) proposed that these three 
structural groups of high potency genotoxic carcinogens should be excluded from the TTC 
approach when applying the TTC value of 0.15 μg/person per day. It should be noted from the 
analysis of Kroes et al. (2004) that after exclusion of these three structural groups of high potency 
carcinogens there still remained another 30 substances with VSDs below 0.15 μg/person per day. 
These represent 4% of the entire database.  
 
An illustration of the conservatism in the TTC values was provided in a workshop in connection 
with the development of the TOR (Munro, 1990). A sub-set of the data in the CPDB at that time 
was used to estimate the conservatism of various hypothetical thresholds, making assumptions 
about the percentage of all chemicals presumed to be carcinogenic. For example, assuming that as 
much as 10% of all substances in the ‘world of chemicals’ are genotoxic carcinogens (see Fung et 
al., 1995), the probability of any untested chemical being a carcinogen with a VSD below 1.5 
μg/person per day was 4%; the corresponding percentage for the lower value of 0.15 µg/person per 
day was 1%. These estimates also make a worst-case assumption that any untested substance that 
                                                      
 
7 The BMDL10 (benchmark dose lower confidence limit 10%) can be used as a reference point on the dose-response 
curve. It represents the lower bound of a 95% confidence interval on a BMD (benchmark dose) corresponding to a 10% 
tumour incidence above the control incidence. The choice by the SC of a 10% incidence (rather than 5%) as the 
benchmark response (BMR) was based on the fact that in most cases a tumour incidence of 10% would be  the lowest 
observable  value in experimental animal studies. 
8 An exposure causing a 10%  tumour incidence is equivalent to a 1 in 10 risk. At exposure 10,000 times lower that that, 
the corresponding risk is 1 in 100,000.   
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was a carcinogen would have a potency as great as that of the 15% most potent carcinogens in the 
CPDB, which is unlikely. Thus, the Scientific Committee notes that while it is possible that an 
untested substance may have a VSD below 0.15 µg/person per day, such an outcome would have a 
very low probability. The Scientific Committee also notes that TTC values, based on linear 
extrapolation, that give a high probability of protection against carcinogenic effects would also be 
more than adequate to protect against toxic effects other than cancer. 
 
The Scientific Committee of EFSA notes that the opinion on the TTC approach that has been 
prepared (adoption is expected in 2012) by the Scientific Committees advising the European 
Commission on non-food risks (SCCS, SCHER and SCENIHR) recommends preliminary 
acceptance of the TTC  value of 0.15 µg/person per day. However, they recommend that its 
scientific basis should be strengthened  and further refined, using an extended database, allometric 
adjustment factors, and/or the T25
9 or a benchmark dose (rather than the TD50) as points of 
departure for linear extrapolation. If such an analysis is undertaken, depending on the outcome, the 
currently proposed TTC value for substances with a structural alert for genotoxicity may need to be 
reviewed. 
 
Taking all the above considerations into account, it is evident that there is conservatism in the TOR 
of 1.5 µg/person per day for substances without a structural alert for potential genotoxicity and in 
the TTC value of 0.15 µg/person per day proposed by Kroes et al. (2004) for substances with a 
structural alert for potential genotoxicity. The Scientific Committee therefore considers that there 
is a very low probability (somewhere between zero and 4%) of any appreciable cancer risk to 
human health from exposures to untested substances below the TTC value of 0.15 µg/person per 
day.  
 
Since genetic alterations include not only the possibility of cancer in somatic cells but also other 
effects, such as inherited changes that can be transmitted via germ cells, the Scientific Committee 
has also considered whether the TTC value of 0.15 μg/day would be adequate to protect against 
possible heritable effects from substances that are genotoxic. Based on the limited available 
quantitative data on chemically-induced transmissible effects,
10 the mutation frequencies that 
would be associated with a TTC value of 0.15 µg/day can be calculated by linear extrapolation. 
Data show in all cases an extremely low, or negligible, incremental risk, suggesting that the TTC 
value of 0.15 μg/day is likely to cover heritable  effects as well as cancer (see Appendix F for 
details).  
4.2.  TTC values for non-cancer endpoints 
In order to investigate the robustness of the database compiled by Munro et al. (1996), which 
comprises toxicological data on 613 substances, covering endpoints other than carcinogenicity, an 
analysis was undertaken of aspects of the database as indicated below.  
i.  A review of the information in the toxicological data sources used and the criteria 
for data inclusion. 
ii.  A summary of the types of endpoints that determined the NOELs. 
iii.  An assessment of the original published papers and reports referenced in the 
database on the substances in the lowest 10
th percentile of the distribution of 
NOELs for Cramer Class I and Cramer Class III, in order to assess the quality of 
the studies and whether the NOELs identified were appropriate.  
                                                      
 
9 The T25 represents a 25% tumour response in the animal study and is obtained by interpolation in between 2 data 
points of the dose-response data 
10 It is unlikely that much further data will be generated given the resources required to conduct tests for germ cell 
mutations.   
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4.2.1.  Appraisal of sources of toxicity data used for derivation of TTC values 
The reference database compiled by Munro et al. (1996) included data on chronic, sub-chronic, 
reproductive and developmental toxicity studies. They were mainly derived from the reports of the 
US National Toxicology Program (NTP), the toxicological monographs of JECFA, the Integrated 
Risk Information System (IRIS) of the US Environmental Protection Agency (EPA), and the 
Developmental and Reproductive Toxicology (DART) database compiled by the US National 
Library of Medicine. These sources were considered to contain well-validated toxicological data 
for well-defined chemical structures, covering pesticides, food additives, industrial and other types 
of chemical. Only studies using the oral route of administration (gavage, diet, drinking water or 
capsule) were included.  
The majority of studies in the reference database were conducted in rodents or rabbits. Studies in 
other species, such as dogs, humans and ferrets, were initially included in the reference database 
but were not included in the final published database because they did not meet the criteria for 
inclusion (e.g. duration of the study was too short). In particular, dog studies were not included in 
the final published database due to small numbers of animals and the frequency of effects such as 
reduced body weight attributable to problems such as palatability and vomiting.  
A further criterion for inclusion in the reference database was stated to be that studies should 
demonstrate a LOEL as well as a NOEL in order to ensure that a study was rigorous enough to 
detect toxic effects. However, a number of major food ingredients were also included in the 
database and these did not necessarily show toxicity, even at the highest doses tested. For such 
substances, which comprise 10% of the database, the highest dose tested was chosen as the NOEL 
in order to maintain a conservative approach.  
In all, the reference database contained 2941 NOELs from studies conducted on the 613 
substances, and from these the most conservative (lowest) NOEL for each substance was entered 
on the published database. The NOELs in the reference database were those selected by the 
original author(s) of each study, apart from the studies in the IRIS database, for which the NOELs 
selected by the EPA were used. Munro et al. (1996) commented that some authors were highly 
conservative in their selection of a NOEL, but such NOELs were still used for the database to 
maintain a conservative approach. Munro et al. (1996) also stated that in the calculation of the TTC 
values they divided NOELs from sub-chronic studies by a factor of 3 to approximate the NOELs 
that are likely to be derived from a chronic study. This applies to 229 out of the 613 substances in 
the database. It should be noted that the NOEL values listed in the Appendix in Munro et al. (1996) 
are not adjusted in this way, but adjusted values were used for plotting the distributions of NOELs 
from which the TTC values are derived. 
4.2.2.  Endpoints determining the NOELs 
The information contained in the Appendix to Munro et al. (1996) on the 613 substances in the 
published database was examined to ascertain the type of toxicological endpoint on which the 
overall NOEL for each substance was based, according to the study authors. The results are 
summarised in Table 3. Among the 613 overall NOELs, multiple effects (which were not otherwise 
specified by Munro et al., 1996) were reported as the most frequent endpoint (28 %), followed by 
body weight changes (18 %) and organ weight changes (9 %). Reproductive, hepatic and renal 
effects were the next most frequent endpoints.  
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Table 3: Reported toxicological endpoints for the NOELs for the 613 substances as described in the 
database of Munro et al. (1996), separated according to Cramer structural class. 
Endpoint  Class I  Class II  Class III  Sum 
Blood effects   3    24  27 
Body weight changes  15  4  89  108 
Cardiovascular effects        0 
Endocrine     4  4 
Food consumption  4    2  6 
Gastrointestinal 3  1  6  10 
Lethal 2  2  9  13 
Hepatic   1    28  29 
Immunotoxic      0 
Musculo-skeletal 2    1  3 
Multiple effects  31  3  136  170 
Neurological   1    10  11 
No effects  47  7  7  61 
Non-specific effects    1  12  13 
Ocular     1  1 
Ovarian     2  2 
Organ weight changes  11  3  42  56 
Pulmonary     1    1 
Renal   7  2  18  27 
Reproductive   5  2  38  45 
Spleen     5  5 
Teratogenic 4  2  10  16 
Testicular   1    4  5 
Sum  137  28  448  613 
 
The purpose of the present analysis of endpoints was to obtain an overview of which ones most 
frequently drove the pivotal  NOEL and whether all the major toxicological endpoints were at least 
represented in the database. The fact that some endpoints drive NOELs more frequently than others 
reflects the outcome of the analysis, which generally included more than one study on each 
substance. It should be noted that the majority of the studies examined multiple endpoints and 
some endpoints are more frequently affected at the LOEL than others. 
None of the NOELs were based on cardiovascular or immunotoxic effects. The absence of 
cardiovascular effects is likely to reflect the low frequency of such effects as the critical endpoint 
for chemicals other than pharmaceuticals, and the fact that very few studies in dogs, which would 
have been more likely to detect cardiovascular effects, were included in the final published 
database. The absence of immunotoxic effects as a critical endpoint may reflect both the 
comparatively limited attention paid to this endpoint until recent years as well as the low frequency 
with which they are identified as the most sensitive effect for substances showing other toxicities. 
In none of the rat and rabbit studies was immunotoxicity identified as the critical endpoint 
determining the NOEL. The Scientific Committee notes that immunotoxicity was later evaluated 
by Kroes et al. (2000) using other studies and that the NOELs were not lower than those for 
Cramer Class III substances (see 4.3.1). 
In view of the importance of the endpoints of endocrine activity, reproductive toxicity, 
developmental toxicity and neurotoxicity in relation to TTC values, these are addressed in more 
detail later (see chapter 4.3).   
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4.2.3.  Assessment of original papers and reports on substances in the lowest 10th 
percentile of the NOEL distribution 
4.2.3.1.  Cramer Class I substances 
The values for the NOELs for all the substances in each of Cramer Class I and Cramer Class III 
were scrutinised and the substances falling below and around the lowest 10
th percentile
11 of the 
two distributions of NOELs were identified. For these substances, an attempt was made to assess 
the quality of the critical studies and verify the NOEL values. The lowest 10
th percentile was 
chosen because it includes the substances that determine the TTC values for the respective classes 
(Munro et al. 1996 derived TTC values by dividing the 5
th percentile NOEL by a factor of 100). 
Any discrepancies in the numerically higher NOELs of the remaining substances above the 10
th 
percentile would have to be substantial to have any impact on the TTC value.  
From a total of 137 substances classified in Cramer Class I by Munro et al. (1996), 16 substances   
below and around the lowest 10
th percentile of the distribution of NOELs were examined.  Their 
identity together with the respective NOEL value and critical endpoint(s) determining the NOEL 
are shown in Appendix C, Table 1. The respective NOEL and cited source were retrieved from 
Munro et al. (1996). The detailed reasons for non-confirmation of NOELs can be found in 
Appendix C. Where possible, the original reference for each substance was obtained and reviewed 
to reach an independent view on its quality and the NOEL. A full search for more recent studies on 
the 16 substances in Class I (and thus possibly different NOELs) was not performed. 
The original papers or reports on the critical studies could only be obtained for 8 of the 16 
substances. Thus, the quality of the remaining 8 studies could not be fully assessed. However, the 
Scientific Committee notes that, given the source of these studies (see 4.2.1), the original study 
reports will have been scrutinised by national or international risk assessment or regulatory bodies 
(i.e. NTP, EPA, JECFA). For 6 of the 8 studies not available to the Scientific Committee in 
original form, descriptions of the studies were available from JECFA monographs, most of which 
identified a NOEL. The other 2 studies were published only as abstracts. 
The NOELs used by Munro et al. (1996) were verified, or were judged to be very conservative, for 
14 of the 16 substances, when compared with the original study report or JECFA descriptions. In 
the case of the remaining 2 substances, the findings were as follows: for ethyl acrylate the NOEL 
identified by Munro et al. (1996) was only slightly higher (by less than one order of magnitude) 
than the NOEL identified during this evaluation; for 2-phenyl-1-propanol, (listed as Phenyl-1-
propanol, 2- in Munro et al., 1996) a NOEL could not be identified in this evaluation as effects on 
body weight were reported at the lowest dose tested.  
For retinol, although the correct NOEL was identified by Munro et al. (1996) from the 1989 study 
cited on the teratogenic effects of a single dose in pregnant mice, it should be noted that other data 
available at that time indicated that the NOEL for teratogenicity in the rabbit was lower, by around 
an order of magnitude (Rosa et al., 1986).   
The impact that any adjustments to NOELs might have on the TTC value for Class I substances is 
difficult to predict from the limited analysis undertaken here. Discarding some of the overly 
conservative NOELs might move the 5
th percentile NOEL upwards. On the other hand, taking 
account of lower NOELs, including any derived from a scrutiny of more recent data on the same 
substances, might move the 5
th percentile NOEL downwards. Ideally, such an exercise would be 
done on the entire group of Class I substances. However, based on the present analysis of the 
lowest 10
th percentile of substances, it does appear that the Munro et al. (1996) dataset provides a 
generally conservative estimate of Class I NOELs. 
                                                      
 
11 The number selected is slightly different from the exact 10
th percentile because of ties in the ranks of the NOELs.   
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The Scientific Committee also considered the selection of the 5
th percentile NOEL value for 
derivation of the TTC value for Cramer Class I substances. The Committee noted that the 5
th 
percentile NOEL for Cramer Class I is 3 mg/kg bw per day and that the NOELs below this value 
ranged down to 0.5 mg/kg bw per day (excluding the outlier isopropyl alcohol – see appendix C). 
The application of the 100 fold uncertainty factor to the 5
th percentile NOEL results in a TTC value 
that is approximately 17-fold lower than the lowest NOEL value in Munro et al. (1996) database. 
Thus, the lowest NOEL value in the distribution is covered. 
The Scientific Committee notes that the use of the 5
th percentile NOEL and an uncertainty factor of 
100 to derive the TTC value gives a very low probability (somewhere between zero and 5%) of 
any appreciable non-cancer risk to human health from exposures to substances below the Cramer 
Class I TTC value of 1.8 mg/person per day. 
4.2.3.2.  Cramer Class III substances  
From a total of 448 substances classified in Cramer Class III by Munro et al. (1996), 50 substances 
below and around the lowest 10
th percentile of the distribution of NOELs were examined. Their 
identity and respective NOEL values and the critical endpoint(s) determining the NOEL are shown 
in Appendix C, Table 2. The respective NOEL and cited source were retrieved from the Munro et 
al. publication. Almost all substances could be identified from the information provided, but in a 
few cases the name of the substance given was not entirely consistent with the CAS number (e.g. 
ivermectin), and in one or two cases the CAS number was incorrect or in doubt (trenbolone acetate 
and 17 α-hydroxytrenbolone). 
 
In the majority of cases, the cited source was a company report, which had been cited in IRIS and 
was not retrievable, but again the Scientific Committee notes that the original study reports will 
have been scrutinised by national or international risk assessment or regulatory bodies. The NOEL 
was checked to determine whether (a) it was the critical NOEL for the study cited, and (b) still 
considered the critical NOEL for the compound, given more recent evaluations, such as by EFSA, 
JMPR and EPA. It should be noted that this comparison with more recent data was conducted for 
Class III substances but not for Class I substances  because more recent studies for  Class III were 
readily available and the issue was regarded as more critical for Class III substances, which are 
defined as suspect for toxicity, than for class I substances. Moreover, in the application of the 
Cramer classification scheme, the majority of substances fall into Cramer Class III. 
 
In general, the NOEL provided by Munro et al. (1996) was the critical NOEL for the cited study, 
and was numerically correct. In a few instances, a lower NOEL could have been selected (e.g. 
heptachlor using a different study) or a higher NOEL could have been used, for example because 
two studies were available and a combined NOEL could have been obtained (e.g. cypermethrin and 
avermectin B1). In some cases, the NOEL appears to be slightly lower than that cited (e.g. 
coumaphos, 22,23-dihydroavermectin-B1a - and B1b (ivermectin) and disulfoton). In one case 
(zeranol) the JECFA summary does not reflect the ovarian toxicity used by Munro et al. (1996). 
The reasons for this are not apparent from the paper. 
 
Using current databases and risk assessment criteria, many of the NOELs cited by Munro et al. 
(1996) would no longer be considered the pivotal NOELs. For example, some endpoints are no 
longer considered relevant to humans, particularly benign adaptive hepatic hypertrophy (e.g. 
dieldrin). A major difference is in the assessment of cholinesterase inhibitors. Less weight is now 
placed on inhibition of plasma cholinesterase. On the other hand, for a number of such compounds, 
the current NOELs are lower than those given in Munro et al. (1996) (e.g. aldicarb, dichlorvos and 
fonofos). In the case of acrylamide, this is now considered to be a genotoxic carcinogen, and 
therefore in retrospect should not have been included in the Munro et al. database.  
 
Overall, the NOELs analysed here (the lowest 10th percentile as these are likely to be the ones 
where changes would have the biggest impact on the calculation of the TTC) compared with those   
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cited by Munro et al. (1996) are generally the same or higher, other than for some 
organophosphates. Thus, from this analysis, the Munro et al. database does appear to provide a 
conservative assessment for Class III substances, other than for the cholinesterase inhibitors. The 
case for re-evaluating cholinesterase inhibitors, using the most recent data available, is discussed in 
section 4.3.2. 
 
The Scientific Committee also considered the selection of the 5
th percentile NOEL value for 
derivation of the TTC value for Cramer Class III substances. The Committee noted that the 5
th 
percentile NOEL for Cramer Class III is 0.15 mg/kg bw per day and that the NOELs below this 
value ranged down to 0.005 mg/kg bw per day. The application of the 100-fold uncertainty factor 
to the 5
th percentile NOEL results in a TTC value that is approximately 3-fold lower than the 
lowest NOEL value in Munro et al. (1996) database. Thus, the lowest NOEL value in the 
distribution is covered.  
The Scientific Committee notes that the use of the 5
th percentile NOEL and an uncertainty factor of 
100 to derive the TTC value gives a very low probability (somewhere between zero and 5%) of 
any appreciable non-cancer risk to human health from exposures to substances below the Cramer 
Class III TTC value of 0.09 mg/person per day. 
4.2.3.3.  Cramer Class II substances 
Using the Cramer decision tree, in general very few chemicals become assigned to Class II (Munro 
et al, 1996; Tluczkiewicz et al., 2011; Kalkhof et al., 2011).  The reason for this is the absence of 
clear structural indicators of chemicals that have intermediary toxicological properties. Thus the 
TTC value for this class is not well supported. Moreover, the extended databases do not enable a 
significantly improved scientific basis for the assignment of chemicals to Cramer Class II,  and the 
practical utility of retaining this class for the world of chemicals in general  is very limited. The 
Scientific Committee considers that consideration should be given to treating substances that 
would be classified in Cramer Class II under the Cramer decision tree as if they were Cramer Class 
III substances.  It is recognised however that it could be useful for some specific groups of 
chemicals, such as flavourings for which a significant number can be assigned to Cramer Class II. 
4.2.3.4.  Comparison of Munro et al. TTC values with subsequent published data 
An independent dataset has been utilised (Kalkhof, 2010; Kalkhof et al., 2012) to evaluate the 
TTC-values derived from the database of Munro et al. (1996). The dataset comprises 861 new 
industrial chemicals registered in Europe between 1982 and 2008 selected from the European List 
of Notified Chemical Substances (ELINCS) because they have been tested in subacute or 
subchronic studies. This dataset has no overlap with the database of Munro et al, (1996). The full 
ELINCS database is available to European Competent Authorities. The analysis was based on the 
results of 28-day subacute tests conducted according to OECD TG 407 on 776 chemicals. Another 
85 chemicals were tested according to OECD TG 408 in 90-day studies. The NOAELs
12 were 
adjusted by the authors to obtain estimated chronic NOAEL values by using a scaling factor of 6 
for the results of the 28-day studies and a scaling factor of 2 for the results of the 90-day studies (as 
recommended in the following publications: ECETOC 1995; ECHA 2008; Kalberlah & Schneider, 
1998). The results of this analysis are shown in Table 4 below. Cramer Class II is not included 
since very few substances were classified in that class. It can be seen that the results of this study, 
while limited because of the lack of chronic studies for industrial chemicals, support the TTC 
values derived by Munro et al. (1996). 
 
                                                      
 
12 In this opinion, the terms NOAEL (No-Observed-Adverse-Effect Level) and NOEL (No-Observed-Effect Level) are 
both used, depending on the term that the original authors used in the literature cited. Sometimes the term NOAEL is 
used to distinguish between any observed effect and an observed effect interpreted as adverse, but often they are used 
interchangeably.   
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Table 4: Comparison of Munro et al. (1996) 5
th percentile NOELs with NOELs derived from an EU 
database on industrial chemicals (ELINCS), adjusted for study duration. 
 
Database 5
th percentile NOEL (mg/kg bw per day) 
Cramer class I  Cramer Class III 
Munro et al. 
 
3.0 0.15 
ELINCS 28-day  
 
ELINCS 90-day 
 
1.7 (65*) 
 
12.5 (9*) 
0.8 (691*) 
 
0.8  (76*) 
        *Number of chemicals  
 
Tluczkiewicz et al., published in 2011 results from a combined oral dataset called the TTC 
RepDose database. This database comprises oral repeated-dose toxicity studies taken from the 
originalRepDose database (developed at the Fraunhofer ITEM Institute in Germany; Bitsch et al., 
2006), the Munro et al. (1996) database, the US EPA ToxRef database, and the ToxBase database 
from TNO, Netherlands. It does not include reproductive or developmental studies. The TTC 
RepDose database contains subacute, subchronic and chronic studies in rats and mice on 521 
substances, of which 197 were extracted from the original RepDose database, 124 from the Munro 
et al. database, 30 from the ToxBase database and 170 from the ToxRef database. The majority of 
the substances in the TTC RepDose database are classified in Cramer Class III (77%), with around 
21% in Cramer Class I, and only 2% in Cramer Class II.  The Munro et al. (1996) database 
contains similar percentages: 75% of the substances were allocated to Cramer class I, 22% to 
Cramer class III, and only 1. 4% to Cramer class II. The initial comparison of 5
th percentiles was 
done on a mmol/kg bw per day basis, which was then converted to TTC values in μg/person per 
day. The results are shown in Table 5. The TTC values derived from this combined database are 
similar to those derived by Munro et al. (1996). 
 
Table 5: Comparison of TTC values from TTC RepDose database (Tluczkiewicz et al., 2011) 
and Munro et al. database (1996) 
 
Database  TTC values (μg/person per day) 
Cramer class I  Cramer Class III 
Munro et al. 
 
 1800   90 
TTC RepDose 
 
1930 (109 *)  74 (400 *) 
           *Number of chemicals  
 
The conservative nature of the TTC values is also supported by an evaluation (Pinalli et al., 2011) 
of a dataset of 232 substances used in plastic food contact materials (FCMs), which have been 
evaluated by EFSA or by the former Scientific Committee on Food, and which have been allocated 
a Tolerable Daily Intake (TDI) based on oral toxicity data. Pinalli et al. (2011) back-calculated 
“noels” for these substances by multiplying the TDIs by the normally used uncertainty factor of 
100 and then added these noel values to the Munro et al. (1996) dataset to form an extended 
dataset. For both Cramer Class I and Cramer Class III substances the noels for FCMs were all 
higher than the lowest NOELs in the respective classes in the Munro et al. (1996) dataset. For the 
extended dataset, the authors then determined the ratios between the TDIs (i.e. Munro NOELs or 
FCM noels divided by 100) and the relevant TTC values to identify for which substances the TTC 
approach would be less severe than the TDI. The TTC approach was found to be more 
conservative for 96% of the 845 substances included in the extended dataset. The chemical 
structures of the 35 substances for which the TTC approach was less conservative than the TDI 
were examined. For all but 9 of these 35 substances, known limitations for using the TTC approach 
were recognised (Pinalli et al., 2011).    
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4.3.  Adequacy of TTC value in protecting against specific endpoints 
4.3.1.  Previous evaluations of endpoints of specific concern 
The TTC concept and the TOR approach for food contact materials were discussed by the EC 
Scientific Committee for Food in 1996 and one of the issues raised was whether, for certain 
endpoints of specific concern, toxic effects might occur at low dose levels which would not be 
covered by the human exposure thresholds derived by Munro et al. (1996). In particular, concerns 
were raised about whether effects on the nervous system, immune system, endocrine system and 
development would be absent at the human exposure threshold values (SCF, 1998). Although the 
original database published by Munro et al. in 1996 did include some studies measuring these 
endpoints of specific concern, they were insufficient in number to provide a robust answer to the 
question of potential low-dose effects.  
An Expert Group was therefore set up by ILSI Europe to examine this question in more detail 
(Kroes et al., 2000). Expanded databases were developed for the toxicological endpoints of 
neurotoxicity (82 substances), immunotoxicity (37 substances), developmental neurotoxicity (52 
substances) and developmental toxicity (81 substances). They were analysed to see if toxic effects 
involving these endpoints occurred at lower doses than those for structural Cramer Class III 
substances in the original database of Munro et al. (1996). The analysis showed there was no 
difference between the cumulative distributions of NOELs for Cramer Class III substances and 
those for the four selected endpoints, other than for neurotoxicity. The cumulative distribution of 
NOELs for neurotoxicity was not only lower than those of the other selected endpoints, but it was 
also clearly lower than that for structural Cramer Class III substances. Consistent with the earlier 
findings of Cheeseman et al. (1999), the TTC value of 1.5 μg/person per day, based on cancer 
endpoints, covered all these effects, being 2-3 orders of magnitude lower than the neurotoxicity 
NOELs divided by an uncertainty factor of 100.  
Subsequently Kroes et al. (2004) further explored whether particular neurotoxicants should be 
considered as a separate class. Using the expanded database from the earlier work (Kroes et al., 
2000) and locating the most sensitive indicators of effects that they could find, the NOELs for the 
most potent neurotoxicants, the organophosphorus compounds (OPs), were plotted separately from 
the other neurotoxicants. They noted that the 5
th percentile NOEL for OPs was lower, by around an 
order of magnitude, than the corresponding 5
th percentile NOEL for other neurotoxicants. The 
other neurotoxicants resulted in a plot comparable to the Cramer Class III chemicals examined by 
Munro et al. (1996). By applying an uncertainty factor of 100 to the 5
th percentile NOEL for OPs, 
Kroes et al. (2004) derived a human exposure threshold of 18 μg/person per day (Table 6) and 
recommended that this figure be used for OPs rather than the value of 90 μg/person per day used 
for other substances in structural Class III. 
   Table 6: Human exposure threshold value for organophosphates from Kroes et al., 2004. 
 
Structural class  Fifth percentile NOEL 
(mg/kg bw per day) 
Human exposure threshold 
(μg/person per day) 
 
Organophosphates 
 
 
0.03 
 
18 
 
4.3.2.     Anti-cholinesterase-related neurotoxicity endpoints  
The Scientific Committee investigated whether the proposed TTC value for OPs of 18 µg/person 
per day (corresponding to 0.0003 mg/kg bw per day) adequately covers neurotoxic effects of 
substances with anti-cholinesterase (AChE) activity, including their acute effects. An analysis was 
undertaken using the comprehensive EFSA internal database on pesticides. Article 41 of 
Regulation (EC) 369/2005 on maximum residue levels requires EFSA to develop, maintain and 
continuously update a database containing toxicological reference values, i.e. Acute Reference 
Doses (ARfDs) and Acceptable Daily Intakes (ADIs) for active substances in pesticides for which   
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Maximum Residue Levels (MRLs) have been established. Listed are reference values established 
by the European Commission (COM), the Joint FAO/WHO Meeting on Pesticide Residues 
(JMPR), European Member States, the European Community Co-ordination Peer Review Meetings 
(ECCO), and EFSA and its Pesticide Risk Assessment Peer Review Unit (PRAPeR). For a number 
of active substances, more than one ADI/ARfD is listed in the EFSA database because of the 
several different bodies involved in the setting of reference values.  Notably, this pesticide database 
also contains a significant number of active substances belonging to the chemical classes of OPs 
and carbamates, which cause inhibition of AChE, a mechanism leading to neurotoxicity at low 
doses, and consequently also to establishment of low ADIs. 
 
In order to investigate if and to what extent the ADIs of highly potent neurotoxic substances (i.e. 
AChE inhibitors) are lower than the proposed TTC value for OPs, the ADIs of all OPs and 
carbamate pesticides in the database (status as of 6
th May 2010) were extracted and compared with 
the proposed TTC value of 18 μg/person per day (equivalent to 0.3 μg/kg bw per day). 
 
The ADIs for OPs and carbamates that are listed in the database are shown in Table 1 in Appendix 
D. From Table 1, Appendix D, substances with ADIs at or below the proposed TTC value for OPs 
were extracted and are listed in Table 2 of Appendix D.  
 
In summary, for 59 OPs and 14 carbamates, 93 and 27 ADIs have been retrieved, respectively. Out 
of the 93 ADIs established for OPs, 83 were above the proposed TTC value, 7 were at the proposed 
TTC value, and only 3 were below the proposed TTC value (i.e. the ADIs for diazinon, mevinphos 
and prothiofos). For the 14 carbamates, only one ADI was below the proposed TTC value (i.e. one 
out of the 3 ADIs for carbofuran
13). Given that the TTC concept is based on a probabilistic 
approach, the present analysis on OP and carbamate ADIs supports the validity of the proposed 
TTC value for inhibitors of AChE of 18 µg/person per day (equivalent to 0.0003 mg/kg bw/day) 
and establishes that it can be applied to both OPs and carbamates. Although some of the critical 
effects listed in Table 2, Appendix D, cannot be definitely attributed to neurotoxicity, critical 
effects on brain AChE are included and this analysis shows that the TTC of 18 μg/person per day 
would be protective.  
4.3.3.  Reproductive and developmental toxicity  
Reproductive toxicity deserves specific consideration in the context of the TTC concept as it has 
unique features as compared to other forms of toxicity. Infertility and birth defects are  severe 
adverse effects that may require dedicated preventive measures. In the REACH legislation, 
chemicals with reproductive toxicity are grouped with those chemicals resulting in carcinogenesis 
and mutagenesis in needing specific restriction and authorisation. Reproductive toxicity can be 
expressed in many different manifestations dependent on the nature, timing, duration, and 
magnitude of exposure relative to the phase of the reproductive cycle and has many different 
underlying mechanisms. It is therefore difficult to group reproductive toxicants in a single analysis. 
One analysis has combined developmental toxicants based on published literature of in vivo 
reproductive and developmental toxicity studies (Kroes et al., 2004). It was concluded from that 
analysis, albeit limited, that more stringent TTC values than those applied for non-cancer endpoints 
would not be necessary to protect against reproductive and developmental toxicity. Subsequent 
analyses on 91 substances assessed under the EU existing chemicals programme (Bernauer et al., 
2008), 93 industrial chemicals  (van Ravenzwaay et al., 2011), and 283 chemicals (Laufersweiler et 
al., 2012) came to similar conclusions. 
 
The approach followed here by the Scientific Committee was to analyse the applicability of the 
TTC concept for those substances carrying an EU classification for reproductive and/or 
                                                      
 
13 There are 3 ADIs listed for carbofuran: one set by the EU in 2006 based on a 1-year dog study, one set by JMPR in 
2008 based on acute toxicity in the rat, and one set by the EU in 2009 based on acute neurotoxicity in the rat.    
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developmental toxicity. Substances classified according to Directive 67/548/EEC by the European 
Union for developmental toxicity (category 1, 2 or 3) or effects on sexual function and fertility 
(category 1, 2 or 3) were selected. The analysis was performed on 85 developmental toxicants 
(chemicals classified with EU risk phrases R61
14 or R63
15) and 54 fertility toxicants (chemicals 
classified with EU risk phrases R60
16 or R62
17). Using the Toxtree software version 2.1.0   
(http://ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?c=TOXTREE) to generate Cramer 
classifications (by the classical Cramer scheme), it was found that the majority of chemicals were 
placed in Cramer Class III, followed by Cramer Class I. Very few chemicals were classified into 
Cramer Class II. In the case of the developmental toxicity dataset, the breakdown of chemicals by 
Cramer class was:  71 Cramer Class III, 1 Cramer Class II and 13 Cramer Class I. In the case of the 
fertility toxicity dataset, the breakdown was: 43 Cramer Class III, 3 Cramer Class II and 8 Cramer 
Class I.  
 
Chemicals from the developmental and fertility datasets were merged (102 reproductive toxicants) 
and divided into two subsets of chemicals, classified into Cramer Class I or Cramer Class III, and 
the NOEL value distributions were analysed. Since the 5
th percentiles of the NOEL distributions 
for the Cramer Class I and Cramer Class III subsets in this analysis (Table 7) are higher than the 
corresponding 5
th percentile values for Cramer Class I and Cramer Class III calculated by Munro et 
al. (1996), it can be concluded that the TTC values derived by Munro et al. (1996) are protective 
for developmental and fertility effects. The Scientific Committee is aware that there is likely to be 
overlap in the dataset used in the analysis above and those of Bernauer et al. (2008) and van 
Ravenzwaay et al. (2011). This analysis supports the conclusions of the previous studies referred to 
above.    
 
 
Table 7. Cumulative distribution analysis of a dataset of substances classified on the basis of 
developmental and fertility toxicity.  
 
 
 
 
 
 
 
 
Data provided by RIVM (Muller et al., 2012) 
 
4.3.4.  Endocrine-mediated toxicity 
Consideration of the situation with regard to substances that may have endocrine-mediated toxicity 
is important since some have concluded that the TTC approach might not be applicable to such 
substances due to uncertainty about low-dose effects (Kroes et al., 2004). Kroes et al. (2004) and 
Cheeseman et al. (1999) also identified steroids as a group that includes some potent carcinogens. 
For humans, concerns in this area include reproductive organ development, reproductive function 
and effects on the hypothalamic-pituitary-thyroid axis. Also, the possibility of effects on 
glucocorticoids, insulin and neuroendocrine systems has to be considered. The adequacy of hazard 
assessment methods for detection of endocrine-mediated toxicity has been an issue of extensive 
                                                      
 
14 May cause harm to the unborn child. 
15 Possible risk of harm to the unborn child. 
16 May impair fertility. 
17 Possible risk of impaired fertility. 
18 Some substances have been classified both for fertility and developmental endpoints. 
 Structural 
Cramer 
Class 
No. of chemicals 
(developmental + 
fertility NOEL)
18 
Calculated 5
th 
percentile 
NOELs  derived 
in this analysis 
(µg/kg bw/day)  
5
th percentile 
NOELs from Munro 
et al. (1996) 
(µg/kg bw/day) 
 
Class I  15  3840  3000 
Class II  4     
Class III  83  550  150   
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debate in the scientific community, while the relevance of findings from in vitro and animal studies 
for human hazard and risk assessment of endocrine-active substances is currently being discussed 
extensively in the scientific community (see, for example, EFSA, 2010b). These discussions 
involve, inter alia, issues of potency, adversity and the influence of homeostatic mechanisms at 
low exposures. 
Intensive discussions are also taking place within the European Union under the aegis of the 
Community Strategy for Endocrine Disrupters
19, which is addressing the key requirements of 
further research, international co-operation, communication to the public, and appropriate policy 
action. A draft of the measures concerning specific scientific criteria for the determination of 
endocrine disrupting properties in relation to human health impacts is anticipated to be ready by 
the end of 2013. These measures are required, in particular, for the legislation governing REACH
20 
and the Plant Protection Products Regulation
21, but the intention is to develop a systematic 
approach for the identification and assessment of endocrine disruptors which can be applied across 
the different pieces of EU legislation. The general concept should be consistent and should ensure 
that endocrine disruptors are dealt with in a consistent and co-ordinated manner across the EU (EC, 
2011). 
The OECD has also been very active in this area since 1997 (see, for example, OECD, 2010b, 
2011). OECD has developed a conceptual framework for testing and assessment of endocrine 
disrupting chemicals, adopted new and updated test guidelines for identifying chemicals with 
endocrine activity/disrupting properties, prepared guidance documents on assessment of chemicals 
for endocrine disruption, and detailed review papers on endpoints for detection of endocrine 
disruptors. This work is ongoing through its Endocrine Disruptor Testing and Assessment 
Advisory Group (EDTA-AG), including a review of the conceptual framework. The European 
Commission's future work will take into account the ongoing international initiatives and in 
particular the work of the OECD and WHO/IPCS/UNEP (EC, 2011). 
 
With respect to the TTC approach, the Scientific Committee notes that the Munro et al. (1996) 
database underpinning the approach contains apical studies that have assessed some toxicity 
endpoints (e.g. reproductive and endocrine organ pathology, reproductive function and embryo-
fetal development) that can be affected adversely by substances with an endocrine mode of action. 
The previous section (4.3.3) also offers an analysis of TTC values in relation to currently 
established NOELs for reproductive and developmental toxicity, based on standard testing 
protocols used in the past, and the data so far indicate that the TTC values are adequately 
protective for the types of adverse effect that such studies can detect.  
In the light of the above considerations, the Scientific Committee recommends that if there are data 
showing that a substance has endocrine activity, but the relevance of the observation for humans  is 
unclear, then these data should be taken into consideration, case-by-case, in deciding whether or 
not to apply the TTC approach. If there are data showing that a substance has endocrine-mediated 
adverse effects, then, as would be the case for adverse data on any other endpoint, the risk 
assessment should be based on the data. .  
                                                      
 
19 Communication from the Commission to the Council and the European Parliament-Community Strategy for Endocrine 
Disrupters. COM (1999) 706 final 
20 Regulation (EC) No 1907/2006 of the European Parliament and the Council of 18 December 2006 concerning the 
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). OJ l 396, Vol 49. 30.12.2006, p1 
21 Regulation (EC) No 1107/2009 of the European Parliament and the Council of 21 October 2009concerning the placing 
of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. OJ l 309, Vol 
52, 24.11.2009, p1   
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However, in most situations where the TTC approach might be applied, there would be no a priori 
knowledge that a substance has endocrine activity. A clear exception to this is steroid structures
22, 
for which it is known that some have potent endocrine activity leading to adverse effects, including 
cancer. The Scientific Committee therefore recommends that untested steroid structures should not 
be put through the TTC approach.  
In view of the extensive work, currently ongoing, to develop an EU-wide approach for defining 
and assessing endocrine disrupters
23 , once that approach is finalised it will be necessary to 
consider any impact it may have on the use of TTC approach. In the meantime, the Scientific 
Committee recommends that untested substances, other than steroids, can be evaluated using the 
TTC approach recommended in this opinion.   
4.4.  Substances currently not suitable for the TTC approach 
 
It is necessary to consider whether it may not be appropriate to apply the TTC approach to certain 
categories of substances. Several categories for exclusion have already been identified by Cramer 
et al. (1978) and Kroes et al. (2004) as indicated below. 
4.4.1.  Categories previously recommended for exclusion by others  
4.4.1.1.  High potency carcinogens 
Kroes et al. (2004) recommended that the TTC approach should not be applied to aflatoxin-like, 
azoxy- or N-nitroso-compounds. This is because for these substances the upper bound lifetime risk 
for cancer was estimated to be greater than one in a million even at an exposure of 0.15 µg/day (the 
TTC value for substances with a structural alert for genotoxicity). 
4.4.1.2.  Metals 
There is a wealth of information in both animals and humans on the toxicity of many of the heavy 
metals, such as arsenic, cadmium, lead and mercury. In addition, metals are not represented in the 
Cramer et al. (1978) decision tree on the three structural classes, nor are they represented in the 
toxicity database of Munro et al. (1996). Some metals, such as cadmium and lead, also 
bioaccumulate. For these reasons it was recommended by Kroes et al. (2004) that the TTC 
approach should not normally be applied to non-essential metals in elemental, ionic or 
organometallic forms. 
4.4.1.3.  Polymers 
Cramer et al. (1978) recommended that polymers should be excluded because they are not 
structurally defined in terms of chain length, molecular weight and cross-linking.  
4.4.1.4.  Certain substances that bioaccumulate 
Kroes et al. (2004) recommended that substances with extremely long half-lives that show very 
large species differences in the extent of bioaccumulation, such as TCDD and its structural 
analogues should be excluded. In their decision tree, they specifically excluded polyhalogenated-
dibenzodioxins, -dibenzofurans and -biphenyls. 
                                                      
 
22 A steroid is a type of organic compound, either natural or synthetic, containing a characteristic arrangement of 17 
carbon atoms in four cycloalkane rings that are joined to each other, including three cyclohexane rings and one 
cyclopentane ring. Steroids vary by the functional groups attached to this four-ring core and by the oxidation state of the 
rings. 
23 See footnote 19   
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4.4.1.5.  Inorganic substances 
Inorganic substances should be excluded as they are not represented in the Cramer et al. (1978) 
decision tree on the three structural classes, nor are they represented in the toxicity database of 
Munro et al. (1996).  
4.4.1.6.  Proteins 
Proteins were recommended for exclusion by Kroes et al. (2004) because of the possibility of 
allergenicity at low exposures. In their view, a specific TTC value would need to be developed to 
cover the endpoint of allergenicity once sufficient low-dose response data were available. Proteins 
were not included in the Munro et al. (1996) database, although proteins that are common 
components of food would be classified as Class I or Class II substances under the structural 
decision tree of Cramer et al. (1978).  
4.4.1.7.  Substances with endocrine activity 
Kroes et al. (2004) considered that there were a number of important uncertainties surrounding 
low-dose effects of substances with endocrine activity and, by implication, the TTC approach 
should not be applied to a substance known to have such activity.  
4.4.2.  EFSA considerations of categories previously recommended for exclusion  
The Scientific Committee agrees that the categories mentioned in 4.4.1. above are not suitable for 
the TTC approach. In addition, the Scientific Committee recommends some further exclusions as 
indicated below. 
4.4.2.1.  High potency carcinogens 
Kroes et al. (2004) also identified some benzidines, hydrazines and steroids as high potency 
carcinogens but did not recommend these specific groups for exclusion. The Scientific Committee 
recommends  that these three groups of substances should also be excluded from the TTC approach 
in order to ensure a conservative approach is maintained. 
4.4.2.2.  Metals 
The Scientific Committee also is of the opinion that, metals in elemental, ionic or organic form are 
generally to be excluded from the TTC approach (see 4.4.1.2.). However, in the case of organic 
salts, where the counter ion is an essential metal (e.g. sodium) and therefore not requiring 
evaluation by the TTC approach, the Scientific Committee recommends that the TTC approach 
could be applied to the organic ion.  
4.4.2.3.  Polymers 
The Scientific Committee notes that EFSA currently uses toxicity data on monomers to support the 
evaluation of polymers and oligomers. 
4.4.2.4.  Substances with a potential for bioaccumulation 
The Scientific Committee also agrees that substances with a potential for bioaccumulation
24 are not 
suitable for the TTC approach. Thus, in considering whether to apply the TTC approach it would 
be important to assess the potential for bioaccumulation using any available information on 
properties that are associated with bioaccumulation.  
                                                      
 
24 Bioaccumulation refers to the increasing retention of a chemical by an organism over time, in comparison with the 
concentration in the environmental media to which the organism is exposed (air, water, soil, food, etc.) 
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The majority of the substances studied for bioaccumulation have been either polyhalogenated 
aromatic compounds or metals. Only a limited number of polyhalogenated hydrocarbons are in the 
databases that underpin the TTC approach. The correlation between bioaccumulation and 
toxic/carcinogenic potency is neither straightforward nor consistent. Because of their 
bioaccumulation, the impact of the daily exposure giving rise to an increased risk of cancer can be 
significantly underestimated. However, most of the polyhalogenated hydrocarbons are not 
genotoxic.  
 
The potential of a substance to bioaccumulate can be predicted by using computational methods 
such as QSARs (based on structural and physicochemical properties only) or physiologically-based 
biokinetic (PBBK) models (which also take into account physiological parameters). Structural and 
physicochemical properties of substances that facilitate bioaccumulation, and which have been 
found useful for predictive purposes, include:  
a) the octanol-water partition coefficient, reflecting the tendency to be retained in the body 
due to concentration in tissues such as adipose tissue, and/or the tendency for re-
absorption,  
b) steric hindrance of metabolism, and  
c) stability of chemical bonds. 
 
Most currently available models predict bioconcentration (as a surrogate for bioaccumulation) and 
have been developed in relation to aquatic organisms (Pavan et al., 2006); relatively few models 
have been developed for the food web (Gobas et al, 2003) or for humans (Undeman et al, 2011; 
Tonnelier et al, 2011). For the application of the TTC approach, there is therefore a need to 
develop models for predicting bioaccumulation in humans. 
4.4.3.  EFSA recommendations for additional exclusion categories 
4.4.3.1.  Nanomaterials 
For nanomaterials, in either natural or engineered form, there is not sufficient toxicity information 
available to investigate whether they would exhibit toxicity directly attributable to their nanoform 
at exposures below the existing TTC values (EFSA, 2009, 2011). Accordingly, they should be 
excluded from the TTC approach at present. 
4.4.3.2.  Radioactive substances 
Radioactive substances should be excluded from the TTC approach since they may induce adverse 
effects by mechanisms due to their radioactive properties (i.e. physical mechanisms) which are 
different from the adverse effects that may arise from the chemical properties of the substance.  
4.4.3.3.  Mixtures 
It is possible to apply the TTC approach to mixtures containing only substances with closely 
related chemical structures, but then dose addition should be assumed and the exposures should be 
summed (see section 4.9). However, there has been little evaluation of the applicability of the TTC 
approach to mixtures containing  substances of unknown structure. Accordingly, such mixtures 
should be excluded from the TTC approach. 
4.5.  Applicability of the TTC values for infants and children 
Concern has been raised about the fact that the TTC values of 1800, 540, and 90 µg per person per 
day for Cramer Class I, II, and III substances, respectively, are expressed on a per person (60 kg 
adult) basis and these may not be   adequately protective for infants and children due to their lower 
body weights. Other concerns brought forward are the fact that infants and children, on a per kg 
body weight basis, have a higher food intake than adults, and also have other dietary habits and 
food preferences, and therefore it is important to take these into consideration when making   
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exposure estimates for the TTC approach. In addition, infants and children are often assumed to be 
potentially more sensitive to (some) toxicological insults than adults.  
4.5.1.  Consideration of toxicokinetic differences 
Potential differences between infants or children and adults in dietary exposure and susceptibility 
to chemicals were addressed at an ILSI Europe Workshop on the Applicability of the ADI to 
infants and children (Clayton et al., 1998). The considerations on the applicability of the ADI 
raised in this Workshop are also of value for the consideration of the TTC values of the three 
Cramer structural classes for infants and children. 
According to the original premises defined by the JECFA and the SCF, the appropriately assigned 
uncertainty factor used in the derivation of an ADI is intended to cover differences in species 
sensitivity, synergistic or antagonistic actions among food additives and other components of food, 
the heterogeneity of the exposed human population with regard to pregnancy, physiological status 
and nutrition, age differences between exposed individuals and the variability in susceptibility with 
age to the potential adverse effects of an ingested chemical substance. The default uncertainty 
factor of 100 has later been rationalised as comprising a factor of 10 for interspecies differences 
(most sensitive animal species to humans) and 10 for inter-individual differences between humans 
(WHO, 1999a, 2009a).  
From examination of the differences in toxicokinetics, the Workshop (Clayton et al., 1998) found 
that the elimination/clearance of xenobiotics in children is either similar or, in many cases, higher 
than in adults. In consequence, children frequently will have a lower body burden than adults for 
the same daily exposure to a chemical when expressed on a body weight basis. Based on this, the 
Workshop concluded that an increased uncertainty factor was not required for differences in 
toxicokinetics between post-suckling infants or children and adults. However, the Workshop 
emphasised that this conclusion does not apply to neonates and infants before the age of 12 weeks 
during which period the maturation of xenobiotic metabolising enzymes and elimination processes, 
such as renal excretion, take place.  
Since then, several newer studies have confirmed the immature status of xenobiotic metabolising 
enzymes and elimination processes in newborns up to the age of 3-6 months (De Zwart et al., 
2002; Abraham et al., 2005; Dorne & Renwick, 2005; Mielke & Gundert-Remy, 2009). At birth, 
renal function has a reduced capacity to excrete substances into the urine, characterised by a renal 
clearance of 30% to 50% compared to adults. In the first weeks of life, renal function gradually 
increases to a functional status comparable to the adult. Similarly, the expression level of some 
phase-I and phase-II enzymes is 10% to 50% of adult level, which may result in a relatively slow 
elimination of substances in the first months of life. Thus, the metabolic capacity gradually reaches 
adult levels within the first half year of life. In infants, this physiological pattern may lead to higher 
internal exposure as compared to children of more than 6 months and to adults. For some 
substances, this might result in higher toxicity at the same level of external exposure.  The 
Scientific Committee noted that the toxicokinetic differences between young infants and children 
or adults are transient and  generally not more than 2- to 5-fold (Renwick et al., 2000; Ginsberg et 
al., 2004, Kearns et al, 2003). Thus there is capacity in the first weeks of life to metabolise and 
eliminate substances, particularly when exposures are low. In the light of the above discussion, the 
Scientific Committee considers that the TTC approach can be applied to assess exposures in young 
infants, but in cases where the estimated exposure is in the range of the TTC value, additional 
consideration needs to be given as to whether the outcome of the TTC approach should be used for 
risk assessment. Additional considerations might include prediction of metabolic routes for the 
structure concerned (see 4.8) and other issues such as frequency and duration of the exposure.    
4.5.2.  Expression of TTC values on a body weight basis 
Bearing in mind that the low bodyweights of infants and children could have a significant impact 
on systemic exposure to a substance present in the diet, the Scientific Committee concluded that   
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the TTC values should be converted to a μg/kg body weight basis for comparison with exposure 
estimates for different age groups. For the conversions shown in Table 8 below, a body weight of 
60kg has been used as the divisor since this was the body weight originally used to derive the TTC 
values on a per person basis from animal toxicity data expressed on a per kg body weight basis.
25  
 
Table 8. Conversion of TTC values into μg/kg body weight per day. 
 
Type of TTC value  TTC value in 
μg/person per day 
TTC value in μg/kg bw 
per day 
With structural alert for genotoxicity  0.15  0.0025 
OPs and carbamates  18  0.3 
Cramer Class III  90  1.5 
Cramer Class II  540  9.0 
Cramer Class I  1800  30 
 
4.6.  Genotoxicity prediction tools 
In applying the TTC approach, it is necessary to assess the potential for genotoxicity. Traditionally, 
the set of structural alerts originally defined by Ashby and Tennant (1991) has been used. Since 
then a wide range of software tools have become freely and commercially available for the 
qualitative prediction of potential genotoxicity and genotoxic carcinogenicity. Some of these are 
based on more extensive lists of structural alerts than the Ashby alerts. The current status of 
software models has been reviewed recently (Serafimova et al., 2010), and the applicability of 
selected models in predicting the genotoxic potential of pesticides has been evaluated (Worth et al., 
2010). In general, the models are either based on expert knowledge, including structural alerts 
(molecular substructures) associated with genotoxicity and/or carcinogenicity, or they are based on 
statistical models which use molecular descriptors as predictor variables. Some are so-called 
hybrid models, based on a combination of expert rules and statistical models. For the most part, 
available models are based on potential chemical reactivity with DNA and are comparable in 
performance to the Ames test (Benigni et al., 2010). Relatively few models have been designed to 
predict in vivo genotoxicity, and few models explicitly capture molecular mechanisms other than 
DNA reactivity (e.g. covalent binding to proteins, and non-covalent interactions with DNA and 
protein). It is outside the scope of this document to give guidance on which specific software tools 
are fit-for-purpose and further work is needed on this aspect. However, a range of key principles 
are commonly applied when assessing the adequacy of model prediction (Worth et al, 2010). In 
particular, it is useful to demonstrate that the model is applicable to (gives reliable predictions for) 
the class of chemical being predicted.   
4.7.  Metabolic prediction tools 
A number of reviews (Boobis et al, 2002; Kulkarni et al, 2005; Norinder & Bergström, 2006; 
Mostrag-Szlichtyng & Worth, 2010a, b) have assessed the ability to predict metabolic fate by using 
metabolic prediction tools. The general conclusion is that qualitative prediction is often possible, 
i.e. the profile of metabolites that will be formed, although it is sometimes difficult to set the 
stringency (probability constraints) during the prediction such that the complexity of the metabolic 
fate of a compound is not either over- or under-predicted.  In addition, most currently available 
tools do not offer adequate information on the quantities of individual metabolites that may be 
                                                      
 
25 Note that this is not in conflict with EFSA’s recent recommendation to use a default value of 70kg, when appropriate, 
for adult body weight (EFSA, 2012). In the case of the TTC approach, the body weight value of 60kg used by Munro et 
al. to derive the generic human exposure threshold values must be used if converting these values back from a per person 
basis to a body weight basis.   
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formed. International efforts are underway to address this. For example, the expert data system for 
pesticides, ‘Metapath’, originally developed by the US Environmental Protection Agency, but now 
with wide OECD member country participation, is a data-rich dossier submission tool, that 
eventually, when well-populated, will offer metabolism prediction facilities, and will be included 
in the freely available OECD QSAR Toolbox. It will also have applications beyond pesticides. 
One area where some consideration of metabolic fate may contribute to the application of the TTC 
approach more generally is that of genotoxicity. In addition to the possible genotoxicity of the 
parent substance, the potential for metabolism into a genotoxic product must be considered. To 
some extent, this potential is implicitly captured in structural alerts for genotoxicity, such as the 
Ashby-Tennant alerts (Ashby & Tennant, 1991). As genotoxicity is one of the few endpoints where 
conclusions on toxicological relevance are based more on qualitative than on quantitative grounds, 
metabolic prediction might have some potential utility here. In the absence of specific information, 
all TTC schemes require some early consideration of the potential for genotoxicity including that 
of metabolites.  
Metabolic prediction has been reviewed recently under an EFSA contract relating to the work of 
the EFSA PPR Panel. Further information can be obtained from the report of that evaluation (JRC 
2010).  Most of the programs available for metabolic prediction are commercial and hence there is 
an underlying cost in their application. The predictive output from the programs would have to be 
input to another package to predict likely genotoxicity. In some cases, the respective programs 
have an integrated interface, so that the process is relatively seamless.  
More information on metabolic prediction tools can be found in reviews (Boobis et al, 2002; 
Kulkarni et al, 2005; Norinder & Bergström, 2006; Mostrag-Szlichtyng & Worth, 2010a, b). 
However, it is not straightforward to apply such tools in a regulatory context, and further work in 
this area is needed for practical application to the TTC approach. In particular, there is a need to 
develop tools capable of quantitatively predicting metabolite and degradate formation. 
4.8.  Chemoinformatic analysis of TTC datasets 
During 2010-2011, an EFSA-funded study (Bassan et al., 2011) was carried out by an external 
contractor. The goals of the project were: 
 
1)  To assess whether the chemical structures in the two main datasets underpinning the TTC 
approach (the Munro et al. and CPDB datasets) were adequately representative of 
chemical space and therefore of the ‘world of chemicals’ in general.  
2)  To critically evaluate the Cramer scheme on classification of chemical structures to 
assess whether it is robust. 
3)  To explore whether the TTC approach could be refined and improved by incorporating 
physicochemical data (experimental and computed) or toxicity data generated by non-
testing methods such as Quantitative Structure-Activity Relationships (QSARs). 
 
In order to undertake these analyses, the Munro et al. and CPDB
26 databases were compiled into 
two new electronic datasets (freely available from the EFSA website
27), including chemical 
structures, that were quality-checked, and toxicity data (NOEL and TD50 values, respectively), and 
a wide range of calculated molecular descriptors encompassing both structural features and 
physicochemical properties that are useful for characterising chemical space. 
  
Chemical space is a representation of the structural features and/or molecular properties covered by 
a defined set of chemicals. The molecular properties may include intrinsic properties (defined 
                                                      
 
26 Revised compilation of the CPDB dataset, developed and donated  by Dr Chihae Yang (USA) as of January 2010. 
27 http://www.efsa.europa.eu/en/supporting/pub/159e.htm   
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purely by chemical structure) such as size and shape, derived properties such as chemical 
reactivity, as well as extrinsic and biologically relevant properties such as metabolic activity. By 
using chemoinformatic methods, it is possible to visualise and characterise chemical space in a 
consistent manner, so that different datasets (including regulatory inventories and datasets suitable 
for model development) can be compared. Such comparisons enable regions of overlap and 
divergence to be identified, as the basis for targeted model development, testing, and/or regulatory 
action. It should be noted that the development and application of chemoinformatic methods is an 
active area of research, and as yet there is no single agreed approach for the use of chemical space 
analysis in toxicology. 
 
Chemical space analysis was performed by the use of chemoinformatics methods, including 
Principal Components Analysis (PCA), Cluster Analysis, Soft Independent Modelling of Class 
Analogy (SIMCA) and Partial Least Squares (PLS).  
 
For the investigation of whether the two main TTC databases are representative of the ‘world of 
chemicals’, the chemical space occupied by the structures within each dataset was investigated and 
each dataset was also compared with a subset of 502 chemicals drawn randomly from and   
representative of the Distributed Structure-Searchable Toxicity (DSSTox) Database compiled by 
the US Environmental Protection Agency. The DSSTox Database
28 contains approximately 10,000 
substances in total, including industrial chemicals, pesticides, consumer chemicals and food-use 
chemicals. This database is considered to be broadly representative of the ‘world of chemicals’. 
The TTC datasets were also compared with another subset from the DSSTox Database, defined as 
“food-use” chemicals (food additives and food contact substances). The results of this analysis 
were as follows. 
  
1)  The Munro et al. and CPDB datasets can be clustered into subgroups, where the individual 
subgroups have more homogeneous structural characteristics (e.g. degree of branching, 
globularity, number of ring atoms) than the original datasets. 
2)  The Munro et al. and CPDB datasets are overlapping in chemical space, and are broadly 
representative of the ‘world of chemicals’, as demonstrated by comparison with the 
chemical space of the DSSTox Database. 
3)  The CPDB dataset includes a higher proportion of polyaromatic compounds than the 
DSSTox subset of food-use chemicals, which is expected since the CPDB contains 
chemicals that are presupposed to be carcinogenic. 
 
To explore the possibility of developing models for the quantitative prediction of chronic toxicity 
(NOEL values) and carcinogenic potency (TD50 values), correlation analysis, PLS and ranking 
methods were applied (Pavan & Todeschini, 2008, 2009: Pavan & Worth, 2008). The results 
indicated that no predictive QSAR models could be developed for the Munro et al. and CPDB 
datasets with respect to NOELs or TD50s, which is not unexpected given the biological complexity 
of the many toxicological mechanisms involved. However, the results of ranking analysis, based on 
molecular descriptors, indicated that trends can be established and used for interpolation between a 
substance of unknown toxicity and substances with similar molecular descriptors and known 
toxicological properties. This enables a semi-quantitative prediction of the NOEL to be made. 
 
To assess the robustness of the Cramer classification scheme, the available experimental data on 
the substances in the Munro et al. (1996) and the CPDB datasets were compared with the Cramer 
classification scheme. For the substances in the Munro et al. dataset, the outcome of the Cramer 
classification scheme was also compared against the predictive value of various combinations of 
molecular descriptors and QSAR approaches.  
 
                                                      
 
28 http://www.epa.gov/ncct/dsstox/   
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An experimental classification for the 587 substances in the Munro et al. dataset was obtained as 
follows. The chronic toxicity NOEL values were converted into mol/kg bw/day and sorted in 
ascending numerical order of their log(1/NOEL). They were then divided into three groups, using 
arbitrarily defined ranges for the log(1/NOEL) of <0.2, 0.2 – <1.5, and >1.5, such that the three 
groups were populated with similar numbers of substances (168 substances termed ‘low hazard’, 
227 substances termed ‘medium hazard’, 192 substances termed ‘high hazard’). The substances in 
each of these three experimental classification groups were then compared with their respective 
Cramer classification, to see how often the Cramer scheme misclassified ‘high hazard’ substances 
into Cramer Class I and vice versa. The analysis showed that of 192 ‘high hazard’ substances, 179 
were in Cramer Class III, 3 in Cramer Class II, and 10 in Cramer Class I, a misclassification rate of 
just less than 5.2% for Cramer Class I.  Of the 168 ‘low hazard’ substances, 80 were in Cramer 
Class I, 11 in Cramer Class II, and 77 in Cramer Class III, a misclassification rate of 52%.  Thus, 
in this analysis, the Cramer classification scheme performed better in identifying high potency 
substances than in identifying low potency substances. Even so, there remains a possibility for 
misclassification of a ‘high hazard’ substance into Cramer Class I.  
 
The Scientific Committee notes that because of this possibility for misclassification using the 
existing Cramer classification scheme and taking into account more recent knowledge on the 
toxicity and metabolism of certain structural groups, updating of the Cramer classification scheme 
would be appropriate. This has also been recommended by the Scientific Committees advising the 
European Commission on non-food risks (SCCS, SCHER and SCENIHR) in their opinion on the 
TTC approach (to be published in 2012).  
 
An experimental classification for the 461 substances in the CPDB dataset was obtained as 
follows. The TD50 values were converted into mol/kg bw/day and sorted in ascending numerical 
order of their log(1/NOEL). They were then divided into three groups, 65 substances with a 
negative Ames (Salmonella) test and a log(1/ TD50) of <0, 117 substances with a negative Ames 
test and log(1/ TD50) of >0, and 279 substances with a positive Ames test. Results from Salmonella 
assays were used because it is a rich database and many rodent carcinogens are positive in this 
assay. The substances in each of these three experimental classification groups were then compared 
with their respective Cramer classification (even though the Cramer scheme was not designed to 
deal with genotoxic and/or carcinogenic substances). The analysis showed that the majority of 
carcinogenic substances (409 out of 461) were classified into Cramer Class III, as were the 
majority of  substances that were positive in the Salmonella assay (266 out of 279). 
 
The following conclusions can be drawn. 
1)  For the structures in the Munro et al. dataset, the Cramer classification scheme performs 
better in identifying high potency substances than low potency substances, confirming that 
it tends to be conservative.  
2)  The Cramer classification scheme was also found to be conservative when a applied to  
carcinogens in the CPDB dataset, not all of which are genotoxic; thus its use within the 
TTC approach is broadly protective, not only with respect to chronic toxicity but also for 
carcinogenicity where the mode of action is non-genotoxic. 
3)  The Cramer classification scheme, when applied to the Munro et al. dataset, could be 
slightly improved by combining it with a ranking classification model which utilised the 
molecular descriptors most closely correlated to chronic toxicity (NOEL values); this 
indicates that statistically-based methods and molecular descriptors encode some useful 
information not already included in the Cramer rules. 
4)  However, none of the classification schemes developed in the project, using a wide variety 
of statistical methods and molecular descriptors were significantly better than the Cramer 
scheme. 
 
Finally, statistical analysis of the TD50 values in the CPDB showed that mutagenic (Salmonella 
positive) substances tend to have higher carcinogenic potencies (their TD50 values are around 6.5   
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times lower) than non-mutagenic (Salmonella negative) chemicals. This confirms an earlier, 
similar analysis by Cheeseman et al. (1999) and supports the usefulness of incorporating 
genotoxicity alerts into an overall TTC scheme and the lower TTC human exposure value for 
substances with such alerts.  
 
Overall, the results of the study confirm that the Munro et al. and CPDB databases are broadly 
representative of chemical space and therefore of the ‘world of chemicals’ in general. The analysis 
of the Munro et al. database confirms the protectiveness of the Cramer scheme within the TTC 
approach for non-cancer endpoints. The results also indicate the potential of modern 
chemoinformatics methods for exploring relationships between chemical structure and toxicity, 
indicating these methods could be useful in the future for developing alternative hazard 
classification schemes associated with TTC values. Such schemes should aim, wherever possible, 
to incorporate computational methods based on an understanding of toxicologically relevant 
modes-of-action. 
4.9.  Exposure 
The estimates of exposure for substances to which the TTC approach is applied should, ideally, 
take into account not only exposure via the diet but also any systemic exposure resulting from non-
oral routes and sources. However, in the risk assessment community, it is recognised that this is 
often difficult to achieve in practice for substances that may have both food and non-food uses, 
and/or occurrence in food, consumer products, and other environmental media. If the TTC 
approach is applied to a substance present in the diet for which there are known to be other routes 
or sources of human exposure, and aggregate exposure for all routes and sources cannot be 
estimated, this additional uncertainty should be taken into account in reaching any conclusions 
based on the outcome of the TTC approach (EFSA, 2006). Similarly, if the TTC approach is to be 
applied to a group of substances with closely related structures and to which there is co-exposure, 
then it may be appropriate to sum their exposures, as would be done in a cumulative risk 
assessment on substances with the same mode of action.   
4.9.1.  Dietary exposure estimates for TTC 
4.9.1.1.  High exposure estimates 
It is essential for application of TTC to have a good estimate of high exposures. Most EFSA Panels 
use mean and high percentile food consumption (e.g. 95
th percentile) and average measured 
chemical concentration values to estimate chronic dietary exposure for average and high 
consumers. In other Panels, maximum predicted concentrations in food are used, sometimes in 
conjunction with a standard food basket. In some Panels, acute exposure (24 hours or less) is also 
considered using different methodology and this would be important, for example, when using the 
TTC value for OPs and carbamates. It may also be important to consider exposure in specific 
population subgroups, for example infants and children.  
 
For some types of chemicals the high exposure estimate is obtained by using maximum predicted 
exposure, from different food categories.  This is only feasible for substances that have a 
preregistered use such as additives and flavourings, where the concentration in the food is known. 
For most substances, the maximum permitted  level (MPL) in food groups is combined with 
standard consumption figures for those food groups to give a predicted maximum exposure. This 
also provides a level of conservatism, for which the same principle applies as for the use of food 
baskets. For contaminants, normally results from chemical analysis of foods are used to estimate 
exposure.  
If the TTC value is not exceeded using the high exposure estimate,  it may be concluded that 
further analysis of toxicity or exposure is not necessary. If the TTC value is exceeded, then a more   
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refined approach for exposure assessment may be appropriate, along with other considerations 
such as the possible need for chemical-specific toxicity data.   
4.9.1.2.  Refinement of dietary exposure estimates  
If it is considered that the exposure estimate should be refined, this can be done with different 
approaches but in most situations when the TTC is applicable, it is possible that there will be 
insufficient data to make such refinement. One method for assessing dietary exposure is 
probabilistic exposure assessment. This method combines random sampling from the available 
occurrence data and from food consumption data, which results in a prediction of the probability of 
different exposure levels in the population. It takes into account all measured levels of the 
substance and also those below the limit of quantification (see also EFSA, 2010c) and all volumes 
of consumption, including from multiple food sources. Thus it gives a good estimate of high-end 
exposures in consumers, which is what is needed for application of the TTC approach.  
A drawback of this method is that it requires high quality input data, i.e.  adequate occurrence data 
as well as national data on food consumption. Also it requires considerable infrastructure and 
expertise to perform. Detailed national consumption data are being gathered in the EFSA 
Comprehensive European  Food Consumption Database, with figures on national consumption at 
individual food or food group level (EFSA, 2011a
29). The intention of the database is to provide a 
refined tool for EFSA, its Scientific Panels, and potentially for other scientists in European 
Member States, to allow detailed estimates of consumers’ exposure.  
4.9.2.  Duration of exposure 
Exposure to substances in food or feed in the working field of EFSA will generally be of a chronic 
nature.  However, there may be situations where a short-term or intermittent exposure period may 
be considered, such as incidents or presence of a substance during time-limited production period. 
The TTC approach may be applicable in these situations. Some authors have proposed alternative 
methods for applying the TTC approach to short-term and less than life time exposures in the area 
of pharmaceutical impurities (Müller et al., 2006; EMEA, 2006
30), cosmetics (Kroes et al., 2007), 
and trace chemicals with structural alerts for genotoxicity in food (Felter et al., 2009). 
Felter et al. (2009) proposed that there are two ways in which short-term exposures might be 
addressed. The first is to modify the exposure assessment to determine an equivalent daily 
exposure. This kind of an approach was recommended by Kroes et al. (2007) for evaluating 
exposures associated with cosmetics that are not used on a daily basis. The Scientific Committee 
notes that this requires fairly robust data on the nature of the exposure and its duration. 
 
A second approach would be to establish TTC-based limits for short-term exposure durations that 
are less well-defined. An example of this might be that a substance in food is only present for a few 
months; protection for lifetime exposure may then be overly conservative. This was the rationale 
used by Müller et al. (2006) to establish different TTC tiers for genotoxic impurities in 
pharmaceuticals corresponding to different exposure durations. The basis for this approach comes 
from the use of lifetime cumulative dose (Felter et al., 2009). They referred to Haber’s law 
(concentration * time = constant [toxicity]) but also indicated that this is a simplified representation 
of the processes leading to toxicity.  
 
Although the proposals above have been put forward, the Scientific Committee is not confident 
about the general applicability of these proposals for the use of the TTC value for substances with 
structural alert for genotoxicity. It therefore recommends that the issue of less than chronic 
                                                      
 
29 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm?wtrl=01 
30 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf   
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exposure should be addressed case-by-case. This could be done for example by considering the 
margin between the appropriate TTC value (without any adjustment for duration of exposure) and 
the estimated dietary exposure.  
 
The Scientific Committee notes that the current TTC values for non-cancer endpoints are derived 
from databases that do not address effects from acute exposure, other than those for OPs and 
carbamates. TTC values for shorter than chronic duration of exposure should ideally be derived 
from databases with NOELs/NOAELs/PODs from acute or short-term toxicity studies.   The 
Scientific Committee is currently unable to recommend a reliable/appropriate general means of 
adjusting the TTC values for non-cancer endpoints for shorter durations of exposure, and 
recommends that these should also be addressed case-by-case for the time being.  The EFSA PPR 
panel has recently conducted an analysis of acute references doses for pesticides approved for use 
in Europe, the results of which suggest that it might be possible to establish TTC values for acute 
exposure to some substances, such as degradation products of pesticides.  
4.10.  Routes of exposure other than oral 
Most of EFSA’s risk assessment work relates solely to oral exposure to substances via food and 
feed. However, included in the remit of some Panels is a requirement to assess exposure of 
users/workers to the same substances by other routes, such as those working with pesticides or 
substances added to animal feed.  Thus, consideration of the applicability of the TTC approach to 
substance exposure by routes other than the oral route is relevant to the work of EFSA.  When 
several routes of exposure are to be taken into account (see 4.9), where possible these should be 
reflected in the exposure assessment used in the application of the TTC approach. 
There are two possible approaches that could be taken in applying the TTC concept to routes of 
exposure other than oral. The first would be to use the oral TTC values as the basis but carry out 
route-to-route extrapolation, as is often done in conventional risk assessment in cases where only 
oral toxicity data are available. The second would be to derive separate inhalational and dermal 
TTC values using existing data from inhalational and dermal toxicity studies. Kroes et al. (2007), 
for example, discussed the application of the TTC approach to cosmetic ingredients and impurities 
and proposed that default factors be used to adjust from an external topical dose to an internal dose, 
followed by application of the oral TTC values derived by Munro et al. (1996), recognising that 
these would not cover any local effects at the site of application.  Others have considered the use of 
inhalational and dermal toxicity data to derive local and systemic TTC values for non-oral routes 
of exposure. 
4.10.1.  Existing databases for non-oral toxicity data and derivation of TTC values for  non-
cancer endpoints 
Carthew et al. (2009) collated a database of subacute, subchronic and chronic inhalation toxicity 
studies in rats on 92 substances. Genotoxic carcinogens or in vivo mutagens were not included, and 
other exclusion criteria were also applied. From these data, they derived TTC values both for local 
and for systemic effects by application of a 25-fold uncertainty factor to the 5
th percentiles of the 
distributions of NOAECs (no-observed-adverse-effect concentrations) and NOAELs. The proposed 
systemic TTC values were 980 µg/person per day for substances in Cramer Class I and 170 
µg/person per day for substances in Cramer Class III.  
The RepDose database of Fraunhofer ITEM, Germany (http://www.fraunhofer-repdose.de/), gives 
information on 650 substances, including 203 substances for which administration was by the 
inhalation route (Escher et al., 2010). The latter were reduced to 136 substances after exclusion of 
those with structural alerts for genotoxicity, and from these they derived systemic TTC values of 
180 µg/person per day for substances in Cramer Class I and 4 µg/person per day for substances in 
Cramer Class III. These values are 5-fold and 40-fold lower than the respective TTC values of 
Carthew et al. (2009). Escher et al. discuss the differing exclusion criteria as one possible   
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explanation for the different values. They come to the conclusion that further refinement 
concerning the size of the database and of the definition of structural classes is desirable.  
The possibilities for establishing a dermal sensitisation threshold for local effects on the skin have 
also been explored (Safford, 2008; Safford et al., 2011). 
4.10.2.  Considerations for route-to-route extrapolation 
In general, toxicodynamic as well as toxicokinetic aspects have to be considered when planning to 
apply the TTC concept to routes of exposure other than the oral route for which the existing TTC 
levels were derived. A more detailed discussion on these aspects can be found in Appendix G. 
 
The following general criteria have been proposed by Pepelko (1987) as a basis for deciding 
whether route-to-route extrapolation can be performed. These criteria were taken up by the UK 
IGHRC (Interdepartmental Group of Health Risk from Chemicals) in their guidelines (IGHRC, 
2006). 
 
•  Absorption is the same between routes, or the difference is known and can be quantified. 
•  The critical target tissue is not at the portal of entry of the compound. 
•  There is no significant metabolism of the chemical by oral, gut or skin enzymes or in 
pulmonary macrophages, or transformation by other processes in the gut or lung. 
•  First pass effects are minimal. 
•  The chemical is relatively soluble in body fluids. 
 
However, it is not straightforward to apply the above mentioned criteria as a tool for adapting the 
TTC concept to routes of exposure other than the oral route since for most substances to be 
evaluated by the TTC approach the relevant information would not be available.  
4.10.3.  EFSA considerations on route-to-route extrapolation 
The Scientific Committee recognises that the use of the oral TTC values derived by Munro et al. 
(1996) for extrapolating to systemic effects from the dermal route of exposure would require 
knowledge of the oral bioavailability of the substances in the Munro database. This information is 
not available. It should also be borne in mind that local (portal of entry) effects, which may be 
relevant, would not be covered. The oral TTC values could be considered for use if it was known 
from experimental data that dermal absorption was low (e.g. 10% or lower) because there would be 
reasonable confidence that these TTC values would not underestimate the risk from the dermal 
route of exposure.  However, it would be preferable either to develop a specific database to 
establish dermal TTC values, or to develop a systematic scheme for extrapolating from the oral to 
dermal route. The Scientific Committee noted that there is an ongoing EU 7th framework project 
(COSMOS - http://www.cosmostox.eu/) that is addressing oral to dermal extrapolation within the 
TTC. 
  
If the route of exposure is by inhalation, given the most recent findings, it seems inadvisable to 
base the TTC approach on the Munro et al. (1996) data and perform route-to-route extrapolation. 
The proposals of Carthew et al. (2009), who used inhalation data to derive TTC values, are based 
on a small number of chemicals (92) and because of the long list of exclusion criteria, the proposed 
TTC values can only be applied if several properties of the substance in question are known from 
experimental data. The publication of Escher et al. (2010) is based on 136 chemicals. They derived 
TTC values which are one order of magnitude lower than the Munro et al. (1996) TTC values and 
which are recognised to be conservative because they include consideration of toxicity resulting 
from local effects on the respiratory tract. Further extension of this database would be desirable 
before establishing TTC values for inhalation. The Scientific Committee noted that further work on 
application of TTC to the inhalation route is ongoing under a CEFIC Long Range initiative project 
(http://www.cefic-lri.org/).   
                          Opinion on Threshold of Toxicological Concern   
 
EFSA Journal 2012;10(7):2750                             44 
5.    Potential for application of the TTC concept in the different EFSA Panels 
Areas where there is a potential for the application of the TTC concept in EFSA’s work are 
discussed below. 
5.1.  Panel on Food Additives and Nutrient  Sources (ANS) 
The Panel on Food Additives and Nutrient Sources has responsibility for evaluating additives in 
human food and the safety of substances used in nutrient sources. For these substances usually 
toxicological data on the main components will be available since they are required under EU 
legislation. The TTC approach could be relevant for evaluating impurities and breakdown/reaction 
products in food additives and nutrient sources.  
5.2.  Panel on Food Contact Materials, Enzymes, Flavourings (CEF) 
The Panel on Food Contact Material, Enzymes and Flavourings has responsibility for evaluation of 
several different types of substances, i.e. food contact materials, flavouring substances, enzymes 
and processing aid. For flavourings, the TTC approach is already used by the Panel (see Appendix 
B) and it would seem logical that the same approach might also be used for food contact materials, 
where exposures can be low. Currently, food contact materials (FCMs) are evaluated through a 
tiered approach that was adopted by the Scientific Committee on Food at the end of the 1980s and 
which continues to be used by EFSA. Under this tiered approach, different toxicological datasets 
are requested according to the migration of the substance in food simulants, with more testing 
required for higher migration. The TTC approach could be useful for substances with low-level 
migration from food contact materials. Migration of impurities and side-products resulting from 
the manufacture of the final article also may need to be considered and application of the TTC 
approach to such situations could be helpful. The CEF Panel is currently revising its guidelines, 
including the exposure scenarios to be used by the Panel in the future. 
The fact that different approaches are used for the safety evaluation of flavourings and food contact 
materials is currently under discussion in the Panel and special attention will be paid to the 
recommendations in this opinion of the Scientific Committee.  
In preparatory work for the revision of guidelines on FCMs, substances for which a TDI has been 
set by the SCF or by EFSA on the basis of oral toxicity data were evaluated using the TTC 
approach. The TTC approach was found to be more conservative than the risk assessment based on 
oral toxicity data. This could support the introduction of the TTC concept into a tiered evaluation 
of FCMs (Pinalli et al., 2011). 
5.3.  Panel on Contaminants in the Food Chain (CONTAM) 
The Panel on Contaminants in the food chain deals primarily with contaminants that are often data 
rich and in many cases do not qualify for the TTC approach (e.g. dioxins, aflatoxins, heavy metals, 
some mycotoxins). Examples of areas in which application of the TTC concept could be envisaged 
are trace contaminants in (bottled) water and trace contaminants resulting from previous cargoes. 
From time to time, the Panel also has to give advice on contaminants for which there are few or no 
toxicity data, with no obvious stakeholder that can be asked to provide toxicity data. In such cases, 
the TTC approach could be useful in order to advise whether human exposures are so low that data 
need not be sought, or to set priorities on which substances toxicity data are needed, as was 
recently done in the case of Alternaria toxins in food and feed (EFSA, 2011c).  
5.4.  Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) 
The Panel on Feed Additives deals with additives and products or substances used in animal feed. 
The Panel is responsible for the assessment of safety for target species, i.e. animal species for 
which the additive is intended to be used, safety for consumers (integrating toxicology and carry-
over to consumers via edible tissues/products), safety for users (taking into account inhalation and   
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dermal exposure), safety for the environment, and efficacy, the latter two items being outside the 
remit of this opinion. 
 
Within this general framework, the assessment may present specific features depending on the type 
of additive. For instance, no carry-over studies are normally foreseen for the wide group of micro-
organisms and enzymes. As for established nutrients (vitamins, trace elements) pivotal elements 
for risk assessment are the carry over into edible tissues/products and additional exposure of 
animals and consumers, compared to existing background. 
There would be possibilities for the application of the TTC approach to consumer safety within the 
FEEDAP Panel’s remit. Since exposure of consumers is related to the metabolism by target 
species, comparative pharmacokinetic studies should show whether the same metabolites are: 
-  covered by testing  in toxicological studies on laboratory animals, and  
-  present as residues in target farm animals.  
On occasion, one or more metabolite(s) are encountered in target farm animals that are not formed 
in laboratory animals and represent at least 10% of the total residues (metabolites representing less 
than 10% of the total residue are normally not considered). Such metabolites are chemically 
identified, but not toxicologically characterised. Currently, toxicological testing for such 
metabolites is required on a case-by-case basis and the TTC approach could be an appropriate tool 
in order to address whether, and to what extent, testing should be performed. 
Another area in which the TTC approach might be applied would be for human exposure to 
impurities in feed additives, in cases where there is carry over into food, provided an exposure 
assessment can be made. 
5.5.  Panel on Plant Protection Products (PPR) 
The Panel on Plant Protection Products is not directly involved in the approval process for plant 
protection products.  Rather, it is consulted when there is a toxicological issue that cannot be 
resolved during the normal approvals process.  In addition, the Panel is increasingly becoming 
involved in the preparation of guidance documents. 
 
In addressing a specific toxicological issue, the Panel would adopt a chemical-specific approach.  
In general, for active substances, the data requirements are specified by EU legislation, and hence 
the need for the TTC approach would not be an issue.  It could be argued that for plant protection 
products resulting in minimal residues on crops, the TTC approach might be relevant, but to date 
this has not been foreseen in the legislation. 
 
An area where the TTC approach is being actively considered by the PPR Panel is that of the 
toxicological relevance of metabolites and degradates of pesticide active substances. The broader 
issue of how to assess such substances will be the subject of a forthcoming opinion of the Panel.  
As part of this activity, there has been an assessment of the applicability of the TTC approach to 
such an evaluation.  The report of this activity is available on the EFSA website EFSA, 2010a).  
The PPR Panel is of the view that the TTC has potential application in the assessment of the 
toxicological relevance of plant metabolites and degradates of pesticide active substances.   
Metabolites either predicted by software tools or identified analytically would be assessed for 
structural alerts for genotoxicity, using appropriate software, and for the respective Cramer class, 
which can also be achieved using a freely available software package.  Predicted dietary exposure 
to the plant metabolite or degradate would be compared with the appropriate TTC value.  A 
number of aspects of this strategy are still under discussion and will not be finalised until the Panel 
adopts its opinion in 2012.  
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5.6.  Scientific Committee’s consideration of potential applicability of the TTC approach 
in EFSA’s work 
From a scientific perspective, the TTC approach could, in principle, be applied to any substances, 
for which exposures are low and toxicity data are sparse. However, in the context of the EU there 
is a legislative requirement to submit toxicity data in several areas (e.g. the technically active 
substances in pesticides, food additives, feed additives, etc).  
For the work of EFSA in the area of food and feed, the TTC approach is recommended as a useful 
screening tool either for the setting of priorities for data needs and for risk management action or 
for deciding whether exposure is so low that the probability of adverse health effects is low and 
consequently further data are not needed.   
 
It is clear from the above discussion on potential applications of the TTC approach in the work of 
particular EFSA Panels that the context in which the TTC approach might be used differ will 
between the Panels, ranging from consideration of substances that are not yet on the market where 
risk assessors may have the option to request more data, to issues such as environmental 
contaminants where the likelihood of obtaining more data, especially in the short-term, is very 
limited. In EFSA’s work the main uses of the TTC approach are likely to be in the areas of 
impurities, breakdown and reaction products, metabolites, and low-level contaminants in food and 
feed, on which there are few or no toxicological data.  
 
In this opinion, the Scientific Committee has considered the TTC approach in a generic way, in 
particular looking at whether existing TTC values are adequately supported by scientific data to be 
used in EFSA’s work. In applying the TTC approach to some aspects of the work of EFSA Panels 
in the future, there may be a need to adapt the approach to the particular context in which it is 
being used, as was done in the past by JECFA and EFSA for the evaluation of existing flavouring 
substances (see Appendix B), and which has been done more recently by the CEF Panel for the 
evaluation of new flavouring substances (EFSA, 2010e).  
 
With respect to possible wider use of the TTC approach in EFSA’s work, beyond the ones 
mentioned above,  its use can also be envisaged, for example, as part of tiered approaches in which 
toxicity testing requirements are linked to the level of human exposure.  Such uses of the TTC 
approach should be considered on a case-by-case basis, in consultation with risk managers. The 
Scientific Committee further recommends that in such cases, if there is a structural alert for 
genotoxicity, then genotoxicity testing data on the substance or information (e.g. from read-across) 
should be sought, as is currently the practice in EFSA when the TTC approach is used for the 
evaluation of flavouring substances. 
 
CONCLUSIONS AND RECOMMENDATIONS  
The Scientific Committee has considered a number of published analyses and conducted some 
analyses itself of the data originally used to establish human exposure threshold values (TTC 
values). The Scientific Committee has also conducted analyses of data from studies that are not 
necessarily included in the original Munro et al. database, using EFSA’s databases on pesticides 
and an EU database of substances classified for reproductive toxicity. EFSA also commissioned a 
project from a contractor to examine the databases underpinning the TTC approach, using in silico 
chemoinformatic methods to assess the representativeness of the databases and the opportunities 
for refining the basis for grouping chemicals. Further analyses of oral toxicity data and TTC values 
have also been conducted and published by others using independent databases. The outcomes of 
these analyses have been discussed and the Committee’s conclusions and recommendations follow. 
 
1.  The TTC approach is applicable to substances for which the chemical structure is known 
but for which there are few or no relevant toxicity data. For the work of EFSA, the TTC   
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approach is recommended as a useful screening tool either for priority setting or for 
deciding whether exposure to a substance is so low that the probability of adverse health 
effects is low and that no further data are necessary.  
 
2.  For application of the TTC approach it is essential to have exposure assessments that take 
account of high exposure scenarios, and, where possible, take account of exposure from all 
routes and sources. The EFSA Panels already have in place exposure assessment 
methodologies for predicting or estimating average and high exposures in relevant sub-
populations, and the EFSA Comprehensive European Food Consumption Database is 
expanding. 
 
3.  The classification of chemicals according to chemical structure is an essential component 
of the current TTC approach. The classification scheme most widely used is that described 
by Cramer et al. (1978). The Scientific Committee is mindful that this scheme is based on 
the metabolic and toxicological information available at that time. With advances in 
knowledge over the last three decades, revision and refinement of the scheme is 
recommended.  Nevertheless, the Scientific Committee’s analyses, together with those in 
several other published studies (referenced elsewhere in this opinion) have demonstrated 
that the application of the Cramer classification scheme in the TTC approach is 
conservative and therefore protective of human health.  
 
4.  The Scientific Committee notes that the TTC value for Cramer Class II substances derived 
by Munro et al. in 1996 was based on toxicological data on very few substances. Databases 
compiled subsequently have similarly found few chemicals classifiable as Cramer Class II, 
apart from flavouring substances. The Scientific Committee considers that the TTC value 
for Cramer Class II is not well supported by the presently available databases and therefore 
concludes that consideration should be given to treating substances that would be classified 
in Cramer Class II under the Cramer decision tree as if they were Cramer Class III 
substances.  
 
5.  The Committee’s analysis of the lowest 10
th percentiles of the NOELs in the database of 
Munro et al. (1996) for substances in Cramer Class I and Class III, and confirmation by 
others of similar NOELs using different datasets (Tluczkiewicz et al., 2011), demonstrate 
that the respective TTC values of 1800 and 90 μg/person per day derived by Munro et al. 
are sufficiently conservative to be used.  
 
6.  Following the Scientific Committee’s analysis of NOELs for organophosphate and 
carbamate substances, the TTC value of 18 μg/person per day, first proposed by Kroes et 
al. (2004), is considered sufficiently conservative to cover the anti-cholinesterase activity 
of substances with organophosphate or carbamate structural features.  
 
7.  Removing organophosphate and carbamate substances from Cramer Class III (being the 
most potent substances in that class) would have an impact on the existing TTC value for 
Cramer Class III.  However, pending any future revision of the TTC approach, the 
Scientific Committee concludes that it would be prudent to maintain the value for Cramer 
Class III at 90 μg/person per day.  
 
8.  The Scientific Committee considers that further additions to or subdivisions of existing  
Cramer Classes are likely to detract from the advantageous features of the current TTC 
scheme, that is, its ease of use,  maintaining consistency in application of the approach, 
and its in-built conservatism. 
 
9.  Following the Scientific Committee’s analysis of NOELs for reproductive and 
developmental toxicity for substances classified as such under EU legislation, the TTC   
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values for Cramer Classes I and III are considered sufficiently protective for adverse 
effects on reproduction or development. 
 
10. Regarding the issue of substances that may have endocrine-mediated toxicity, the 
Scientific Committee concludes as follows: 
 
a.  In most situations where the TTC approach might be applied, there would be no a 
priori knowledge that a substance has endocrine activity.  
b.  If there are data showing that a substance has endocrine activity, but the human 
relevance is unclear, then these data should be taken into consideration, case-by-
case, in deciding whether or not to apply the TTC approach.  
c.  If there are data showing that a substance has endocrine-mediated adverse effects, 
then, as would be the case for adverse data on any other endpoint, the risk 
assessment should be based on the data, rather than the TTC approach.  
d.  In view of the extensive work, currently ongoing, to develop an EU-wide approach 
for defining and assessing endocrine disrupters, once that approach is finalised it 
will be necessary to consider any impact it may have on the use of TTC approach. 
e.  In the meantime, the Scientific Committee recommends that untested substances, 
other than steroids, can be evaluated using the TTC approach recommended in this 
opinion.   
 
11. For substances with a structural alert for genotoxicity, the TTC value of 0.15 μg/person per 
day was derived by Kroes et al. (2004). This value is sufficiently conservative to be used in 
EFSA’s work, provided the structures already designated as high potency carcinogens are 
excluded from the TTC approach. The Scientific Committee is aware that further 
substances have been added to the Carcinogenic Potency Database since this value was 
derived. However, because a large number of substances were already in the Carcinogenic 
Potency Database, the Committee does not consider that the TTC value for substances with 
a structural alert for genotoxicity would change appreciably. 
 
12. The Scientific Committee has considered the possibility that a genotoxic metabolite could 
be produced from a parent substance. If such metabolites were to be predicted and 
considered relevant, then the TTC value of 0.15 μg/person per day should be applied. The 
Scientific Committee recognises that there is no general agreement at present on how to 
interpret the outcome from the currently available tools used to make such predictions, 
because they have a tendency to generate a large number of potential metabolites.  
 
13. The original FDA Threshold of Regulation value of 1.5 μg/person per day is of historical 
importance, but has little practical application in the overall TTC approach. This is because 
substances without structural alerts for genotoxicity can proceed down the TTC decision 
tree to be considered in relation to the higher TTC values for organophosphates and 
carbamates or Cramer Classes I and III.  
 
14. Non-genotoxic carcinogens are considered to have a threshold and, in general, NOELs for 
these are in the same range or higher than NOELs for other types of toxicity.  Thus the 
TTC values that are higher than the value of 0.15 μg/person per day are appropriate to be 
used for any substance that does not have a structural alert for genotoxicity. 
 
15. The Scientific Committee also notes that the work of the EFSA-commissioned project 
demonstrated that the range of structures in the two main datasets (Carcinogenic Potency 
Database and Munro et al.), which underpin the human exposure threshold values, are 
broadly representative of the world of chemicals, in terms of chemical space, as described 
by molecular descriptors encompassing both structural features and physicochemical 
properties. This provides further confidence in the general utility of the TTC approach.   
                          Opinion on Threshold of Toxicological Concern   
 
EFSA Journal 2012;10(7):2750                             49 
 
16. A number of proposals have been put forward for adjusting the TTC value for substances 
with a structural alert for genotoxicity for shorter than chronic durations of exposure. The 
Scientific Committee is not confident about the general applicability of these proposals   It 
therefore recommends that the issue of less than chronic exposure should be addressed 
case-by-case. This could be done for example by considering the margin between the 
appropriate TTC value (without any adjustment for duration of exposure) and the 
estimated dietary exposure.  The Scientific Committee also notes that, with the exception 
of the TTC value for organophosphate and carbamate structures, the current TTC values 
for non-cancer endpoints are derived from databases that do not address effects from acute 
exposure. The Scientific Committee is currently unable to recommend a 
reliable/appropriate general means of adjusting the TTC values for non-cancer endpoints 
for shorter durations of exposure, and recommends that these too should also be addressed 
case-by-case for the time being. 
 
17. For application of the TTC approach to the whole population including infants and 
children, all TTC values should be converted to corresponding values that take into 
account body weight (see Figure 2).  
 
18. The Scientific Committee has also considered whether the TTC approach could be applied 
to young infants under the age of 6 months, in whom not all metabolic and elimination 
processes are yet mature. The toxicokinetic differences between young infants and children 
or adults are transient and  generally not more than 2- to 5-fold. Thus there is capacity in 
the first weeks of life to metabolise and eliminate substances, particularly when exposures 
are low. The Scientific Committee concludes that the TTC approach can be applied to 
assess exposures in young infants, but in cases where the estimated exposure is in the 
range of the TTC value, additional consideration needs to be given under which conditions 
the TTC approach could be used. Additional considerations might include prediction of 
metabolic routes for the structure concerned and other issues such as frequency and 
duration of the exposure. 
 
19. The Scientific Committee has considered whether TTC approach can be applied in cases 
where exposures are by dermal or inhalation routes (e.g. for assessment of occupational 
exposures). It is concluded that more work is needed in this area to establish separate TTC 
values for routes of exposure other than oral and/or develop systematic schemes for route-
to-route extrapolation. It is noted that such work is ongoing elsewhere. 
 
20. The Scientific Committee considered whether routinely undertaking metabolic prediction 
would be helpful for application of the TTC approach other than for prediction of 
genotoxicity. As the Cramer decision tree and the databases used to derive the TTC values 
for non-cancer endpoints reflect at least in part the toxicity of metabolites formed in the 
test species, the Scientific Committee concluded that it is not essential to undertake such 
metabolic prediction.  However, there are situations where this has been helpful, e.g. in the 
case of flavourings where metabolic data on closely structurally-related substances are 
available. 
 
21. The Scientific Committee considered both previously proposed exclusions and additional 
exclusions that might be necessary and concludes that the TTC approach should not be 
used for the  following (categories of) substances: 
a.  High potency carcinogens (i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, 
benzidines, hydrazines). 
b.  Inorganic substances 
c.  Metals and organometallics 
d.  Proteins   
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e.  Steroids 
f.  Substances that are known or predicted to bioaccumulate  
g.  Nanomaterials  
h.  Radioactive substances 
i.  Mixtures of substances containing unknown chemical structures 
 
22. When the TTC approach is used, it is important for both risk assessors and risk managers 
to keep in mind that it is a probability-based screening tool and, in common with other risk 
assessment approaches, it does not offer complete certainty. The derivation of the various 
TTC values are based on frequency distributions and the TTC values that have been 
proposed for use are not based on the lowest value in each of the distributions but on a 
point close to the lowest value. Thus, when using either the cancer or non-cancer TTC 
values, there is a chance that a substance with an exposure below the relevant TTC value 
may still pose a potential risk. That probability can be estimated to lie between zero and 
5%.  
 
23. Lastly, the Scientific Committee has considered where the TTC approach could be applied 
in EFSA’s work and concludes as follows: 
 
a.  In principle, the science supports the application of the TTC approach in any area 
of chemical risk assessment for which human exposures are low, whether exposure 
is from deliberate addition or due to contamination. However, for substances for 
which EU legislation requires the submission of toxicity data, the TTC approach 
would not be used 
b.  Within EFSA, the Scientific Committee recommends that the TTC approach can 
be used to assess impurities, breakdown and reaction products, metabolites, and 
low-level contaminants in food and feed where an exposure assessment can be 
conducted, on which there are few or no toxicological data. 
c.  Wider use of the TTC approach in EFSA’s work, beyond the ones mentioned 
above, can also be envisaged, for example, as part of tiered approaches in which 
toxicity testing requirements are linked to the level of human exposure.  Such uses 
in a particular area of EFSA’s work should be considered on a case-by-case basis, 
in consultation with risk managers. The Scientific Committee further recommends 
that in such cases, if there is a structural alert for genotoxicity, then genotoxicity 
testing data on the substance or information (e.g. from read-across) should be 
sought.  
d.  The Scientific Committee recognises that when the different EFSA Panels apply 
the TTC approach to their respective areas, specific considerations may apply and 
the generic scheme shown in Figure 2 may need to be adapted. 
 
 
From the above conclusions, a generic scheme for the application of the TTC approach has been 
developed and it is shown in figure below. 
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Is the substance a member of an 
exclusion category? *
Is there a structural alert for 
genotoxicity
(including metabolites)?
Exposure > 0.3 µg/kg bw/day? ***
Is substance an OP/Carbamate?
Exposure > 1.5 µg/kg bw/day? ***
Is substance in Cramer Class II or III?
Exposure
> 0.0025 µg/kg bw/day? 
Substance
requires non-TTC approach
(toxicity data, read-across etc.)
Low probability of
health effect
**
Low probability of
health effect
**
Exposure > 30 µg/kg bw/day? ***
No
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
*** If exposure only short duration
→ consider margin betweenhuman 
exposure & TTC value
** If exposure of infants < 6 months
is in range of TTC  
→ consider if TTC is applicable
No
No
No
Yes
* Exclusion categories
high potency carcinogens; inorganic substances; 
metals and organometallcs; proteins; steroids; 
substances known/predicted to bioaccumulate; 
nanomaterials; radioactive substances; mixtures.
Does the substance have a known structure and 
are exposure data available?
Yes
No TTC approach cannot 
be applied
 
Figure 2: Generic scheme for the application of the TTC approach 
 
Recommendations for future work 
 
1.  In the short-term, it is recommended that the Cramer classification scheme should be 
revised, making it more transparent and easier to understand. 
2.  In the longer term it may be desirable to develop classification schemes that are more 
discriminating between substances with different toxic potencies. 
3.  Further work is needed on improving the accuracy, breadth of applicability, and practical 
availability of computer-based models suitable for supporting TTC assessments. This 
includes the development and refinement of computational models for predicting 
genotoxic potential, carcinogenic potency, bioaccumulation in humans, and the 
quantitative simulation of metabolite/degradate formation. New models should be based, 
as far as possible, on an understanding of toxicologically relevant modes of action.  
4.  In the light of the evolving work in the EU and elsewhere to develop a consistent approach 
for the risk assessment of substances with an endocrine mode of action, it will be necessary 
to consider the possible impact of the outcome of this work on the use of the TTC 
approach as a screening tool for untested substances.   
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APPENDICES 
APPENDIX A  
Historical development of the TTC concept 
Frawley (1967) was the first to propose the idea that there was a general threshold level for 
chemicals in the diet, below which the risk to human health would be negligible. His proposal was 
made in the context of safety assessment of substances used in food packaging materials, many of 
which were then untested and of unknown toxicity. He analysed a data set of 2-year, chronic 
toxicity studies in animals on 220 different chemicals given via the diet and identified the doses 
below which no toxicological effects were observed. The substances involved were food additives, 
industrial chemicals, chemicals found in consumer products including cosmetics, chemicals used in 
food packaging materials, pesticides and heavy metals. The studies represented about 90% of all 
the available chronic toxicity data at that time. From this analysis, Frawley selected a concentration 
of 10 mg/kg of diet, since very few chemicals (19 out of 220) and only those of a type not likely to 
be used in food packaging (i.e. heavy metals and pesticides) showed toxicity below this level.  This 
concentration was divided by 100 to provide a margin of safety, giving a figure of 0.1 mg/kg of 
human diet. This was the dietary concentration for any substance migrating from food packaging 
materials which he considered could be consumed without risk to human health.  
 
The issue of toxicologically insignificant levels of chemicals in food was further considered in 
guidelines issued in 1969 by the Food Protection Committee of the US National Academy of 
Sciences (NRC, 1969). The Committee noted that certain categories of chemical could have 
deleterious effects at low doses, namely certain impurities or contaminants of natural origin (such 
as aflatoxin and botulinum toxin), certain essential nutrients and hormones, certain heavy metals 
and their compounds, and certain organic compounds employed for their biological activity 
(included in the latter three categories were pesticides, pharmaceuticals and antipersonnel agents 
that may have biological activity at levels as low as 0.1 ppm). Aside from these, they noted that the 
analysis of Frawley (1967) had shown that no other substance had produced toxic reactions in 
experimental animals below a dietary concentration of 40 mg/kg. The Committee concluded that, 
with the exception of the potentially more toxic types of chemical mentioned above, a 
concentration of 0.1 ppm (0.1 mg/kg) of a chemical in the human diet could be presumed to be 
toxicologically insignificant. For substances with simple structures and known purity, that would 
be readily metabolised, and which belonged to a group of substances that were known or presumed 
to be of low toxicity, the Committee concluded that a higher concentration of 1 ppm (1 mg/kg) 
could be presumed to be toxicologically insignificant. 
 
Development of human exposure threshold values for the endpoint of cancer  
US FDA ‘Threshold of Regulation’ 
The first regulatory body to formally derive a threshold value related to the toxicological endpoint 
of cancer was the US Food and Drug Administration (FDA). The FDA was concerned that the 
agency should focus its limited resources for risk assessment of food contact materials on issues of 
tangible concern rather than trivial ones. The Threshold of Regulation (TOR) policy was developed 
over 10 years (Rulis, 1986, 1989, 1992), during which the agency examined relevant scientific data 
that would enable them to set a threshold, intended to protect against all types of toxicity including 
carcinogenicity, for application in food packaging regulation. In 1995, the FDA adopted the TOR 
policy for substances present in food contact materials (FDA, 1995). Such substances are also 
termed indirect food additives in the USA and are regulated as such. The TOR policy contains 
elements of both scientific and risk management judgments. The term “Threshold of Regulation” is 
used, rather than “threshold of toxicological concern”, but the science underlying the policy is   
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analogous to the TTC concept. A threshold value was derived from cancer data since this was 
considered to be the toxicological endpoint most likely to be triggered by exposure to low doses of 
chemicals. The approach was based on an analysis by Gold et al. (1984) of nearly 500 chemical 
carcinogens, later expanded to over 700 (Gold and Zeiger, 1997), that had been tested in animals 
using lifetime exposures, known as the carcinogenic potency database (CPDB). In this database, 
the potency of each chemical is expressed as a TD50. The TD50 is defined as the daily dose-rate in 
mg/kg body weight per day for life to induce tumors in half of the test animals that would have 
remained tumor-free at zero dose. In cases where there are multiple data, the TD50 is derived from 
the most sensitive species, strain and sex. The TD50s were plotted as a distribution (see Figure 1). 
Linear extrapolation was then used to derive an estimate of the dietary concentration of most 
carcinogens which would give rise to less than a one in a million lifetime risk of cancer (1 x 10
-6, 
termed a ‘virtually safe dose’), assuming that the risks in animals are representative of those in 
humans, and these were also plotted as a distribution (see Figure 1). From the distribution of 
virtually safe doses, a dietary concentration of 0.5 ppb was selected as the value to use for the 
TOR. 
 
 
 
 
Figure 1. Distribution of TD50s for chemical carcinogens and extrapolation to 1 in a million risk 
Reproduced from Cheeseman MA, Machuga EJ and Bailey AB (1999). A tiered approach to Threshold of 
Regulation, in Food and Chemical Toxicology Vol. 37, pp387-412. Copyright, with permission from 
Elsevier. 
 
From the dietary concentration of 0.5 ppb, a human daily exposure level of 1.5 μg/person was 
derived, assuming that an adult may consume 1500 g of food and 1500 g of fluids daily and that 
the substance is distributed throughout the total diet. If dietary exposure to an individual substance 
was below the threshold, the agency considered that consumers would be protected “with 
reasonable certainty of no harm”, even if that substance was later shown to be a carcinogen. With 
respect to other non-cancer effects, the agency noted as follows: “A 0.5 ppb threshold is 2000 times 
lower than the dietary concentration at which the vast majority of studied compounds are likely to 
cause non-carcinogenic toxic effects and 200 times lower than the chronic exposure level at which 
potent pesticides induce toxic effects” (FDA, 1993). Application of the TOR policy in the USA 
means that substances in food-contact articles that are present in the diet at concentrations at or 
below 0.5 ppb are exempted from regulation as a food additive and no toxicity testing on them is 
required. Substances that have been shown to be carcinogens in humans or animals, or, on the basis 
of their structure, are suspected of being carcinogens are excluded from consideration under the 
TOR.  
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Following the adoption of the TOR policy in the USA, subsequent work by the FDA on 
carcinogenic potency provided support for the use of thresholds for human dietary exposure that 
were higher than 1.5 μg/person per day. Using the then expanded carcinogenic potency database of 
709 chemicals (Gold and Zeiger, 1997), together with short-term toxicity data, results of 
genotoxicity testing and structural alerts, Cheeseman et al. (1999) identified potent and non-potent 
subsets. This work confirmed the validity of 1.5 μg/person per day as an appropriate threshold for 
most carcinogens, but went on to propose a tiered threshold of regulation. Examination of the 
expanded database led them to conclude that a threshold of 4 - 5 μg/kg of diet could be appropriate 
for substances without structural alerts and even for substances with structural alerts if they were 
negative in tests for genotoxicity. If substances had no structural alerts, were negative in tests for 
genotoxicity, and had acute toxicity (LD50) above 1000 mg/kg bw, they proposed that a threshold 
of 10 - 15 μg/kg of diet could be used. To date, these proposals for a tiered approach within the 
TOR have not been adopted by the FDA. 
 
Proposal of a threshold for substances with a structural alert for genotoxicity 
As can be seen from Figure 1, approximately one-third of carcinogens have TD50s that result in 
extrapolated virtually safe doses below 0.5 ppb.  Kroes et al. (2004) have therefore refined the 
threshold for the endpoint of cancer by deriving a lower value for substances containing a 
structural alert for potential genotoxicity. They used the same modeling approach as previously 
used by the FDA (i.e. linear extrapolation from the TD50), to calculate exposures estimated to 
increase the lifetime risk of cancer by 1 in a million (1 x 10
-6 risk). Analysing of a database of 730 
substances (709 substances extracted by Cheeseman et al. (1999) from the Gold CPDB (Gold and 
Zeiger, 1997) plus additional substances), they focused on identifying the structural alerts that 
would give the highest calculated risks if present at very low concentrations in the diet. In order to 
identify the structural groups of most concern, the scheme of structural alerts proposed by Ashby 
and Tennant (1991) and by Cheeseman et al. (1999) was examined. The differences between the 
different structural alerts was most apparent in the data for the fraction of substances within each 
group giving an estimated upper bound risk of cancer of greater than 1 x 10
-6 when present in the 
diet at a concentration of 0.15 µg/person per day. This value was therefore selected as the generic 
TTC for substances with a structural alert for genotoxicity, and is 10-fold lower than the US TOR 
of 1.5 µg/person per day. The substances for which the risk was greater than 1 x 10
-6 at an 
exposure of 0.15 µg/person per day were further examined (see below). 
In the mean time, the Gold database has been updated and a supplement was added in 2007
31. The 
database contains now more than the 730 substances used by Kroes et al. (2004) to derive the TTC 
of 0.15 ug/person and day. However, because of the large number of substances already in the 
earlier database, the Scientific Committee considers that the distribution of 1 x 10
-6 risk levels 
derived by linearised low-dose extrapolation for these 730 carcinogens would not be expected to 
change substantially if the new substances were to be included in the analysis, provided structural 
groups of high potency carcinogens as defined by Kroes et al. (2004) were excluded. 
 
Exclusion of very potent carcinogens 
During their assessment of variations in carcinogenic potency, Cheeseman et al. (1999) identified 
some groups of substances in which a high percentage of those tested had virtually safe doses 
below 0.5 ppb. They therefore proposed that such groups should be excluded from exemption 
under the TOR. These were (1) substances with N-nitroso or benzidine-like structural alerts, even if 
they were negative in the Ames assay, and (2) hydrazines, triazenes, azides, azo and azoxy 
substances, and substances with strained heteronuclear rings, that test positive in the Ames assay. 
The issue of very potent carcinogens was further explored by Kroes et al. (2004). They identified 3 
structural groups of genotoxic carcinogens ― aflatoxin-like compounds, N-nitroso-compounds and 
                                                      
 
31 http://potency.berkeley.edu/database.html, accessed on 17.3.2009   
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azoxy-compounds ― which are of such high potency that if a TTC were to be established to cover 
all these it would need to be set at a much lower dietary concentration than the generic TTC for 
other structural groups of genotoxic carcinogens. They also identified some unusual high-potency 
non-genotoxic carcinogens ― TCDD and steroids. They concluded that establishing a TTC that 
would cover these high-potency structural groups, termed the “cohort of concern”, would not be 
appropriate. They therefore concluded that compounds with these structural alerts for high potency 
require compound-specific toxicity data and should be excluded from the TTC approach. 
Development of human exposure threshold values for non-cancer endpoints 
 
The work of Munro and colleagues 
 
Around the same time as the FDA was developing the TOR policy, Munro and colleagues were 
developing the TTC concept (Munro 1990, 1996; Munro et al., 1996, 1998, 1999). In a key paper 
(Munro et al., 1996) they proposed the use of generic thresholds for acceptable human exposures 
based on an exploration of the relationship between chemical structures and toxicity. They 
compiled a large reference database (hereinafter referred to as the Munro et al. database) consisting 
of 613 chemicals for which toxicity data were available on a variety of non-cancer endpoints from 
subchronic, chronic, reproductive and developmental toxicity studies. Over 2900 no-observed-
effect levels (NOELs) were available from these studies. The chemicals in the Munro et al. (1996) 
database were divided into three structural classes, based on a “decision tree” developed earlier by 
Cramer et al. (1978).  The criteria for the three structural classes are shown in section 3.1 of the 
main opinion.  
 
The Cramer et al. (1978) decision tree is based on a series of 33 questions relating mostly to 
chemical structure, but natural occurrence in food and in the body are also taken into consideration. 
The logic of the sequential questions was based on the then available knowledge on toxicity and on 
how chemical structures were metabolised in mammalian metabolic pathways. Cramer et al. (1978) 
predicted that the majority of substances would fall into either Class I (likely to be of low oral 
toxicity) or Class III (no strong presumptions of safety or suggestive of significant toxicity), rather 
than Class II (intermediate), and that is indeed borne out by the Munro et al. database and by 
subsequent experience with the TTC approach. Cramer et al. (1978) tested the validity of their 
decision tree by classifying 81 chemicals (used as food additives, drugs, industrial chemical or 
pesticides), on which toxicity data from short-term or chronic studies were available, into the three 
structural classes and tabulating the NOELs. There was overlap in the range of magnitudes of the 
NOELs between the three structural classes, but it was clear that the NOELs of Class I substances 
were generally higher than those of Class III, with those of Class II being in between. 
Munro et al. (1996) followed the approach of Cramer et al. (1978), classifying each of the 613 
substances in their database into its Cramer structural class. There were 137 substances classified 
in Class I, 28 in Class II and 448 in Class III. They then identified the lowest NOEL for each 
substance from the available toxicity data and plotted the magnitude of the NOELs for each class 
in cumulative distributions (see Figure 2). 
From each of the three lognormal distributions, they estimated the 5
th percentile of the distributions 
of NOELs. To derive “human exposure thresholds” for each structural class, the 5
th percentile 
values were multiplied by 60 (assuming an individual weighs 60kg) and then divided by a factor of 
100 to ensure a margin of safety. The three “human exposure thresholds” obtained, in mg/person 
per day, are shown in Table 1. These human exposure thresholds are also referred to as TTCs.  
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Table 1: Derivation of human exposure thresholds from toxicity data 
 
Structural class  Fifth percentile NOEL 
(mg/kg bw per day) 
Human exposure threshold 
(µg/person per day)* 
I 3.0  1800 
II 0.91  540 
III 0.15  90 
* The human exposure threshold was calculated by multiplying the 5th percentile NOEL by 60         
(assuming an individual weight of 60 kg) and dividing by an uncertainty factor of 100. 
 
Munro and colleagues emphasised that the human exposure thresholds are intended to apply only 
to structurally defined chemicals for which there is no evidence of genotoxic carcinogenicity and 
no structural alerts for genotoxicity. According to this scheme, a threshold can be selected for a 
chemical of known structure but unknown toxicity; if human exposure to a chemical is below the 
relevant threshold of concern for its structural class, Munro and colleagues considered that “the 
substance can be judged, with reasonable confidence, to present a low probability of risk” (Munro 
et al., 1996). 
Cheeseman et al. (1999) also examined the underlying premise of the US TOR policy, that by 
using a threshold that protects against carcinogenic effects, it would also protect against other toxic 
effects. They analysed information from the Registry of Toxic Effects of Chemical Substances 
(RTECS) on 3306 substances for which there were oral reproductive toxicity data and 2542 
substances for which there were data from other repeat-dose toxicity tests.  For each substance, 
they searched for the lowest dose at which a toxic effect was seen and divided this lowest low 
effect level (LLEL) by an uncertainty factor of 1000 to derive a range of “pseudo-acceptable daily 
intakes” (PADIs). The most likely (median) value for the Pseudo Acceptable Daily Intake for the 
reproductive toxins was 10 ppm (10 mg/kg diet), which was 8300-fold above 1.2 ppb,   
corresponding to the median value for the one in a million risk levels for carcinogens, estimated 
from the carcinogenic potency database. These results supported the presumption that a ‘virtually   
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safe dose’ based on carcinogenicity data would protect against other non-cancer, toxic effects. 
Comparison of the Pseudo Acceptable Daily Intakes  (LLEL ÷ 1000) for non-cancer effects with 
the “ADIs” from the Munro et al. (1996) database (NOELs ÷ 100) showed that the Pseudo 
Acceptable Daily Intakes were one order of magnitude more conservative than the “ADIs”, 
reflecting the 10-fold difference in the uncertainty factor applied. 
Exclusion of certain groups of substances from the TTC approach 
In addition to recommendations to exclude substances with structural alerts for high potency 
carcinogenicity (see 2.3.), Kroes et al. (2004) made a number of other recommendations for 
exclusion of particular groups from the TTC approach. They recommended exclusion of 
polyhalogenated-dibenzodioxins, -dibenzofurans and -biphenyls, along with heavy metals, because 
they are known to accumulate in the body. Other non-essential metals in elemental, ionic or 
organic forms were also recommended to be excluded because they were not included in the 
original database of Munro et al. (1996), nor are inorganic substances covered by the structural 
scheme of Cramer et al. (1978). Proteins were also recommended to be excluded since they were 
not included in the Munro et al. (1996) database, and their potential for allergenicity and the potent 
biological activities of some peptides make them unsuitable for the TTC approach.  
Evaluation of endpoints of specific concern 
The TTC concept and the TOR approach for food contact materials were discussed by the EC 
Scientific Committee for Food in 1996 and one of the issues raised was whether, for certain 
endpoints of specific concern, toxic effects might occur at low dose levels which would not be 
covered by the human exposure thresholds derived by Munro et al. (1996). In particular, concerns 
were raised about whether effects on the nervous system, immune system, endocrine system and 
development would be absent at the human exposure threshold values (SCF, 1998). Although the 
original database published by Munro et al. in 1996 did include some studies measuring these 
endpoints of specific concern, they were insufficient in number to provide a robust answer to the 
question of potential low-dose effects.  
An Expert Group was therefore set up by ILSI Europe to examine this question in more detail 
(Kroes et al., 2000). Expanded databases were developed for the toxicological endpoints of 
neurotoxicity (82 substances), immunotoxicity (37 substances), developmental neurotoxicity (52 
substances) and developmental toxicity (81 substances). They were analysed to see if toxic effects 
involving these endpoints occurred at lower doses than those for structural Class III substances in 
the original database of Munro et al. (1996). The analysis showed there was no difference between 
the cumulative NOELs for Class III substances and those for the four selected endpoints, other than 
for neurotoxicity. The cumulative distribution of NOELs for neurotoxicity was not only lower than 
those of the other selected endpoints, but it was also clearly lower than that for structural Class III 
compounds. Consistent with the earlier findings of Cheeseman et al. (1999), the TTC value of 1.5 
μg/person per day, based on cancer endpoints, covered all these effects, being 2-3 orders of 
magnitude lower than the neurotoxicity NOELs divided by an uncertainty factor of 100.  
Subsequently Kroes et al. (2004) further explored whether particular neurotoxicants should be 
considered as a separate class. Using the expanded database from the earlier work (Kroes et al., 
2000) and locating the most sensitive indicators of effects that they could find, the NOELs for the 
most potent neurotoxicants, the organophosphorus compounds (OPs), were plotted separately from 
the other neurotoxicants. They noted that the 5th percentile NOEL for OPs was lower, by around 
an order of magnitude, than the corresponding NOEL for other neurotoxicants. The other 
neurotoxicants resulted in a plot comparable to the Class III chemicals examined by Munro et al. 
(1996). By applying an uncertainty factor of 100 to the 5th percentile NOEL for OPs, Kroes et al. 
(2004) derived a human exposure threshold of 18 μg/person per day and recommended that this 
figure be used for OPs rather than the value of 90 μg/person per day used for other substances in 
structural Class III.  
For references, see list in main text.   
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APPENDIX B 
The TTC approach for flavouring substances 
The application of the TTC approach for flavouring substances as used by EFSA is illustrated in 
Figure 1 below. It is a modification of the procedure used by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA). In both procedures, the first consideration is the known or 
predicted metabolic pathway of the flavouring substance, which asks the question “Can the 
substance be predicted to be metabolised to innocuous products?”. If “Yes” then the substance 
goes down the “A” side of the procedure. If “No”, it goes down the “B” side. For a substance going 
down the A side, provided the exposure is below the relevant TTC value for its structural class, it is 
considered to be of no safety concern. If the exposure exceeds the relevant TTC value, but the 
substance or its metabolites are endogenous, then again it is concluded there is no safety concern.  
If the substance or its metabolites are not endogenous, then toxicity data are required, either on the 
substance itself or on a structurally-related substance, which allow a NOEL to be identified that 
provides an adequate margin of safety. If none of those conditions are met then additional data are 
required. For a substance going down the B side and for which the estimate of dietary exposure is 
below the relevant TTC value, in order to conclude there is no safety concern, either toxicity data 
on the substance itself or on a structurally-related substance are required, allowing a NOEL to be 
identified that provides an adequate margin of safety, or (in JECFA evaluations) dietary exposure 
must be below 1.5 μg/day. If these conditions are not met then additional data are required. 
Similarly, if dietary exposure is above the relevant TTC value then data are required on the 
substance itself or a closely related substance to perform a safety evaluation (Munro et al., 1999; 
Renwick, 2004).  
The EFSA procedure is similar to that of JECFA, but EFSA does not use the threshold value of 1.5 
μg/day, although it should be noted that JECFA does not use that TTC value either if a flavouring 
substance is known to be genotoxic. In order to ensure that high chronic exposure is taken into 
account, JECFA and EFSA have introduced in their procedure a dietary exposure estimate that 
reflects potential exposure by those regularly consuming food products to which a particular 
flavouring has been added (WHO, 2009c; EFSA, 2010e). JECFA has already performed safety 
evaluations based on this estimate (WHO, 2010).  
 
It should be noted that in the application of the TTC approach, the flavouring substances are 
assessed in structurally-related groups and some toxicity data are often available on one or more 
members of the group.  
For references, see list in main text.   
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Figure 1: Procedure for Safety Evaluation of Chemically Defined Flavouring Substances as used by EFSA
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Data must be available on the 
substance or closely related 
substances to perform a safety 
evaluation
Does a NOEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances?
Does a NOEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances?
  Substance would not be 
expected to be of safety concern 
Is the substance or are its metabolites endogenous?
Additional data required
Step 1. 
Step 2. 
Step A3.
Step A4.
Step A5.
Step B3.
Step B4.
 Yes   No
 Yes 
 No
No
No
Yes
No
Yes
Yes
Yes
 No  
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APPENDIX C 
EFSA’s analysis of NOELs for substances in Cramer Class I and III in the Munro et al. 
Database 
 
Verification of the NOELs for substances in the lowest 10th percentile of the Cramer Class I 
distribution of NOELs 
The Scientific Committee examined the critical studies for the substances in the lowest 10
th percentile 
of the Cramer Class I and Cramer Class III distributions of NOELs presented by Munro et al. (1996) 
to ascertain whether the numerical value of the NOEL cited by Munro et al. could be verified.  The 
results of this evaluation have been described in the main text of the opinion and are summarised in 
Tables 1 and 2 below. For Cramer Class I, some additional commentary to that in the main text of the 
opinion is given below. 
For isopropyl alcohol the original paper on the critical study is in Russian, but the study is cited in a 
JECFA monograph (WHO, 1999b). The JECFA description of the study does not identify the overall 
NOEL for all the effects reported by the original authors. Munro et al. (1996) used the lowest dose 
tested (0.018 mg/kg bw per day) as the NOEL, commenting that the original authors reported 
teratogenicity even at this low dose. However, they went on to note that metabolic considerations 
would not raise suspicion for toxic effects and that other developmental toxicity studies using much 
higher doses than the critical study did not find any teratogenic effects. Nevertheless Munro et al. 
(1996) retained this NOEL in the database, in order to be conservative.  
The NOEL for triethylene glycol could not be verified as the original reference is to an abstract and 
we were not able to locate any subsequent full publications. However, from the abstract it is evident 
that the NOEL could be as high as 550 mg/kg bw per day, not 0.5 mg/kg bw per day as cited by 
Munro et al. (1996). This is because the doses in the abstract were expressed in units of ml/kg bw/day 
with 0.5 ml/kg bw per day being the NOEL stated by the original authors. This has probably been 
erroneously recorded by Munro et al. (1996) as 0.5 mg/kg bw per day, making the NOEL overly 
conservative for this substance. 
The NOELs of 0.6 and 1.4 mg/kg bw per day for 2,6- and 3,4-dimethylphenol, respectively, were 
taken by Munro et al. (1996) from the IRIS database and were verified by us from the original paper. 
It was not possible to judge the quality of this study on the two dimethylphenols from the original 
paper, but it was notable that the study was not conducted to a standard protocol, and that few 
methodological details were given (no indication of mode of oral administration, no group sizes, no 
indication of what was examined except from table of results). 
The NOEL from the critical study on oleylamine could not be verified because it has been published 
in abstract only and we were not able to locate any subsequent full publications. The abstract gives the 
same NOEL of 3 mg/kg bw per day as listed by Munro et al. (1996). 
The original paper for riboflavin could not be obtained, but the study is cited in a JECFA monograph 
(WHO, 1981b). Munro et al. (1996) identified the NOEL as 4 mg/kg bw per day. The JECFA 
monograph states that the doses were 4 and 40 ppm given in the diet to young rats and no effects were 
identified. Using standard conversion factors, 40 ppm in the diet equates to an oral exposure of around 
4 mg/kg bw per day, which was the NOEL listed by Munro et al. (1996).  
The original paper was obtained for isoamyl acetate. The conduct of the study was comparable to that 
of a 90-day repeated-dose OECD protocol and the NOEL of 4.7 mg/kg bw per day used by Munro et 
al. (1996) was verified.   
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The NOEL for ascorbic acid could not be verified from the original study report on developmental 
toxicity as it is unpublished, neither could it be verified from the brief description of the study by 
JECFA (WHO, 1981a). However, it is evident that Munro et al. (1996) used the lowest dose tested of 
5.5 mg/kg bw per day as the NOEL. This was a conservative approach as no significant effects were 
reported in either the critical study or another developmental toxicity study, in both of which the 
highest doses tested were >500 mg/kg bw per day. 
The original publication on the critical study for ethyl acrylate showed that it was well-designed and 
well-reported. The NOEL of 8.4 mg/kg bw per day used by Munro et al. (1996) was obtained by 
utilising standard conversion factors for rat body weight and food consumption to derive the average 
amount of test substance consumed. Using the actual data on body weight and food consumption from 
the original publication, a NOEL of 5.6 mg/kg bw per day can be derived, which is slightly more 
conservative than the NOEL used by Munro et al. (1996). 
The original publication on the critical study for methyl methacrylate showed that it was well-
designed and well-reported. The NOEL of 8.4 mg/kg bw per day used by Munro et al. (1996) was 
obtained by utilising standard conversion factors for rat body weight and food consumption to derive 
the average amount of test substance consumed. The designated NOEL by Munro was based on 
reduced food consumption in rats but only fluid consumption was reduced, and the effects seen on 
body weight were reversible. As no treatment related effects were found, the NOEL from this study 
was found to be 2000 ppm, the highest dose tested. Using the actual data on body weight and food 
consumption from the original publication, a NOEL of 146.5 mg/kg bw per day can be derived, which 
is less conservative than the NOEL used by Munro et al. (1996). 
 
For dodecyl gallate the original paper is in Russian, but the study is cited in a JECFA monograph 
(WHO, 1993). The JECFA description of the study indicates the same NOEL of 10 mg/kg bw/day as 
listed by Munro et al. (1996). The NOEL is verified.  
 
The original report on the critical study on ionone could not be obtained as it is unpublished, but the 
study is cited in a JECFA monograph (WHO, 1984a). The JECFA description of the study indicates it 
was well-conducted as it was specifically designed to investigate possible haematological and renal 
effects indicated in a previous subchronic study. The JECFA description of the study indicates the 
same NOEL of 10 mg/kg bw per day as listed by Munro et al. (1996). The NOEL is verified based on 
the JECFA analysis.  
 
The original paper on the critical study for 4-methyl-1-phenylpentan-2-ol showed that it was well-
designed and well-reported. The NOEL of 10 mg/kg bw/day reported by the study authors and used 
by Munro et al. (1996) was verified.  
 
The original paper on the critical study for 2-phenyl-1-propanol showed that it was well-designed and 
well-reported 90-day study. The NOEL of 10 mg/kg bw per day reported by the study authors and 
used by Munro et al. (1996) could not be verified since there were statistically significant reductions 
in body weight in all treated females, including the lowest dose group of 10 mg/kg bw per day, at all 
of the 2-weekly time points measured.  
 
The original paper on the critical study for retinol was a non-standard developmental toxicity study in 
which retinol was given to mice at 0, 10 or 100 mg/kg bw as a single gavage dose on day 11 of 
gestation. The NOEL of 10 mg/kg bw reported by the authors and used by Munro et al. (1996) was 
verified. However, in the light of current knowledge on the teratogenicity of retinol, which indicates 
that duration of exposure can also be important, the design used for the critical study would not be 
expected to give the lowest NOEL for developmental toxicity and, indeed, other studies in rabbits and 
humans have indicated that the NOEL for developmental toxicity is lower than 10 mg/kg bw/day, at 
2.5 mg/kg bw/day in rabbits, and possibly as low as around 0.05 - 0.1 mg/kg bw/day for humans 
(SCF, 2002; UK FSA, 2003). Thus the Munro et al. (1996) database is not conservative with respect 
to the NOEL for retinol.    
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The original report on the critical 2-year rat study on styrene could not be obtained as it is 
unpublished, but the study is cited in a JECFA monograph (WHO, 1984b). The JECFA description of 
the study indicates it was well-conducted and that the NOEL was 12 mg/kg bw per day, which is the 
same as that used by Munro et al. (1996). 
 
Table 1. Lowest 10
th percentile of substances from the Munro et al. (1996) database in Cramer Class I.   
The commentary on Class I can be found in the main text (chapter 4.2.3.1)   
Substance Code 
(Munro 
et al., 
1996)  
CAS 
number 
NOEL  
cited by 
Munro et 
al.  
(mg/kg 
bw/d) 
Reference & 
remarks on 
citation 
Appropriate 
NOEL for 
study?*  
 
Endpoint from which 
the  Munro et al. 
NOEL was derived 
Ascorbic acid  7  50-81-
7(a) 
5.5  Food & Drug 
Research 
Laboratories 
Unpublished 
1974 
 
Cited in JECFA 
23M WHO 
Food Add Ser 
14 
Yes. Not 
verifiable but is 
conservative 
based on JECFA 
evaluation 
Musculoskeletal. 
 
2,6-
Dimethylphenol  
39 576-26-
1 
0.60  Veldre & Janes  
Environ Hlth 
Perspect 
30,141-
146,1979 
 
Munro took 
description of 
study from IRIS 
DB #0230 
Yes  Multiple effects (body 
weight, blood pressure 
and pathology of 
internal organs) 
3,4-
Dimethylphenol 
40  95-65-8  1.40  Veldre & Janes  
Environ Hlth 
Perspect 
30,141-
146,1979 
 
Munro took 
description of 
study from IRIS 
DB #0230 
Yes  Multiple effects (body 
weight, blood pressure, 
peripheral blood 
parameters and 
pathology of internal 
organs) 
 
Dodecyl gallate  44  1166-
52-5 
10 Mikhailova  et  al 
Vopr Pitan 
2,49,1985 
 
Cited in JECFA 
41M WHO 
Food Add Ser 
32 
Yes  
 
 
Multiple effects. 
Deaths, changes in 
serum lipids and 
enzymes, reduction in 
weight of the spleen 
and, pathological 
changes in the liver, 
kidney, and spleen.   
 
Ethyl acrylate  47  140-88-
5 
8.40  Borzelleca et al  
Toxicol Appl 
Pharmacol 6, 
29-36,1964 
No. Based on 
measured body 
weights and food 
consumption data 
the NOEL should 
be lower (5.6 
mg/kg bw per 
day). 
Food consumption. 
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Ionone 80  8013-
90-9 
10 Ford  et  al 
Unpublished 
(RIFM) 1983 
 
Cited in JECFA 
28 WHO Food 
Add Ser 19 
Yes 
 
Multiple effects 
reduced weight gain, 
reduced food 
consumption reduced 
serum glucose 
concentrations 
increased water intakes 
and mild renal 
functional changes.  
No histological changes 
were evident in the 
kidneys or livers.  
Isoamyl salicylate  82  87-20-7  4.7  Drake et al  
Food Cosmet 
Toxicol 13, 
185-193,1975 
 
Munro took 
from RIFM DB 
Yes  Organ weight changes. 
Increased relative 
kidney weights and 
adverse effects on 
kidney function  
Isopropyl alcohol  85  67-63-0  0.018  Antonova & 
Salmina  
Gig Sanit 1, 8-
11, 1978   
Cited in SCF 
ADI 11th  
Series Report 
1981  
 
Cited in JECFA 
51M  
WHO Food Add 
Ser 42 only for 
flavourings use 
Yes. It was the 
NOEL from the 
study, but EFSA 
is aware that later 
studies on 
developmental 
toxicity using 
much higher 
doses did not find 
evidence of 
teratogenicity 
Teratogenic 
  
Methyl 
methacrylate 
95 79-41-4  8.40 Borzelleca  et  al 
Toxicol Appl 
Pharmacol 6, 
29-36, 1964 
No. Food 
consumption was 
not reduced so 
NOEL should be 
higher (146.5 
mg/kg bw per 
day) 
Food consumption. 
 
Methyl-1-
phenylpentan-2-
ol, 4- 
97 38502-
29-3 
10  Ford et al  
Food Chem 
Toxicol 21, 
441-447, 1983 
 
Munro took 
from RIFM DB 
Yes 
 
 
Blood effects. a 
decrease in serum 
glucose in males. The 
authors considered this 
of questionable 
toxicological 
significance, however 
effect was also seen in 
highest dose group. 
 
Oleylamine 105  1838-
19-3 
3.0  Mercieca et al  
Teratology 41, 
577, 1990 
 
Munro took 
abstract from 
DART DB 
Yes, based on 
abstract 
Multiple effects. 
Maternal toxicity (body 
weight loss, reduced 
food consumption), no 
developmental toxicity 
was observed. 
Phenyl-1-
propanol, 2- 
  
109 698-87-
3 
10  Gaunt et al  
Food Chem 
Toxicol 20, 
519-525, 1982 
No.  Females of 
all dose groups 
including 10 
mg/kg bw per day 
had statistically 
significant 
reduced body 
weights from 
week 4 onwards  
Liver and kidney 
weights   
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*The column headed “Appropriate NOEL for study?” indicates whether the NOEL was confirmed in our 
analysis.  
 
so no NOEL can 
be identified 
Retinol 115  68-26-2  10  Eckhoff  et  al 
Toxicol Lett 48, 
171, 1989 
 
From DART 
DB 
Yes. This was the 
NOEL from the 
study in the 
mouse, but data 
from the rabbit 
gives a NOEL 
around an order of 
magnitude lower 
for teratogenic 
effects (Rosa et 
al., 1986). 
Teratogenic 
Riboflavin
  
116 83-88-5  4.0  Le  Clerc   
Ann Nut 
Aliment 23, 
111-120, 1974 
 
Cited in JECFA 
25M  
WHO Food Add 
Ser 16 
Yes, based on 
JECFA evaluation 
No effects, NOEL 
highest dose tested 
 
Styrene 124  100-42-
5 
12 Chemical 
Manufacturers' 
Association, 
Litton Bionetics 
1980 
 
Cited in JECFA 
28 WHO Food 
Add Ser19 
Yes, based on 
JECFA evaluation 
Body weight 
 
Triethylene 
glycol 
132 112-27-
6 
0.50 Neeper-Bradley 
et al  
Toxicologist 14, 
160, 1994 
 
Society of 
Toxicology 
abstract, 
Munro took 
abstract from 
DART DB 
No, based on 
abstract, NOEL 
likely much 
higher because 
units were in 
mL/kg bw/day, 
not mg/kg bw per 
day. 
Teratogenic 
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Verification of the NOELs for substances in the lowest 10th percentile of the Cramer Class III 
distribution of NOELs. 
The commentary on Class III can be found in the main text (chapter 4.2.3.2). 
Table 2: Lowest 10
th percentile of substances from the Munro et al. (1996) database in Cramer Class III. 
 
Substance Code 
(Munro 
et al., 
1996) 
CAS 
number 
NOEL cited 
by Munro et 
al.  
(mg/kgbw/d) 
Reference & 
remarks on 
citation 
Appropriate 
NOEL for 
study?*  
Endpoint from 
which the 
Munro et al. 
NOEL was 
derived 
Acrylamide 30  79-06-  1  0.2 Burek  et  al., 
1980 
Yes Neurotoxicity 
Aldicarb 35  16-06-03  0.3  Union 
Carbide, 
1968 
Yes to limited 
extent (from 
IRIS) 
Reproductive 
toxicity 
Avermectin B1  62  65195-55-3  0.03  Merck & Co., 
1985 
Yes to limited 
extent (from 
IRIS) 
Teratogenicity 
Azinphos 
methyl 
64 86-50-0  0.18  Huntingdon 
Research 
Centre, 1966 
No. Insufficient 
detail in JMPR 
report (1969) 
Haematological 
effects  
(details not 
available) 
Bidrin  
(Dicrotophos) 
77 141-66-2  0.1  Shell 
Chemical 
Co., 1965 
Yes to limited 
extent  (from 
IRIS) 
Reproductive 
toxicity 
 (decreased pup 
survival) 
Chlordane 106  57-74-9 0.055  Velsicol 
Chemical, 
1983 
Yes to limited 
extent (from 
IRIS) 
Hepatotoxicity 
Coumaphos 130  56-72-4  0.4  Doull  et  al., 
1960 
No. Insufficient 
detail in JMPR 
report (1969) 
Multiple effects 
  (no further 
information 
could be 
retrieved) 
Cyhalothrin 137  68085-85-8  0.5  Imperial 
Chemicals 
Industries, 
1984 
Yes to limited 
extent (from 
IRIS) 
Body weight 
reduction 
Cypermethrin 138  523  15-07-8  0.5  ICI 
Americas, 
Inc., 1979 
Yes to limited 
extent (from 
IRIS) 
Body weight 
reduction 
2,4-
Dichlorophenol 
162 120-83-2  0.3  Exon  and 
Keller, 1985 
Yes to limited 
extent (from 
IRIS) 
Multiple effects 
(Only decreased 
delayed 
hypersensitivity 
cited in IRIS) 
Dichlorvos 166  62-73-7  0.23  Shell 
Chemical 
Co., 1967 
Yes to limited 
extent (from 
IRIS) 
Multiple effects 
 (Cholinesterase 
[type not stated, 
but not brain] 
inhibition and 
hepatocellular 
vacuolation) 
Dieldrin  168  60-57-1  0.005  Walker er al., 
1969 
Yes Hepatotoxicity   
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22,23-
Dihydroaverme
ctin-B1a,  
(Ivermectin) 
 
173  71827-03-7  0.2  Merck & Co., 
1979 
Yes to limited 
extent (from 
JECFA 
monograph) 
Neurotoxicity 
22,23-
Dihydroaverme
ctin-B1b,  
(Ivermectin) 
 
 
174  71827-03-7  0.4  Merck & Co., 
1979 
Yes to limited 
extent (from 
JECFA 
monograph) 
Non-specific 
effects 
Dimethoate 178  60-51-5  0.05  American 
Cyanamid, 
1986a 
Yes to limited 
extent (from 
IRIS) 
Neurotoxicity 
m-
Dinitrobenzene 
185 99-65-0  0.4  Cody  et  al., 
1981 
Yes Organ  weight 
changes 
 (increased 
spleen weights) 
Diquat 194  85-00-7  0.19 Chevron, 
1985b 
Yes to limited 
extent (from 
IRIS) 
Ocular effects 
 (minimal lens 
opacity 
and cataracts) 
 
Disulfoton 195  98-04-4  0.05  Mobay 
Chemical, 
1975 
Yes to limited 
extent (from 
IRIS) 
Multiple effects 
 (inhibition of 
RBC ChE and 
brain ChE; 
males: increased 
mortality; 
increase in 
absolute and 
relative weights 
of spleen, liver, 
and pituitary, 
decrease in 
absolute and 
relative weights 
of brain and 
seminal vesicles; 
females: decrease 
in absolute and 
relative weight of 
kidneys 
Ethion 206  563-12-2  0.2  FMC  Corp., 
1985 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
 (plasma ChE 
inhibition in 
females) 
Ethyl p-
nitrophenyl 
phenylphosphor
othioate 
208 2104-64-5  0.25  Moribani, 
Nissan,  
du Pont, 
Velsicol, 
1986 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
 (decreased 
plasma ChE 
activity and 
decreased RBC, 
hemoglobin, and 
hematocrit in 
both sexes. Also 
decreased brain 
ChE activity, 
decreased female 
growth) 
Fenamiphos 215  22224-92-6  0.1  Mobay 
Chemical, 
1982 
Yes to limited 
extent (from 
IRIS) 
Body weight 
reduction   
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Fonofos 226  944-22-9  0.5  Stauffer 
Chemical 
Co., 1968 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
  (plasma and 
RBC ChE 
inhibition) 
Glufosinate-
ammonium 
228 77182-82-2  0.4  Hoescht, 
1982 
Yes to limited 
extent (from 
IRIS) 
Organ weight 
changes 
(increase in 
absolute and 
relative kidney 
weights was 
noted in males) 
Haloxyfop-
methyl 
230 69806-40-2  0.005  Dow 
Chemical, 
1985 
Yes to limited 
extent (from 
IRIS) 
Organ weight 
changes 
 (decreased 
relative kidney 
weights) 
Heptachlor 232  76-44-8  LEL   
0,25 
rat 2y  
5 ppm 
liver/bw 
weight  
 
NOEL 
0.15 
3 ppm 
Velsicol 
Chemical, 
1955. 
Available 
from EPA, 
IRIS. 
Accession 
number 0243 
Yes to limited 
extent (from 
IRIS)  
In IRIS also 
present rat 2y:  
LOEL 0,25 
liver/bw weight  
and NOEL 0.15 3 
ppm 
 
JMPR and 
INCHEM set 
lower ADIs 
Reproductive 
toxicity 
Heptachlor 
epoxide 
233 1024-57-3  0,25 
  
rat 3 gen 
 repr  
5 ppm 
 
Velsicol 
Chemical, 
1959. 
Available 
from EPA, 
IRIS. 
Accession 
number 0160 
Yes to limited 
extent (from 
IRIS) 
Reproductive 
toxicity 
 
Hexachloroben
zene 
235 118-74-1  0,08 
 
rat 130 w          
F0 + F1 1.6 
ppm (0.08) 
Arnold et al., 
1985. Food 
Chem 
Toxicol 23, 
779-793. 
Available 
From EPA, 
IRIS. 
Accession 
number 0374 
Yes to limited 
extent (from 
IRIS) and 
Abstract of the 
original paper 
Hepatotoxicity 
Hexahydro-
1,3,5-trinitro-
1,3,5-triazine 
(RDX) 
241 121-82-4  0,3 
 
rat 2y  
 
U.S DOD, 
1983. 
Available 
from Defense 
Tech Center. 
From EPA, 
IRIS. 
Accession 
number 0313 
Yes to limited 
extent (from 
IRIS) 
Multiple organs 
effects 
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Merphos 
(akatributyl 
phosphorotrithi
oite) 
 
272 150-50-5  0,1 
 
rat 112 d 
neurotox 
 
Munro UF 
300 
 
Virginia 
Carolina 
Chemical 
Corp., 1985. 
Available 
from EPA. 
IRIS. 
Accession 
number 0366 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
(RBC ChE 
inhibition) 
Merphos oxide  273  78-48-8  0.25 
 
rat 2y  
 
 
Mobay 
Chemical, 
1969. 
Available 
from EPA, 
IRIS. 
Accession 
number 0367 
Yes to limited 
extent (from 
IRIS) 
Neurotoxicity 
(Brain ChE 
inhibition) 
 
Methidathion 277  950-37-8  0,2 
 
rat 2y  
4 ppm 
Ciba, 1986. 
Available 
from EPA, 
IRIS. 
Accession 
number 0341 
Yes to limited 
extent (from 
IRIS) 
Multiple effects 
(RBC, brain ChE 
inhibition and 
alopecia) 
Methyl 
parathion 
283 298-00-0  0,025 
 
rat 2y 
0.5 ppm 
Monsanto 
Co., 1984. 
Available 
from EPA, 
IRIS. 
Accession 
number 0174 
Yes to limited 
extent (from 
IRIS) 
Organ weight 
changes 
Mirex 292  2385-85-5  0,17 
 
mice 18 m 1 
ppm 
Fulfs et al., 
1977. 
Ecotoxicol 
Environ Saf 
1: 327.  
Available 
from from 
EPA, IRIS. 
Accession 
number 0251 
Yes to limited 
extent (from 
IRIS) 
Hepatotoxicity 
Molinate 293 2212-67-1  0,2 
 
rat fertility 
(time?)  
Stauffer 
Chemical 
Co., 1981. 
Available 
from EPA, 
IRIS. 
Accession 
number 0298 
Yes to limited 
extent (from 
IRIS) 
Reproductive 
toxicity 
Naled 296  300-76-5  0,2 
 
rat 2y  
Chevron, 
1984a. 
Available 
from EPA, 
IRIS. 
Accession 
number 0175 
Yes to limited 
extent (from 
IRIS) 
Non-specific 
effects 
(brain ChE 
inhibition)   
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Ozadiazon 317  19666-30-9  0,5 
 
10 ppm 
Rhone-
Poulenc, 
1981c. 
Available 
from EPA, 
IRIS. 
Accession 
number 0253 
Yes to limited 
extent (from 
IRIS) 
Multiple effects  
(serum proteins 
and liver 
weights) 
Oxyfluorfen 320  42874-03-3  0,3 
 
mouse 20 m  
2 ppm  
Rohm and 
Haas Co., 
1977. 
Available 
from EPA, 
IRIS. 
Accession 
number 0084 
Yes to limited 
extent (from 
IRIS) 
Hepatotoxicity 
Patulin 327  149-297-1  0,04 
calculated 
Becci et al., 
1981. J Appl 
Toxicol 1: 
256-261. 
Cited in: 
Additives and 
Contaminants 
35th Meeting 
of JECFA. 
WHO Food 
Additives 
Series, No. 
26 
Yes from the 
JECFA 
monograph 
Body weight 
reduction 
Photodieldrin 344  13366-73-9 0,35 
 
rat  
59-80 w  
7.5 ppm 
NCI, 1977. 
National 
Cancer 
Institute 
Technical 
Report No. 
17 
Yes to limited 
extent (from 
IRIS) 
Neurotoxicity 
Pirimphos-
methyl 
349 29232-93-7  0,5 
 
dog 2 y 
 
 ChE LEL 
ICI 
Americas, 
Inc., 1973. 
Available 
from EPA, 
IRIS. 
Accession 
number 0257 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
(plasma ChE 
depression) 
Quinalphos 372  13593-03-8  0,03 
mouse 18 m  
Sandoz, Inc., 
1983 1980. 
Available 
from EPA, 
IRIS. 
Accession 
number 0082 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
(plasma ChE 
depression) 
Rotenone 379 83-79-4 0,38 
rat 2 gen 7.5 
ppm 
U.S. Fish and 
Wildlife 
Service, 
1983. 
Available 
from EPA, 
IRIS. 
Accession 
number 0344 
Yes to limited 
extent (from 
IRIS) 
Reproductive 
toxicity 
(Reduced pup 
weight)   
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Sodium 
fluoroacetate 
 
385 62-74-8  0,05 
rat 13 w  
UF 3000 
 
Munro UF 
300 
 
U.S. EPA, 
1988b.  
Available 
from EPA, 
IRIS. 
Accession 
number 0469 
Yes to limited 
extent (from 
IRIS) 
Multiple effects 
(Increased heart 
weight 
in females and 
males; 
decreased testis 
weight and 
altered 
spermatogenesis 
in males) 
Terbutryn 399  886-50-0  0,1 
 
rat 2 y  
2 ppm  
Ciba, 1980b. 
Available 
from EPA, 
IRIS. 
Accession 
number 0285 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
(hemoglobin and 
erythrocytes 
decrease) 
Tetrachloroben
zene, 1,2,4,5- 
401 95-94-3  0,34 
rat 13 w  
UF 1000 
 
Munro UF 
300 
Chu et al., 
1984. 
 Drug Chem 
Toxicol 7: 
113.  
Available 
from EPA, 
IRIS. 
Accession 
number 0107 
Yes to limited 
extent (from 
IRIS) 
Kidney toxicity 
Tetraethyldithio
pyrophosphate 
409 3689-24-5  0,5 
rat 3 m 10 
ppm (0.5) 
UF 1000 
 
Munro UF 
300 
 
 
Kimmerle et 
al., 1974. 
Arch Toxicol 
33: 1-16 
Available 
from EPA, 
IRIS. 
Accession 
number 0330 
Yes to limited 
extent (from 
IRIS) 
Haematological 
effects 
(plasma ChE 
depression) 
Trenbolone 
acetate 
422 10161-34-8  0,044  (0.025) 
rat F0 + F1 
0.5 ppm 
James P, 
Smith JA, 
Parker CA 
1986 
Unpublished 
report 
Huntingdon 
Yes from the 
JECFA 
monograph 
Reproductive 
toxicity 
Trenbolone 
hydroxide, 17a- 
423   0,04 
 
Munro UF 
300 
  Yes from the 
JECFA 
monograph 
Haematological 
effects 
Tridiphane 436  58138-08-2  0,33 
rat 2 gen rep 
5 ppm 
Dow 
Chemical, 
1984. 
Available 
from EPA, 
IRIS. 
Accession 
number 0124 
Yes to limited 
extent (from 
IRIS) 
Reproductive 
toxicity   
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Zeranol 448  55331-29-8  0,02  (0.0125) 
rat  2y 0.25 
ppm  
 
NHEL 
Monkey 
ovariectom-
ised 
(0.05) 
Everett et al., 
1987. 
Unpublished 
report. Cited 
in: JECFA, 
1988.Toxicol
ogical 
Evaluation of 
Certain 
Veterinary 
Drug 
Residues in 
Food. 32nd 
Meeting of 
the JECFA. 
WHO Food 
Additives 
Series, No. 
23 
Yes from the 
JECFA 
monograph 
Ovarian toxicity 
*The column headed “Appropriate NOEL for study?” indicates whether the NOEL was confirmed in our 
analysis.  
 
For references, see list in main text and reference list in Munro et al. 1996.   
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APPENDIX D 
Establishing a TTC value for substances with anti-cholinesterase activity 
 
In total, 93 ADIs for 59 OPs and 27 ADIs for 14 carbamates are listed in the EFSA database 
on pesticides and are shown in Table 1 below.  
 
Table 1: Neurotoxicity data used to establish ADIs and ARFDs on organophosphorus 
and carbamates from the EFSA database on pesticides. 
 
Pesticide class  Compound_name  ADI 
mg/kg 
bw/d 
Uncertainty 
factor 
Source Year Study  Usage 
category* 
organophosphate  Acephate  0.03 10 JMPR  2005 28 d human  IN 
carbamate Aldicarb  0.003 10 JMPR  1995 acute  human  IN+NE+AC 
organophosphate Azinphos-methyl  0.005 100 DE  2008 multigeneration 
rat 
IN+AC 
organophosphate Azinphos-methyl 0.005 100 JMPR  1991 rat 
multigeneration 
IN+AC 
organophosphate Azinphos-methyl  0.03 10 JMPR  2007 30 d human  IN+AC 
organophosphate Azinphos-methyl  0.005 100 SCFCAH 
March 2006 
(Draft review 
report) 
2006 rat 
multigeneration 
IN+AC 
carbamate Bendiocarb  0.004 100 JMPR  1984 2  yr  rat  IN 
carbamate Benfuracarb  0.01 100 EFSA  2006 90 d dogs, rat 
multigeneration 
IN+NE 
carbamate Benfuracarb  0.01 100 EFSA 2009 overall  NOAEL 
dogs, 2 
generation rats 
IN+NE 
organophosphate  Bromophos  0.04 10 JMPR  1977 28 d human  IN 
organophosphate Bromophos-ethyl  0.003 100 JMPR  1975 2  yr  dog  IN 
organophosphate Cadusafos  (aka 
ebufos) 
0.0004 100 EFSA  2006 2 yr rat   IN+NE 
organophosphate Cadusafos  (aka 
ebufos) 
0.0004 100 EFSA 2008 2  yr  rat  IN+NE 
organophosphate Cadusafos  (aka 
ebufos) 
0.0003 100 JMPR 1991 rat 
multigeneration 
IN+NE 
carbamate Carbaryl  0.0075 2000 EFSA  2006 2  yr  mouse  IN+PG 
carbamate Carbaryl  0.008 2000 JMPR  2001 2  yr  rat  IN+PG 
carbamate Carbofuran  0.001 100 EFSA  2006 1  yr  dog  IN+NE+AC 
carbamate Carbofuran  0.001 25 JMPR  2008 rat, acute toxicity  IN+NE+AC 
carbamate Carbofuran 0.00015 200 PRAPeR 
phone 
conference 
January 
2009 
2009 acute 
neurotoxicity 
IN+NE+AC
organophosphate Carbophenothion  0.0005 50 JMPR 1980 2  yr  rat  IN+AC 
carbamate Carbosulfan  0.005 100 DAR 2009 rat  acute 
neurotoxicity 
IN+NE 
carbamate Carbosulfan  0.01 100 EFSA 2006 2  yr  rat  IN+NE 
carbamate Carbosulfan  0.005 100 EFSA 2009 Rat,  acute 
neurotoxicity 
IN+NE 
carbamate Carbosulfan  0.01 100 JMPR  2003 2  yr  rat  IN+NE 
organophosphate Chlorfenvinphos  0.0005 100 JMPR  1994 rat 
multigeneration 
IN   
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organophosphate  Chlorpyrifos  0.01 100 COM  2005 2 yr rat, 2 yr 
mouse, 2 yr dog 
IN+AC 
organophosphate  Chlorpyrifos  0.01 100 JMPR  1982 9 d human  IN+AC 
organophosphate Chlorpyrifos-
methyl 
0.01 100 COM 2005 2  yr  rat  IN+AC 
organophosphate Chlorpyrifos-
methyl 
0.01 10 JMPR  1992 28 d human  IN+AC 
organophosphate Demeton-S-methyl  0.0003 100 JMPR  1989 2 yr rat  IN+AC 
organophosphate Demeton-S-methyl 
sulphone 
0.0003 100 JMPR  1989 3 yr rat  IN 
organophosphate Diazinon  0.0002 100 EFSA  2006 90 d dog, 1 yr 
dog 
IN+AC 
organophosphate  Diazinon  0.005 100 JMPR  2006 90 d rat  IN+AC 
          
organophosphate Dichlorvos  0.004 10 JMPR  1993 human  IN+AC 
organophosphate Dimethoate  0.001 100 EFSA  2006 2 yr rat, rat 
multigeneration, 
rat neurotoxicity, 
rat 
developmental 
neurotoxicity 
IN+AC 
organophosphate Dimethoate 0.002 500 JMPR  1996 rat 
multigeneration 
IN+AC 
organophosphate  Dioxathion  0.0015 100 JMPR  1968 90 d rat 
neurotoxicity 
IN 
organophosphate Disulfoton  0.0003 100 JMPR 1996 2  yr  dog  IN 
carbamate  Ethiofencarb  0.1 100 BE  1982 28 d rat  IN 
carbamate  Ethiofencarb  0.1 100 JMPR  1982 28 d rat  IN 
organophosphate Ethion  (aka 
diethion) 
0.002 100 JMPR 1990 rat 
developmental 
IN+AC 
organophosphate Ethoprophos  0.0004 100 EFSA 2006 2  yr  rat  IN+NE 
organophosphate  Ethoprophos  0.0004 100 JMPR  1999 2 yr rat, rat 
multigeneration 
IN+NE 
organophosphate Etrimfos  0.003 100 JMPR  1986 2  yr  rat  IN+AC 
organophosphate Fenamiphos  (aka 
phenamiphos) 
0.0008 100 EFSA 2006 1  yr  dog  NE 
organophosphate Fenamiphos  (aka 
phenamiphos) 
0.0008 100 JMPR  1997 1 yr dog   NE 
organophosphate Fenitrothion  0.005 100 EFSA 2006 2  yr  rat  IN+AC 
organophosphate Fenitrothion  0.005 100 JMPR  2000 2  yr  dog  IN+AC 
organophosphate Fenitrothion  0.006 100 JMPR  2007 90 d rat, 6 mo rat, 
2 yr rat (overall 
NOAEL) 
IN+AC 
organophosphate Fenthion  0.007 10 DE 2001 human IN 
organophosphate  Fenthion  0.007 10 ECCO  2001 28 d human  IN 
organophosphate  Fenthion  0.007 10 JMPR  1995 25 d human  IN 
organophosphate Fonofos  0.002 100 BE  1986 2  yr  dog  IN 
carbamate Formetanate  0.004 100 EFSA  2006 1  yr  dog  IN+AC 
          
organophosphate Fosthiazate  0.004 100 COM  2003 2  yr  rat  NE 
organophosphate Heptenophos  0.003 100 BE  1987 2  yr  dog  IN 
organophosphate Heptenophos  0.002 DE  1997 90 d dog  IN 
organophosphate Isofenphos  0.001 50 JMPR  1986   IN 
organophosphate Isoxathion  0.0125 100 BE  1987 2  yr  rat  IN 
organophosphate Malathion  0.03 1000 EFSA  2006 2 yr rat    IN 
organophosphate Malathion  0.03 1000 EFSA 2009 2  yr  rat  IN 
organophosphate Malathion  0.3 100 JMPR  1997 2  yr  rat  IN 
organophosphate Mecarbam  0.002 JMPR  1986 metabolism,  IN+AC   
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delayed 
neurotoxicity 
organophosphate Mecarbam  0.0005 200 Scientific 
Committee 
1995 rat 
multigeneration 
IN+AC 
organophosphate Methacrifos  0.006 10 JMPR  1990 human  IN 
organophosphate Methamidophos  0.001 100 COM  2007 2  yr  rat  IN+AC 
organophosphate Methamidophos  0.004 25 JMPR  2002 2  yr  rat  IN+AC 
organophosphate  Methidathion  0.001 100 JMPR  1992 90 d dog, 1 yr 
dog, 2 yr dog 
IN+AC 
carbamate Methiocarb  (aka 
mercaptodimethur) 
0.013 100 EFSA  2006 90 d dog  IN+MO+RE
carbamate Methiocarb  (aka 
mercaptodimethur) 
0.02 100 JMPR 1998 2  yr  dog  IN+MO+RE
carbamate Methomyl  0.0025 100 EFSA 2006 rat  acute 
neurotoxicity 
IN 
carbamate Methomyl  0.0025 100 EFSA 2008 rat  acute 
neurotoxicity 
IN 
carbamate Methomyl  0.02 5 JMPR  2001 human  IN 
organophosphate  Mevinphos  0.00025 100 BE  2001 90 d rat, 2 yr rat IN+AC 
organophosphate  Mevinphos  0.0008 200 JMPR  1996 30 d human  IN+AC 
organophosphate  Monocrotophos  0.0006 10 JMPR  1993 30 d human  IN+AC 
organophosphate  Naled  0.002 100 DAR  2004 2 yr rat, 1 yr dog  IN+AC 
organophosphate Omethoate  0.0003 100 EFSA  2006 rat 
multigeneration, 
2 yr rat 
IN+AC 
          
carbamate Oxamyl  0.001 100 EFSA  2005 rat  acute 
neurotoxicity 
IN+NE 
carbamate Oxamyl  0.009 10 JMPR 2002 acute  human  IN+NE 
organophosphate Oxydemeton-
methyl 
0.0003 100 EFSA  2006 2 yr rat  IN+AC 
organophosphate Oxydemeton-
methyl 
0.0003 100 JMPR  1989 3 yr rat  IN+AC 
organophosphate  Parathion  0.0006 100 DE  2002 90 d rat 
neurotoxicity 
IN+AC 
organophosphate  Parathion  0.0006 100 ECCO 100  2001 90 d rat 
neurotoxicity 
IN+AC 
organophosphate Parathion  0.004 100 JMPR  1995 2  yr  rat  IN+AC 
organophosphate Parathion-methyl  0.001 100 DE 2002 2  yr  rat IN+RE 
organophosphate Parathion-methyl  0.001 100 ECCO 127  2002 2 yr rat  IN+RE 
organophosphate Parathion-methyl  0.003 100 JMPR 1995 2  yr  rat  IN+RE 
organophosphate Phenthoate  0.003 JMPR  1984   IN 
organophosphate  Phorate  0.0007 100 JMPR  2004 2 yr rat, 13 wk 
rat, 1 yr dog 
IN 
organophosphate Phosalone  0.01 100 EFSA 2006 1  yr  dog  IN+AC 
organophosphate Phosalone  0.02 100 JMPR  1997 2  yr  rat  IN+AC 
organophosphate Phosmet  0.003 300 EFSA  2006 2 yr mouse   IN 
organophosphate Phosmet  0.01 100 JMPR  1994 rat 
multigeneration 
IN 
organophosphate Phosphamidon  0.0005 100 DE 1991 2  yr  rat IN+AC 
organophosphate Phosphamidon  0.0005 100 JMPR  1986 2  yr  rat  IN+AC 
organophosphate Phoxim  0.001 IT      IN 
organophosphate Phoxim  0.004 100 JECFA  1999 2  yr  dog  IN 
carbamate Pirimicarb  0.035 100 EFSA  2006 1 yr dog   IN 
carbamate  Pirimicarb  0.02 100 JMPR  2004 90 d dog, 2 yr 
dog 
IN 
organophosphate Pirimiphos-methyl  0.004 100 EFSA  2005 2 yr rat, 2 yr dog, 
human data 
IN 
organophosphate Pirimiphos-methyl  0.03 10 JMPR  1992 28 d human, 58 d  IN   
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human 
organophosphate Profenofos  0.01 100 JMPR  1990 rat 
multigeneration 
IN 
organophosphate  Profenofos  0.03 100 JMPR  2007 90 d dog, 6 mo 
dog, 1 yr dog 
(overall NOAEL) 
IN 
carbamate Promecarb  0.05 BE      IN 
organophosphate Propanil  0.02 100 BE   2  yr  rat HB 
organophosphate Propanil  0.03 300 DAR 2006 2  yr  rat  HB 
organophosphate Propanil  0.03 300 DAR 2010 2  yr  rat  HB 
organophosphate Propanil  0.005 IT      HB 
organophosphate Propanil  0.03 300 IT 2006 2  yr  rat  HB 
carbamate Propoxur  0.02 JMPR  1989   IN 
organophosphate Prothiofos  0.0001 100 DE 1998 1  yr  dog  IN 
organophosphate  Pyrazophos  0.001 100 ECCO 73  1999 2 yr dog  FU 
organophosphate  Pyrazophos  0.004 100 JMPR  1992 2 yr dog, rat 
multigeneration 
FU 
organophosphate  Sulfotep  0.001 10 DE  1990 90 d dog  IN+AC 
organophosphate  Terbufos  0.0006 100 JMPR  2003 1 yr rat, 90 d rat 
neurotoxicity, rat 
multigeneration, 
1 yr dog 
IN 
organophosphate Tetrachlorvinphos  0.05 100 BE  1988 2  yr  dog  IN 
organophosphate  Thiometon  0.003 50 JMPR  1979 2 yr dog, rat 
multigeneration 
IN+AC 
organophosphate Thiometon  0.001 NL      IN+AC 
organophosphate Tolclofos-methyl  0.064 100 EFSA 2005 2  yr  mouse  FU 
organophosphate Tolclofos-methyl  0.07 100 JMPR  1994 2  yr  mouse  FU 
organophosphate  Triazophos  0.001 10 JMPR  2002 3 wk human  IN+AC 
organophosphate Trichlorfon  0.045 100 AT  2006 2  yr  rat  IN 
organophosphate Trichlorfon  0.045 100 DAR    2  yr  rat  IN 
          
organophosphate Trichlorfon  0.002 100 JMPR  2003 human  IN 
organophosphate Trichlorfon  0.002 NL      IN 
          
organophosphate Vamidothion  0.008 10 JMPR  1988 3 wk human  IN+AC 
*Usage category: IN = insecticide, AC = acaricide, FU = fungicide, RO = rodenticide, MO = molluscicide, NE 
= nematocide, RE = repellent, HB = herbicide. In bold, values at or below the proposed threshold for 
neurotoxicity. 
From Table 1 above, substances with ADIs at or below the proposed TTC value for OPs of 18 
μg/person per day (equivalent to 0.3 μg/kg bw per day) were extracted and are listed in Table 2 below. 
For some of the substances, more than one ADI has been allocated, some of which are above the 
proposed TTC threshold value; these are listed as well in Table 2. Some of the effects for the 
substances listed that determine the ADI are related to endpoints other that neurotoxicity, but they are 
listed for completeness.   
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Table 2: Organophosphate and carbamate ADIs at or below the proposed TTC threshold for OPs  
 
Name 
(substance 
group) 
ADI 
(mg/kg 
bw) 
Study type/ 
Effects on which ADI is based 
LOAEL/ 
NOAEL 
ratio  
Uncer
tainty 
factor 
Source Year 
Cadusafos 
(organo 
phosphate) * 
0.0003  Multi-generation rat: 
NOAEL: 0.5 ppm (0.025 mg/kg 
bw/d) 
LOAEL: 5 ppm ↓ reduced bw in F0 
and F1, m+f  
10 100  JMPR    1991 
Cadusafos 
(organo 
phosphate) 
0.0004 2-year  rat: 
NOAEL 1 ppm (0.045 mg/kg bw/d) 
LOAEL: 5 ppm ↓ plasma and RBC** 
AChE** *m+f, ↓ locomotion f 
5 100  EFSA  2008 
Demeton-S-
methyl 
(organo 
phosphate) 
0.0003 
 
2 year rat: 2 studies group ADI 
NOAEL: 1 ppm (0.03 mg/kg bw/d) 
LOAEL: 5 ppm ↓ brain AChE 
5 100  JMPR  1989 
Demeton-S-
methyl 
sulphone 
(organo 
phosphate) 
0.0003 
 
2 year rat: 2 studies group ADI 
NOAEL: 1 ppm (0.03 mg/kg bw/d) 
LOAEL: 5 ppm ↓ brain AChE 
5 100  JMPR  1989 
Diazinon 
(organo 
phosphate) 
0.0002  90- day dog: 
NOAEL: 0.5 ppm (0.02 mg/kg bw/d) 
LOAEL: 150 ppm: ↓ bw gain m+f, 
↓serum AChE m+f, ↓protein levels m, 
↓Ca levels f; 
1-year dog: 
NOAEL: 0.5 ppm (0.02 mg/kg bw/d) 
LOAEL: 150 ppm (4.6 mg/kg bw/d) 
↓bw m, ↓food consumption m+f, 
↓serum AChE m+f; 
300 100  EFSA  2006 
Diazinon 
(organo 
phosphate) 
0.005 90  –day-  rat:   
NOAEL: 0.5 mg/kg bw/d 
LOAEL: 1 mg/kg bw/d ; ↓AChE in 
RBC 
2 100  JMPR  2006 
Disulfoton 
(organo 
phosphate) 
0.0003  2-year dog:  
NOAEL: 1 ppm (0.03 mg/kg bw/d) 
LOAEL: 2 ppm ↓serum and RBC 
AChE 
2 100  JMPR  1996 
Mevinphos 
(organo 
phosphate) 
0.00025  90-day neurotoxicity rat:  
NOAEL 0.025 mg/kg bw/d 
LOAEL: 0.35 mg/kg bw/d 
↓ brain, serum and RBC AChE 
2-year rat: 
NOAEL: 0.025 mg/kg bw/d  
LOAEL: 0.35 mg/kg bw/d ↓ brain 
AChE 
14   100  BE  2001   
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Name 
(substance 
group) 
ADI 
(mg/kg 
bw) 
Study type/ 
Effects on which ADI is based 
LOAEL/ 
NOAEL 
ratio  
Uncer
tainty 
factor 
Source Year 
Mevinphos 
(organo 
phosphate) 
0.0008 30-day  human: 
NOAEL: 1 mg/d or 0.016 mg/kg 
bw/d 
LOAEL: 1.5 mg/d ↓ plasma and RBC 
AChE 
1.5 200  JMPR  1996 
Omethoate 
(organo 
phosphate) 
0.0003  Multigeneration rat: 
NOAEL: 3 ppm (0.03 mg/kg bw/d) 
LOAEL: 18 ppm ↑ post natal loss, ↓ 
pup weight; ↓ fertility and mating in 
F0 and F1 (effects more pronounced in 
F1)  
2-year rat: 
NOAEL 0.03 mg/kg bw/d 
LOAEL:0.04 mg/kg bw/d ↓ RBC in 
m 
(borderline effect - very conservative 
value) 
6 (1.3)  100  EFSA  2006 
Oxydemeton-
methyl 
(organo 
phosphate) 
0.0003  2-year rat:  
NOAEL: 0.03 mg/kg bw/d 
LOAEL: 0.25 mg/kg bw/d: ↓serum 
AChE m+f 
8 100  EFSA  2006 
Oxydemeton-
methyl 
(organo 
phosphate) 
0.0003  2-year rat: (2 studies - group ADI) 
NOAEL: 1 ppm (0.03 mg/kg bw/d) 
LOAEL: 5 ppm ↓ brain AChE 
5 100  JMPR  1989 
Prothiofos 
(organo 
phosphate) 
0.0001  1-year dog:  
NOAEL 0.4 ppm (0.01 mg/kg bw/d) 
LOAEL 300 ppm (7.5 mg/kg bw/d):↓ 
plasma and RBC AChE  
750 100  DE 1989 
Carbofuran 
(carbamate) 
0.00015  Acute neurotoxicity rat:  
LOAEL: 0.03 mg/kg bw 
↓ brain AChE 
----- 200  EFSA   
 
2009 
Carbofuran 
(carbamate) 
0.001 1-year  dog:   
NOAEL 0.1 mg/kg bw/d 
LOAEL: 1 mg/kg bw/d: ↓ RBC 
AChE, miosis in f 
10 100  EFSA  2006 
Carbofuran 
(carbamate) 
0.001  Acute toxicity rat: 
NOAEL: 0.04 mg/kg bw/d 
LOAEL: 0.3 mg/kg bw/d ↓brain and 
RBC AChE 
7.5 25  JMPR  2008 
*Substances with ADIs at or below the proposed TTC value for OPs are listed in bold-face type.  
In bold, values at or below the proposed threshold for neurotoxicity.  
**RBC: red blood cells; ***AChE: acetylcholinesterase.  For JMPR references, see http://www.inchem.org/pages/jmpr.html 
 
The toxicological basis on which the ADIs for OPs and carbamates listed in Table 2 were established 
is described below.   
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Organophosphates 
 
The ADIs for OPs have been established as follows: 
-  For cadusafos, an ADI of 0.0003 mg/kg bw has been established by JMPR (1991) based on 
reduced body weight in dams observed in a rat multi-generation study at a dose exceeding 10 
times the NOAEL. In 2008 EFSA established an ADI of 0.0004 mg/kg bw based on inhibition 
of AChE and reduced locomotion in rats.  
-  JMPR established a group ADI for demethon-S-methyl and demethon-S-methyl sulphone of 
0.0003 mg/kg bw based on inhibition of brain cell AChE at a level exceeding 5 times the 
NOAEL.  
-  EFSA established an ADI of 0.0002 mg/kg bw for diazinon based on clinical signs and 
reduced serum AChE in a 90-day and in a 1-year dog study, the LOAEL exceeding the 
NOAEL 300 times. In this context it is notable that JMPR (WHO,1999c) recommends 
considering reduced AChE solely in serum (without parallel inhibition of AChE in brain or 
red blood cells (RBC) as not adverse.  
-  JMPR established an ADI of 0.005 mg/kg bw for diazinon based on observations of reduced 
AChE in RBC.  
-  For disulfoton an ADI of 0.0003 mg/kg bw has been established by JMPR based on reduced 
serum and RBC AChE in dogs.  
-  While for mevinphos the Belgian competent authority established an ADI of 0.00025 mg/kg 
bw on the basis of inhibition of AChE in brain, serum and RBC in short- and long-term 
studies in the rat. JMPR established an ADI of 0.0008 mg/kg bw based on similar 
observations in humans. 
-  For omethoate an ADI of 0.0003 mg/kg bw has been established based on bases of effects on 
development and fertility in a multi-generation study and on reduced AChE in RBC of rats. 
-  For oxydemeton-methyl an ADI of 0.0003 mg/kg bw has been established by EFSA and 
JMPR, based on inhibition of AChE in serum and brain of rats. 
-  An ADI of 0.0001 mg/kg bw was  established for prothiofos by the German Competent 
Authority on the basis of  reduced AChE in serum and brain in a 1-year dog study, in which a 
LOAEL/NOAEL ratio of notably 750 could be observed. 
 
Carbamates 
 
The ADIs for carbamates have been established as follows: 
-  For carbofuran EFSA has established an ADI of 0.00015 mg/kg bw on basis of a LOAEL 
0.03 mg/kg bw per day (uncertainty factor of 200) from an acute study in rats in which 
reduced brain AChE was seen. The ADI previously established by EFSA was 0.001 mg/kg 
bw based on similar effects seen in dogs. JMPR has established an identical ADI of 0.001 
mg/kg bw based on similar observations in an acute rat study.  
 
For references, see list in main text. 
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APPENDIX E 
Exposure assessment in EFSA’s Scientific Panels 
ANS – Panel on Food Additives and Nutrient Sources  
A feature specific to additives is that they are intentionally added to food and that their presence in 
food products is related to the product formulation, which may vary from brand to brand of every 
single food item. In many cases, formulations are kept confidential and only Maximum Permitted 
Levels present in the legislation or Typical Use Levels or Upper Use Levels reported by industry are 
available. The relationship between such levels and actual use levels is very uncertain. For new 
substances submitted for use as additives, only intended use levels are available and can be used to 
assess anticipated human dietary exposure. 
Few analytical data are currently available in relation to the concentration of additives in foods and 
beverages ready to be consumed and little is known about the influence of storage and processing on 
the residues of these substances in food.  
The tendency of consumers to repeatedly purchase and consume the same (brands of) food products, 
termed consumer or brand loyalty, creates a dependency in the form of a positive correlation between 
the concentrations in different food items consumed by the same consumer. In order to provide a 
conservative dietary exposure assessment, it may be assumed that consumers are loyal to the brands 
with the highest concentrations. This introduces a bias, but provides a more accurate estimate for a 
consumer who is loyal, and also provides higher certainty that the assessment is protective and takes 
into consideration the consumers who are potentially more exposed to the substance of interest. 
Until now the Panel on Food Additives and Nutrient Sources (ANS Panel) in its re-evaluation of food 
additives (mainly colours) has follows the stepwise approach, which was used in the report of the 
Scientific Cooperation (SCOOP) Task 4.2. The approach goes from a conservative estimate that forms 
Tier 1 (screening), to progressively more realistic estimates that form Tier 2 and Tier 3.  
At Tier 1, the ANS Panel uses the concept of total food intake in order to determine if proposed 
maximum use levels of food additives exceed recommended ADI levels; this is referred to as the 
Budget method. The Budget method is a simple calculation which depicts the worst case exposure 
scenario based on the physiological upper limits for food and liquid consumption and the assumption 
that the food additive in question would be present at the maximum permitted levels in a certain 
proportion of all foods and liquids consumed (Hansen, 1966, 1979; EC, 1998). The Budget method 
results in an initial crude estimate of exposure and if it shows that the ADI will be exceeded, more 
precise calculations based on reported use levels and actual food consumption data are performed 
(Tier 2 and 3). 
At Tier 2, refined exposure estimates are performed using maximum permitted use levels. 
At Tier 3, refined exposure estimates are performed using maximum reported use levels or 
analytically determined use levels (if available).  
At both Tiers, exposure estimates for children are performed, based on detailed individual food 
consumption data from 10 European countries. For adults, the Panel uses food consumption data from 
the UK as being representative of the EU adult consumers. 
In the future, exposure assessments for food additives will be based on the EFSA Comprehensive 
European Food Consumption Database, which gives access to aggregate food categories consumed in 
15 European countries (EFSA, 2011b). 
Nutrients 
For nutrients, which are data rich substances, the application of TTC as a risk prioritisation tool is not 
considered relevant, therefore the exposure assessment is not discussed here.   
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CEF – Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Food contact materials 
Exposure assessments for substances migrating into food from food contact materials (e.g. packaging) 
differ in a number of ways from other contaminants. The number of substances used for packaging is 
considerable (e.g. more than  1200 monomers and  1000 additives in plastics manufacturing alone ). 
The level of migration  depends on many factors including the duration of contact between food and 
packaging, and the temperature (during storage, during final preparation, etc.). 
 
Instead of assessing dietary exposure through combination of concentration data in actual foods with 
consumption data, a model is used to calculate the maximum migration of the substance into food 
(EFSA, 2008b). In the model, it is assumed a person may consume daily 1 kg of food that is in contact 
with a particular type of food contact material and that the kg of food is in the form of a cube of 
surface area 6 dm
2. For fatty foods, a reduction factor up to 5 could be introduced due to the fact that a 
person is unlikely to consume daily an amount of food containing more than 200 g of pure fat. 
 
The level of migration may be obtained by different methods: 
-  Most commonly, concentrations in food are estimated from measurements of migration 
obtained in migration tests with standard food simulants. 
-  Migration from food contact materials into food is considered to be complete, i.e. 100% of the 
substance in the food contact material is assumed to migrate into food. 
-  Theoretical migration modelling with packaging-related rate constants and food-related 
uptake properties, intended to overestimate migration.  
 
In some rare cases, full dietary exposure assessment is performed based on concentrations measured 
in foods ready for consumption. However, in these cases and in order to provide a conservative 
dietary exposure assessment, it may be assumed that consumers are loyal to the brands with the 
highest concentrations. This introduces a bias, but provides a more accurate estimate for a consumer 
who is loyal, and also provides higher certainty that the assessment is protective and takes into 
consideration the consumers who are potentially more exposed to the substance of interest. Therefore, 
this approach for estimating exposure to food contact material substances requires data which are 
currently not normally available and is consequently difficult to use. 
 
Flavourings 
In the evaluation of flavouring substances, the dietary exposure considered by EFSA within the 
Procedure to assess their safety has been a per capita estimate, the “Maximised Survey-Derived Daily 
Intake” (MSDI), based on the annual volume of production reported by the applicant. In addition, the 
“modified Theoretical Added Maximum Daily Intake” (mTAMDI) was calculated, based on the 
normal added use levels of the substances as reported by the applicant in the 18 food categories of 
Annex III of Commission Regulation (EC) No 1565/2000 (European Commission, 2000). Both the 
MSDI and the mTAMDI approach take into consideration the dietary exposure of a 60 kg adult. 
Chronic dietary exposure in adults and children 
The Panel has developed a modified approach for estimating high dietary exposures for new 
flavourings which is in line with the methods that have been used until now for flavourings but 
addresses some of their limitations. This method called the “Added Portions Exposure Technique” 
(APET) is used to estimate the dietary exposure for adults and children and is an adaptation of the 
mTAMDI method. The APET is based on the occurrence levels provided by the applicant in each of 
the food sub-categories with the exclusion of complementary foods for infants and young children: 
1)  on the basis of normal occurrence level from added flavourings,  
2)  on the basis of normal occurrence level from other dietary sources,    
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3)  on the basis of normal combined occurrence levels.  
Sub-categories are classified in two groups: “Beverages”, and “Solid foods”. The APET is calculated 
by summing the highest potential dietary exposure within each of the two groups and expressed in 
mg/kg bw per day. For an adult, a body weight of 60 kg is considered and the portions are those 
established by the JECFA (FAO/WHO, 2008) when developing a similar technique (SPET) (Single 
Portion Exposure Technique). 
Dietary exposure to flavouring substances in infant foods  
The diets of infants and young children tend to be less varied than those of older children and adults; 
an ad hoc method is therefore needed for estimating the exposure in this age group. A specific 
exposure assessment could be performed based on the model diet of a 12-month young child fed milk 
and a variety of processed baby foods flavoured with the substance of interest. Due to the high brand 
loyalty in young children the maximum combined occurrence levels will be considered in this 
exposure assessment. 
 
The guidance document on the data required for the risk assessment of flavourings to be used in or on 
foods has recently been published (EFSA, 2010e).  
CONTAM – Panel on Contaminants in the food chain 
The concentration of both natural (e.g. mycotoxins) and environmental (e.g. heavy metals) 
contaminants in food cannot be estimated indirectly because their level is not determined by a 
technical functionality in the food itself like food additives or in the raw commodity like pesticides or 
veterinary drugs. Furthermore, the concentration of chemical contaminant can decrease or increase 
during storage and processing. Therefore analytical measurements are necessary to establish the 
concentration level(s) to be combined with food consumption data in order to assess the dietary 
exposure. The results of analytical measurements will follow a distribution depending on the nature of 
the contaminant but also on where, when and how (e.g. targeted or random sampling) the samples 
were collected.   
For a contaminant with a long-term toxicity, concentrations are generally estimated in 2 different 
ways: 
• The average measured concentration can be used to represent the long-term dietary exposure, 
assuming that a consumer is unlikely to consume regularly highly contaminated food. Available data 
can have been obtained both from single samples and from pooled samples and the mean can be 
weighted for pooled samples by the number of initial samples regrouped before the chemical analysis. 
Non-detects and unquantified results may be dealt with in various ways including assumed zero, 
assumed equal to the limit value or half the limit value, assumed to be distributed uniformly between 
zero and the limit value, or extrapolating a distribution from data above the limit value. 
• The full distribution of contaminant concentrations can be used in a probabilistic modelling of the 
dietary exposure. In that case, the uncertainty is related to the treatment of non-detects and 
unquantifiable data and to the precision of the tails of the distribution. 
 For food consumption data, also two different approaches may be taken: 
• Exposure is calculated for the ‘average’ consumer, those with average consumption of foodstuffs, 
and for the ‘high’ consumer, those with e.g. 95th percentile consumption using the EFSA’s 
Comprehensive European Food Consumption Database) food consumption database. If such data is 
not available, consumption scenarios are used. 
• The full distribution of food consumption data is used in a probabilistic modeling.    
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In many cases the main uncertainty in exposure assessment of chemical contaminants is related to the 
treatment of non-detects and unquantifiable data as for quite a number of contaminants the number of 
non-detects is 60 to 80%. EFSA has published an opinion on how to deal with this in March 2010 
(EFSA, 2010c). 
 For a contaminant with a short-term mechanism of toxicity (e.g. some marine biotoxins), the highest 
concentration recorded in a portion of foodstuff is often used to estimate the consumer exposure. 
These can be useful in some cases but are not the most adequate data as they may underestimate 
concentration peaks. Besides the fact that highest concentration recorded in a portion of foodstuff is 
often used to estimate the consumer exposure, a maximal portion size is often assumed (e.g. 400g for 
shellfish). 
In the context of possibly applying the TTC concept to a compound of unknown toxicity, it is very 
unlikely that the data available will allow for a probabilistic modeling of exposure. Therefore, in most 
cases, human exposure will be calculated by multiplying average measured concentration by food 
consumption estimates for ‘high’ (and ‘average’) consumers. 
FEEDAP – Panel on Additives and Products or Substances used in Animal Feed 
Two main issues characterise consumer exposure assessment for substances used in animal feed. 
Dietary exposure is restricted to specific foods of animal origin 
In particular, since the mission is to assess the safety of intended use of feed additives that can carry 
over into the human diet, only those foods relevant to such intended use are considered. For instance, 
if a compound is not intended for use in laying birds, deposition in eggs is not normally relevant to 
consumer exposure. However, deposition in eggs, hence consumer exposure, might result from 
inadvertent contamination of feed chains, as has occurred with several coccidiostats authorized for use 
in feeds of chickens for fattening but not laying hens. Such cases have been assessed by the 
CONTAM Panel, as undesirable substances. 
 
Dietary exposure of consumers is mediated by the metabolism of the target farm animal species 
Consumer exposure assessment depends on:  
a) pharmacokinetic studies, identifying whether the parent compound or one or more 
metabolite are the most representative residue, and  
b) deposition studies, where the deposition of the additive in edible tissues and products is 
assessed in field conditions, for time length compatible with animal production and at the 
maximum levels intended for use. 
 
When required, such as in the case of substances that are not normally present in the body, the above 
studies lead to the identification of marker residue(s) (i.e., biologically significant and in known 
proportion to total residues) and of maximum residue limits (MRL, based on marker residue, aimed at 
keeping the exposure below the ADI). 
However, in many cases, no such parameters are needed. In particular no need for MRL or marker 
residue is normally foreseen for:  
- biological feed additives (enzymes, probiotics) that normally do not give residues, or  
- natural diet components used as nutritional additives (trace elements, vitamins) where 
consumer exposure assessment is based on the additional intake provided by the use of the 
substance as feed additive, compared to background dietary exposure, and the likelihood that 
the resulting total exposure would be higher than the tolerable upper intake level  (UL) as 
defined in human nutrition. 
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Calculation of the daily intake is based on: 
1.  the concentrations of total relevant residues (as the arithmetic mean ± 2 standard deviations or 
the highest single value in case of less than six animals) as described in section 1.2, and  
2.  default values for daily food consumption by adults shown in Table A. 
Table A.   Default daily adult human consumption figures (grams wet tissue/products) 
 Mammals  Birds  Fish 
Muscle 300  300    300* 
Liver 100  100  - 
Kidney 50  10    - 
Fat 50**  90***  - 
+ Milk  1500   -  - 
+ Eggs  -  100   - 
*: Muscle and skin in natural proportions 
**: For pigs 50 grams of fat and skin in natural proportions 
***: Fat and skin in natural proportions 
 
For additives intended for multi-species use, the daily exposure resulting from the consumption of 
tissues should be independently calculated for all target species for which data is available. The 
highest value for each tissue is taken as representative of human exposure from edible tissues and/or 
milk and/or eggs. If bees are identified as the target species, honey (20 g, 8 samples per time point) 
should be considered.  
The model above is included in EU legislation and is widely used by EMA for veterinary drug 
residues and other international bodies. However, this approach reflects only chronic intake, it only 
addresses adults, and assumes that all adults are consumers of each food item.  
Therefore, as alternative approach the FEEDAP uses the default values shown in Table B. These 
values are derived from the  EFSA Comprehensive European Food Consumption Database and 
represent the high intake (95
th percentile) of consumers only for each food item listed in the table and 
differentiates between chronic and acute intake. 
Table B:    Default values of EU food consumption for high consuming adults and toddlers 
(grams/day) 
 Chronic  intake
1 Acute intake
2 
   Toddlers
3 Adults
4 Toddlers Adults 
Meat
5 90  290  135  390 
Liver -  60  -  170 
Kidney -  15  -  100 
Animal  fat  - 30 - 40 
Milk
6  1050 1500 1500 2000 
Eggs 35  70  50  130 
Honey  - 30 - 50 
Fish 65  125  130  280 
Seafood -  75  -  200 
Fish  +  seafood  - 165 - 360 
1: Chronic intake is the mean value of consumers only derived from the 95
th percentile of EU national surveys available 
2: Acute intake is the mean value derived from the highest observed daily value of each EU national surveys available 
3: Toddlers: 1-3 years of age, 12 kg body weight 
4: Adults: 18-65 years of age, 60 kg body weight (presently under consideration by EFSA) 
5: Meat including processed meat products 
6: Milk including dairy products    
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There is a very low likelihood that the same high consumer will be found in more than two food 
groups at the same time. For risk assessment, the intake of both consumer groups (adults and toddlers) 
should be calculated for all food items listed in the table. The sum of the two highest values is then 
taken as total intake. 
If the ADI or Benchmark Dose is based on a pharmacological effect, the acute intake data should be 
taken for the calculation following the procedure above. 
User/worker exposure 
In addition to consumer exposure, the FEEDAP Panel also has to estimate exposure of user/workers 
through inhalation and dermal route. The dusting potential and the particle size distribution of the 
additive are key parameters to develop exposure estimates. When exposure may occur, worst case 
scenario compatible with the intended use(s) of the additives is developed (EFSA, 2010f). 
 
PPR – Panel on Plant Protection Products and their residues 
Assessment of exposure to a plant protection product via the diet is almost always substance-specific, 
i.e. generic scenarios are not used. Such exposure assessment is based on knowledge of the actual or 
predicted concentrations of the pesticide in foodstuffs and the amount of the foodstuffs consumed. To 
date, most assessments have been based on deterministic approaches, although increasingly 
probabilistic approaches are being introduced. For the calculation of the expected exposure using 
deterministic methodologies, concentrations of the pesticide in foodstuffs for a new active are 
predicted on the basis of field trials in which the substance is applied according to good agricultural 
practice (GAP), taking into consideration the rate and number of applications of the active, the 
method of application and any pre-harvest interval. Parameters are maximised within those possible to 
achieve plausible worst case values. For chronic assessments, the supervised trials median residue 
(STMR) level is now used. Information on food consumption can be obtained in a number of ways, 
for instance by using data provided by MS for the development of the EFSA PRIMo (EFSA Pesticide 
Residue Intake Model).  In future, these data will be replaced with the data provided to EFSA in the 
framework of the EFSA comprehensive European Food consumption data. A wide use was made of 
the EFSA Concise European Food Consumption Database (EFSA, 2008a).  This is now being 
expanded, to produce EFSA’s Comprehensive European Food Consumption Database (EFSA, 2011b) 
Dietary exposure is usually calculated for the ‘average’ consumer, those with average consumption of 
foodstuffs, and for the ‘high’ consumer, those with 95
th percentile consumption. In determining 
exposure a number of issues have to be considered. These include, when using monitoring data on a 
pesticide, how values at the limit of reporting will be treated; possible changes in pesticide 
concentration with processing of the foodstuff; carry-over of pesticide into following crops or into 
meat and dairy products through animal feed.  
Similar considerations apply to metabolites of potential toxicological relevance. In this case, detailed 
information on the pattern and distribution of metabolites in foodstuffs is required. 
EFSA also has to estimate exposure of operators, workers, residents and bystanders.  In these cases, in 
addition to exposure by the oral route, consideration has to be given to exposure by the dermal and 
inhalation routes.  Estimates are obtained using a combination of experimental data, for example for 
dermal absorption and appropriate models, for example the EUROPOEM Predictive Operator 
Exposure Model.  The EFSA PPR Panel has developed draft updated guidance on the assessment of 
dermal absorption and an opinion on the science behind the draft guidance (see 
http://www.efsa.europa.eu/en/scdocs/scdoc/52e.htm).  The PPR Panel has recently published draft 
guidance on the assessment of exposure of operators, workers, residents and bystanders to pesticides 
and an opinion on the science behind the draft guidance (see 
http://www.efsa.europa.eu/en/scdocs/scdoc/1501.htm). 
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APPENDIX F 
Does a TTC value of 0.15 μg/day provide a sufficient margin also for heritable/mutagenic 
effects? 
The dimension of the genetic risk associated with exposure to genotoxic substances at the TTC value 
of 0.15 μg/day (equivalent to 0.0025 μg/kg bw per day) can, in principle, be estimated using 
quantitative data on chemically-induced heritable effects. However, data amenable for the quantitative 
evaluation of genetic risk are only available for a very limited set of substances, and it is expected that 
no further data will be produced as relevant in vivo test methods use large numbers of animals. Most 
available data concern four substances selected for an EC/US exercise on comparative genetic risk 
assessment (Waters & Nolan, 1995): the industrial chemicals acrylamide, 1,3-butadiene and ethylene 
oxide, and the cancer chemotherapeutic agent cyclophosphamide. Other quantitative data on heritable 
effects concern the ethylating agents ethyl methanesulphonate and ethylnitrosourea, selected for a 
molecular dosimetry comparative study, and the chemotherapeutic drug procarbazine. 
A selection of test results, as reported by the authors, on transmissible effects induced by these 
chemicals in male mice is summarised in Table 1 below. Mutation frequencies were estimated using 
two different approaches, i.e. the Direct Method and the Doubling Dose (or Indirect) Method (Ehling, 
1988). Briefly, the Direct Method extrapolates the expected overall genetic burden in humans from 
the observed dominant mutation rate per locus in mice, multiplied by the number of loci in humans at 
which dominant mutations occur. The second approach avoids a specific estimate of the number of 
human loci involved in deleterious dominant mutations, but requires an estimate of the overall 
spontaneous mutation frequency in humans to dominant alleles. The main findings are described 
below. 
Acrylamide 
Acrylamide affected several stages of mouse spermatogenesis. Specific-locus mutations were induced 
both in spermatogonia and post-meiotic stages (spermatozoa and late spermatids). Chromosomal 
effects (dominant lethals and heritable translocations) were mainly induced in later stages (spermatids 
and early spermatozoa). Doubling Doses (DD) range from 53 mg/kg bw, when estimated by the 
specific-locus test, to 0.39 mg/kg bw, when estimated with the heritable translocation test. Based on 
these findings, the frequency of dominant genetic disease burden in the offspring of males exposed to 
the limit concentration of acrylamide in drinking water (0.5 μg/L, corresponding to 1.3 x 10
-5 mg/kg 
bw for a 75 kg person drinking 2 L of water) was calculated. The number of induced genetic diseases 
per million offspring ranged from 7.3 x 10
-5 to 3.0 x 10
-2 (Dearfield et al., 1995). Approximately 6-
fold lower incidences can be calculated for the daily exposure to acrylamide at the TTC level of 0.15 
μg/day.  
Cyclophosphamide 
Post-meiotic cell stages are most sensitive to the genotoxic effects of cyclophosphamide. DD in the 
mouse morphological specific-locus test were 4 and 16 mg/kg bw for treatment of post-meiotic cells, 
while no detectable increase in mutant frequency was observed with treatment of spermatogonial stem 
cells. It must be noted that the above figures are based on a low number of observations (mutants in 
progeny), and thus are highly uncertain. However, based on the DD of 4 mg/kg bw it was calculated 
that the excess incidence of dominant and X-linked diseases for the acute exposure at 1 mg/kg bw 
would be 625 affected individuals per million liveborn (Anderson et al., 1995). Extrapolated to the 
TTC exposure level, such an estimate is approximately 2x10
-3 additional cases per million of 
offspring. 
Ethylene oxide 
The frequency of recessive mutations induced in mouse spermatogonia following inhalational 
exposure to ethylene oxide was calculated to be approximately 0.2 to 2 x 10
-6 for an inhalational 
exposure of 1000 ppm for an hour (Natarajan et al., 1995). Considering the ventilation rate of the 
mouse, the concentration x time value (1000 ppm/h) can tentatively be converted into a weight-to-
weight figure (135 mg/kg bw). The corresponding incremental risk of recessive mutations for an   
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exposure at the TTC level can be calculated by linear extrapolation, and is approximately 3 x 10
-15. 
The incremental risk of dominant visible mutations was estimated to be about 1.3 x 10
-5 at 1000 
ppm/h, which corresponds to ∼ 2.5 x 10
-13 at the TTC exposure level.  
Ethylnitrosourea,  ethylmethansulphonate and procarbazine 
Mutation frequencies after spermatogonial treatments were determined in the offspring of mice using 
different genetic end-points, involving different numbers of loci (Ehling, 1988, Ehling & Neuhäuser-
Klaus, 1989). Based on figures shown in Table 1, the induced mutation frequencies for treatment with 
1 mg/kg bw of ethylnitrosourea and procarbazine range from 3.3 x 10
-6 to 5 x 10
-7 and from 1 x 10
-7 to 
0.5 x 10
-8, respectively. Approximately 4 x 10
5-fold lower frequencies are obtained when extrapolated 
to the TTC exposure level. Also for ethylmethansulphonate, a very small incremental risk is 
associated with exposure at the TTC level, given that such an exposure level is approximately 10
8-
fold lower than the experimentally determined doubling dose (175 mg/kg bw). 
Table 1. Estimated germ cell mutation frequencies in mice  
Substance  Test system  Germ cell mutation frequency  Reference 
   Induced mutation 
Frequency 
Doubling 
Dose 
 
Acrylamide  Mouse 
specific-locus 
test
a 
  53 mg/kg bw  Ehling & Neuhäuser-
Klaus, 1992 
  Mouse 
heritable 
translocations 
 1.8  mg/kg  bw 
3.3 mg/kg bw 
0.39mg/kg bw 
Shelby et al, 1987; 
Adler et al, 1994 
Adler et al, 1990 
Cyclophosphamide   Mouse 
specific-locus 
test
a 
 4  mg/kg  bw
b 
16 mg/kg bw
c 
Ehling & Neuhäuser-
Klaus, 1988 
Ethylene oxide  Mouse 
specific-locus 
test
a,d 
0.21 ± 0.28 x 10
-6/1000 
ppm h  
  Russell et al., 1984 
  Mouse 
specific-locus 
test
e 
1.3 x 10
-5/1000 ppm h    Lewis et al., 1986 
Ethyl methane 
sulphonate 
Mouse 
specific-locus 
test
a 
  175 mg/kg bw  Ehling & Neuhäuser-
Klaus, 1989 
Ethylnitrosourea  Mouse 
specific-locus 
test
a 
5.7 x10
-4 at 160 mg/kg 
bw 
 Ehling,  1988 
  Mouse 
specific-locus 
test
e,f 
7.3 x 10
-5 at 160 mg/kg 
bw 
  
Procarbazine  Mouse 
specific-locus 
test
a 
4.4 x 10
-5 at 600 mg/kg 
bw 
 Ehling,  1988 
  Mouse 
specific-locus 
test
e,f 
0.3 x 10
-5 at 600 mg/kg 
bw 
  
a specific-locus visible recessive mutations (7 loci) 
b treatment of late spermatids and spermatozoa 
c treatment of differentiating spermatogonia and spermatids 
d treatment of spermatogonia  
e dominant visible mutations 
f dominant cataract mutations (30 loci) 
 
Thus, even taking into account the extremely limited database, and additional uncertainties related to 
the route of exposure, stage-related variation in sensitivity of germ cells, the lack of data on female   
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germ cells, and the possible accumulation of genetic damage in pr-meiotic cells during chronic 
exposure, the available data on chemically induced transmissible effects suggest that the incremental 
risk associated with genotoxic chemical exposure at the proposed TTC exposure level is extremely 
low, if any. Based on the available data, when applied to a genotoxic agent the TTC value of 0.15 
μg/day (0.0025 μg/kg bw per day) could also cover transmissible effects, beyond cancer.  
This conclusion could be anticipated to some extent in view of the apparent relative lower sensitivity 
of germ cells compared to somatic ones. Many studies have addressed the relationship between 
somatic and germ cell mutations, reaching the similar conclusion that there is still no evidence of 
germ line specific mutagens, and that when a mutagenic response is elicited in germ cells, an even 
greater response is typically detected in somatic cells. This fact is considered to be attributable to the 
different chemical accessibility of somatic versus germ cells, rather than to intrinsic differences in the 
ability to process pre-mutagenic lesions, as demonstrated by comparative molecular dosimetry studies 
(Van Zeeland et al., 1985). The possibility for a systemically available substance to reach gonadal 
targets is largely modulated by pharmacokinetic and anatomic factors, including the 
compartimentalisation of gonads. The Sertoli cell barrier, in particular, is believed to play a significant 
role in protecting meiotic and post-meiotic male germ cells, limiting the access of exogenous 
chemicals to gonads (Russell, 1990).  
 
For references, see list in main text. 
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APPENDIX G 
Further considerations for route-to-route extrapolation 
Toxicodynamic considerations 
Concerning the toxicodynamic aspect of route-to-route extrapolation, it should be understood that in 
most of the databases the TTC values have been derived from endpoints for systemic toxicity. Hence, 
the existing oral TTC values do not encompass portal of entry effects for routes other than oral, which 
may be particularly relevant for the inhalation route. Local effects in the respiratory tract are reported 
for several chemicals. In the upper respiratory tract not only cytotoxic effects have been described 
which may lead to loss of olfactory function but also development of cancer, e.g. formaldehyde 
(McGregor et al., 2006) and vinylacetate (ECB, 2008). In the lower respiratory tract, sensitisation of 
the airways is an important toxic effect. With other chemicals, cytotoxic effects in the cells lining the 
airways and the alveoli leading to loss of respiratory function and gas exchange have been observed 
particularly at high exposure levels. Lung cancer can also be a portal of entry effect, e.g. styrene 
(Csanady et al., 2003). Portal of entry effects may be also important for dermal exposure with respect 
to skin sensitisation (van Loveren et al., 2008) but it cannot be assessed by route-to-route 
extrapolation (Merk, 2009). For systemic toxicity, as a general rule it can be assumed that similar 
results would be expected by another route of exposure than the oral route if the agent is absorbed by 
the non-oral route to give a similar internal dose. Hence, route-to-route extrapolation can be 
considered for systemic effects, whereas it is not possible for local effects. 
 
Toxicokinetic considerations 
 
Toxicokinetic aspects to be considered relate to the rate and extent of absorption and possible route-
specific metabolism.  
 
Absorption 
 
Physiological processes by which organic substances cross the gastrointestinal wall are diffusion 
through the membranes across the cells, uptake mechanisms by specific transporters and paracellular 
transport. Diffusion is the predominant process. Hence, absorption through the wall of the 
gastrointestinal tract is determined by physicochemical properties favouring the absorption of 
hydrophobic molecules and,  in case of weak bases or acids, the  non-ionised over the ionised species. 
Transporters have been identified which play a role in uptake of a substance into the cell and, in some 
cases, for transport out of the cell back into the gut lumen or into the blood. For the majority of 
exogenous substances, the relative importance of such transporters has yet to be elucidated.  
 
Compared to the gastrointestinal tract the skin has a small surface area which is available for 
absorption which might be further reduced by clothing. The pathway from the outer skin layer 
(stratum corneum) to the circulation comprises several layers of cells and this slows down the rate 
(velocity) of absorption. Absorption through the cell layer of the epidermis can be characterised as 
passive diffusion through a lipophilic structure whereas diffusion through the dermis is characterised 
as diffusion through a watery layer. The epidermis does not contain vasculature and hence absorption 
into the systemic circulation can only occur from the dermis layer. Besides lipid solubility, 
characterised by the octanol/water partition coefficient, water solubility and the molecular mass of the 
substance are influential on the extent of absorption in a complex pattern. Kroes et al. (2007) 
predicted the maximum flux through the skin, which is a measure of absorption based on log P and 
water solubility, and confirmed this complex relationship by examples. They proposed to calculate the 
flux through the skin by using the octanol/water partition coefficient and the saturation solubility in 
the vehicle (mostly water) and proposed a default value for the percentage of the dose absorbed per 24 
hours (for formula see Kroes et al., 2007). They also concluded that the absorption of a substance with 
a molecular weight above 500D will be less than 10%. 
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It should however be considered that solvents and surfactants may influence the extent of absorption 
as well as the concentration and the condition such as covering the dermal application site (occlusion). 
For cosmetics, specific consideration has to be given to whether the products are rinsed off. Current 
EU Guidelines propose a default retention factor of 0.01 for shower gels, shampoo, hair conditioner, 
0.05 for toothpaste and 0.1 for hair styling products and for mouthwash (SCCP, 2006). 
 
In experimental animals, absorption through skin is generally higher than in humans. Further 
considerations on dermal absorption, in particular, the influence of dilution on the extent of 
absorption, can be found in an opinion prepared by the Panel on Plant Protection Products and their 
Residues (EFSA, 2010d). 
 
Absorption following inhalation has to consider the aerodynamic diameter of the studied 
aerosols/particulates. Substances with an aerodynamic diameter of greater than 10 μm (man) and 4-6 
μm (rat) will not reach the alveolar region but will undergo mucociliary clearance and be swallowed 
thus reaching the systemic circulation by the oral route. Absorption of particulates in the alveolar 
region depends on solubility. Insoluble particulates will not be absorbed and will accumulate in the 
alveolar region and may exert local effects. Substances which enter the systemic circulation by 
absorption through the alveolar membrane will reach the general circulation before passing through 
the liver.  
 
Metabolism 
 
The gastrointestinal wall is a metabolically competent tissue. Mucosal cells contain enzymes of the 
cytochrome P-450 family (phase 1) as well as enzymes capable of conjugation reactions (phase 2). 
The enzyme activity is lower than in the liver with the notable exceptions of sulphation of beta-
sympathomimetic drugs (Dollery et al., 1971; Hildebrandt et al., 1994) and oxidation of some 
biogenic amines, e.g. tyramine. 
 
The metabolising capacity of the skin has been estimated to be only about 2% of that of the liver 
whereas others have claimed that the capacity is similar to that in the lung (Baron et al., 2008). 
Esterases may be an exception as a number of esters have been shown to be hydrolysed during 
penetration through the skin (Boehnlein et al., 1994).  
 
The lung contains enzymes of the cytochrome P450 family and also conjugation enzymes. The 
amount of the enzymes present is several orders of magnitude lower compared to the liver. However, 
the enzymes present may be important in forming active metabolites which may lead to the local 
production of carcinogens or other toxicologically active substances (Pelkonen et al., 2008). 
 
Because of the capacity of the liver for metabolising xenobiotics and the anatomical situation, 
substances entering the body by the oral route may undergo pre-systemic metabolism, the 
consequences of which may be different depending on the activity of the parent substance as 
compared to the activity of the metabolite. If the parent substance is the directly toxic species then the 
substance is assumed to be less toxic when administered by the oral route as compared to the non-oral 
route. If the metabolite is the active species then the toxicity might be enhanced when the substance is 
administered by the oral route as compared to the non-oral route. In assessing the relative toxicity of 
the oral and the non-oral route, it is important to consider (1) the target organ for toxicity, and (2) the 
relevant toxicokinetic metric, i.e. the amount of the substance or its metabolite in the systemic 
circulation versus the absolute concentration of the substance or its metabolite in the target organ. 
 
Default approaches 
 
In the absence of data on the extent of absorption, an extrapolation could be based on the 
physicochemical properties of the substance taking into account results from analysing existing data 
or a read-across approach from structurally analogous substances. In the Munro et al. (1996) database 
170 (27.7 %) of the substances were given by gavage and 36 (5.9%) by drinking water as opposed to   
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344 cases (56.1%) where the substance was given by diet. Administration of the dose by gavage 
results in high maximum concentrations in the blood whereas it is expected that dietary administration 
will lead to more moderate maximum concentrations. Administration by drinking water will result in 
maximum concentrations in between. Hence, the Munro et al. (1996) database contains representation 
of different modes of application with high and moderate maximum concentrations. It can be 
concluded that this aspect is well covered. 
 
In order to conduct oral to dermal extrapolation, an assumption has to be made that absorption is the 
same between routes, or the difference is known and can be quantified. An approach that could be 
adopted would be to follow the recent recommendations from EFSA concerning plant protection 
products (PPPs).  
 
In the EU, for establishment of dermal absorption values for PPPs, in the absence of valid measured 
data, a default value of 100% is applied. A lower default value of 10% is applied if the active 
substance has a molecular weight of above 500 and a log Pow value of either below -1 or above 4 
(EC, 2004). EFSA has recently proposed some modifications to the default value of 100% for the 
application to PPPs (EFSA, 2010d).  
 
Kroes et al. (2007) explored the possibility to use the oral Munro et al. (1996) database as a basis for 
assessing substances that are dermally applied. In their view, the only situation where the oral TTC 
would underestimate risk (after correction has been made for absorption through skin as compared to 
the gut wall) would be if the substance exhibited high pre-systemic metabolism. They calculated the 
situation for a substance with a pre-systemic metabolism of 50% and came to the conclusion that this 
case would be covered by the conservative assessment/extrapolation factors.  
 
In addition, they analysed the database of Munro et al. (1996) and came to the conclusion that the 
majority of Cramer class III compounds do not undergo pre-systemic detoxication after oral dosing, 
but that many would show higher toxicity after oral dosing because hepatic first-pass metabolism 
results in the generation of a toxic metabolite. Hence, they concluded that an additional factor would 
not be necessary and the topic seems not to be relevant. 
 
For extrapolation from the oral to the inhalation route the situation is at present not simple. An 
extrapolation approach has been taken by the IGHRC (2006) where specific extrapolation factors have 
been derived. However it should be noted for substances undergoing TTC evaluations, that there 
would normally be very few data available for refining the assumptions on bioavailability.  
 
As an alternative, others have proposed TTC values for local and for systemic effects based on 
existing inhalation data.  Carthew et al. (2009) specifically addressed substances likely to be present 
in consumer products. The data they used excluded  substances with certain properties, such as 
genotoxic carcinogens, in vivo mutagens (presumed carcinogens), potential respiratory sensitisers, 
potential irritants (strong acids or bases), and pharmacologically active substances, together with 
certain other groups of substances, such as heavy metals (neurotoxic), dioxins and PCBs 
(accumulative and biopersistent), organophosphates (neurotoxic), and polymers (require substance-
specific data). Escher et al. (2010) have proposed lower TTC values than Carthew et al. (2009) for 
systemic effects, based on a different database of inhalational toxicity studies. The various 
inhalational TTC values proposed are described in the main text.   
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Abbreviations: 
ADI: Acceptable Daily Intake 
AChE: Anti-cholinesterase 
ANS: Panel on Food Additives and Nutrient Sources Added to Food 
ARfD: Acute Reference Dose 
CEF:   Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CONTAM: Scientific Panel on Contaminants in the Food Chain 
CPDB: Carcinogenicity Potency Database 
DART: Developmental and Reproductive Toxicology database 
DSSTox: Distributed Structure-Searchable Toxicity Database 
EC: European Commission 
ECHA: European CHemicals Agency 
EPA: Environmental Protection Agency 
FDA: Food and Drug Administration 
FEEDAP: Scientific Panel on Additives and Products or Substances used in Animal Feed 
GMO: Scientific Panel on Genetically Modified Organisms 
JRC: Joint Research Centre  
JECFA: Joint FAO/WHO Expert Committee on Food Additives 
JMPR: Joint FAO/WHO Meeting on Pesticide Residues 
IGHRC: Interdepartmental Group on Health Risks from Chemicals 
IRIS: Integrated Risk Information System 
LOEL: Low-Observed-Effect Level 
LLEL: Lowest Low Effect Level  
NDA: Scientific Panel on Dietetic Products, Nutrition and Allergies  
NOEL: No-Observed-Effect Level 
OECD: Organisation for Economic Co-operation and Development  
OP: Organophosphate 
PCA: Principal Component Analysis 
PLS: Partial Least Squares 
PPR: Scientific Panel on Plant Protection Products and their Residues 
QSAR: Quantitative Structure Activity Relationship 
SCCP: Scientific Committee on Consumer Products 
SCF: Scientific Committee on Foods 
SIMCA: Soft Independent Modeling of Class Analogy  
TDI: Tolerable Daily Intake 
TD50: The daily dose-rate in mg/kg body weight per day for life to induce tumors in half of the test 
animals that would have remained tumor-free at zero dose. 
TTC: Threshold of Toxicological Concern 
VSD: Virtually Safe Dose - an estimate of the dietary exposure to a carcinogen which could give rise 
to less than a one in a million lifetime risk of cancer 
WHO: World Health Organization  
 
 
 